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It was a privilege to have the opportunity of initiating and directing 
the Avon Longitudinal Study of Parents and Children (ALSPAC), 
even though when times were particularly tough, it seemed like a self-
imposed treadmill. Such times were more to do with raising enough 
money to keep the Study going rather than the Study itself, which was 
exciting and rewarding in itself. As will be seen from this book, the 
Study was pioneering in many ways, and the Ethics Committee was 
vital in guiding it. It was the late, and much missed, Professor David 
Baum whose idea it was to have such a committee, and it was he who 
had the foresight to suggest Michael Furmston as the Chair. Both ideas 
were inspirational. As will be seen from this volume, the way in which 
the Committee worked derived largely from that choice of Chair.
To put the Study in context, Britain was famous for its longitudinal 
birth cohort studies, especially the three previous national surveys of 
births in 1946, 1958 and 1970. Having worked on the last two of 
these, I was aware of the advantages and defects in such studies – the 
advantages being that they were population-based, with high response 
rates, the disadvantages being that they lacked the depth that could have 
been found with more frequent contacts and observations. I therefore 
developed a design in the 1980s based on the latest (at that time) 
ideas as to what was known and what was not known. Surprisingly 
little was known about the ways in which different features of the 
environment influenced the health and development of the child but 
evidence from the study of malformations and childhood leukaemia 
showed that pregnancy was an important time, and that factors such 
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as medications (for example thalidomide) and infections (for example 
rubella) could have profound effects. What was not known was how 
such features might have more subtle influences that would not be 
apparent until mid-childhood or later. Added to this was the possibility 
that there were subtle genetic effects that may have direct influences 
on development, or that may only have influences in the presence of 
specific environments.
Given this background, it was obvious that the design of the 
Study should be to collect as much information as possible on the 
environment of the parents up until the time of pregnancy and to 
continue to monitor this, and that of the child, thereafter. The obvious 
time to start collecting data was as early in pregnancy as possible. This 
was the first way in which ALSPAC differed from other British birth 
cohorts. The second unique feature concerned the decision to collect 
data using self-completion questionnaires rather than by interview; this 
we considered important for two reasons – it was cheaper but, more 
importantly, the participants would have the advantage of having time 
to find answers (such as by looking at diaries or asking a family member) 
and thus provide more accurate information. Third, the Study was 
innovative in collecting biological samples as a means of identifying 
exposures to chemicals, as well as providing the opportunity to extract 
DNA and assay levels of hormones and metabolites of various sorts. 
Fourth, and equally importantly, it was innovative in its approach to 
ethics and the creation of its own ethics committee.
None of the previous cohorts had felt the need to consider the ethics 
of what they were doing until the mid-1980s, when Neville Butler 
decided that the plans for the medical examination included in the 
16-year-old sweep of the 1970 birth cohort should be considered by 
a Local Research Ethics Committee. However, it was unique to have 
an ethics committee attached to a Study. This proved to be a major 
asset to the Study and to me in particular.
As Director of the Study, I was acutely aware of the responsibilities 
entailed. My husband had been in the army during the Second World 
War and was particularly keen on asking “Where does the buck 
stop?”. Obviously, it stopped with me. Any breach of confidentiality, 
xv
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any error in the science and any difficulty with the financial probity 
of the Study would ultimately fall on me. As Karen has documented 
so well in this volume, as time went on, it became apparent that the 
majority of participants had complete trust in our ability to protect their 
anonymity, and to treat their contributions appropriately. Although the 
Ethics Committee could not take over the responsibility, it provided 
me with the overall advice and support that was needed regarding 
the running of the Study. It was a group of experts from a variety of 
backgrounds to whom I could take my worries and uncertainties, and 
get considered and wise opinions. Nowadays, it is assumed that ethics 
committees need to be independent – I am not sure why. If the aim 
is to ensure that a study is carried out ethically, surely the optimum is 
to work with the study to derive solutions to ethical dilemmas, rather 
than being a jury stating ‘yes’ or ‘no’?
The Study has succeeded, in spite of all odds. This is due to the 
amazing staff who were involved and were particularly important in 
making sure that the Study ran smoothly and within appropriate ethical 
limits, as well as the members of the Ethics Committee who had major 
beneficial impacts on the ways in which the data were collected and 
used. When persuading Karen to write this book, I asked her to ensure 
that she considered the triumphs and failures ‘warts and all’ – she has 
done so admirably (as anticipated). It was important to document 
where it could have been improved and where it fulfilled its aims so 
that others may learn from both. This document tells the story of this 
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Preface
The Avon Longitudinal Study of Parents and Children (ALSPAC), 
also known as ‘Children of the 90s’, is an internationally renowned 
longitudinal birth cohort study, based within the University of Bristol 
in South-West England. ALSPAC’s main goal, in collaboration with 
local, national and international scientists, is to understand the ways 
in which the physical and social environment interact, over time, with 
genetic inheritance to affect health, behaviour and development. Over 
14,000 pregnant women were enrolled during 1991–92 and these 
mothers, with their partners and children and, more recently, others 
from their extended families, continue to give vast amounts of data: 
physical, psychological, social, educational, environmental, biological 
and genetic. The collection and analysis of these unique, diverse and 
complex data sets raised many ethical concerns, and from the outset, it 
became clear that sound ethical and legal advice would be necessary to 
guarantee appropriate protection for the Study participants, including 
those yet to be born.
At the time ALSPAC was established, there were no guidelines 
for the ethical governance of such longitudinal studies and no other 
ethics committees dealing with these issues, so ALSPAC founded 
its own pioneering ethics committee – the ALSPAC Ethics and 
Law Committee. This was the first ethics committee attached to a 
longitudinal study and the first to deal with the ethical issues arising 
from the collection of genetic material from a population sample. This 
aspect of the study design was a research methodology not used before; 
genetic studies had previously been preoccupied with ‘pedigrees’ and 
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individual inheritance. ALSPAC was also the first comprehensive birth 
cohort to enrol participants in utero and to include fathers or partners 
in the Study from the outset.
The aim of this book is to describe the innovative work carried out 
by the ALSPAC Committee in its early years, particularly how the core 
ethical principles were established and then how the policies evolved 
as the Study progressed and became more complex as the children 
grew up and as the interest and understanding of the ethics of such 
studies developed and advanced in academia, politics and beyond. This 
book should be of interest to all those curious about the development 
of ethical protection for participants within longitudinal studies, not 
only ethicists, epidemiologists, historians and other academics, but 
also professionals and lay members of research ethics committees 
and any individual who is, or has been, a participant in longitudinal 
epidemiological research.
The book is enlivened by quotes from Committee members that 
have been interviewed recently, who reflect not only on the pioneering 
work of the Committee, but also on the unusual style and inspirational 
leadership of the first Committee Chair, Professor Michael Furmston. 
The first part of the book documents this unusual style, the changing 
status of the Committee as research governance developed within 
the University and the National Health Service (NHS), and, with it, 
the sometimes difficult relationship with these other official bodies.
The second part of the book describes policy development, with 
separate chapters detailing:
• Confidentiality and anonymisation: the complexities of providing 
a secure system when it was essential to link individual participants’ 
ongoing sequential data. Deductive disclosure was a particular 
concern in such a localised study.
• Informed consent: the practical considerations of all aspects of 
consent and assent, including implied, withdrawal, proxy, dual 
(parent and child), sole (child only) and, most controversial, ‘broad’ 
consent for the use of genetic material. Too much information was 
considered as detrimental as too little.
xvIII
PIONEERING ETHICS IN A LONGITUDINAL STUDY
• Child protection: the principle of non-intervention that was 
inherent in the design of ALSPAC was soon challenged as child 
protection concerns arose when Study families were visited at 
home, attended ALSPAC research clinics or imparted worrying 
information when interviewed or answering questionnaires. 
Intervention could also involve breaking the guarantee of anonymity 
so essential for the carefully nurtured trust of the participants.
• Disclosure of results: the Committee’s general position of non-
disclosure was also challenged with the detection of treatable 
conditions either foreseen (such as anaemia) or incidental (such 
as tumours).
• Disclosure of individuals’ results on request: the Committee 
reviewed all requests on a case-by-case basis but despite conflicting 
legal opinions and considerable pressure, they never felt an 
individual’s circumstances warranted disclosure and, with it, the 
risks of breaking the guarantee of anonymity.
• Requests for help by individual participants: requests for help, 
sometimes quite harrowing, were also reviewed on a case-by-case 
basis and, very occasionally, the guarantee of anonymity was broken 
on compassionate grounds.
• Linkage to third-party databases: opt-out consent was initially 
acceptable but this became inadequate over time as more 
comprehensive protection of patients became obligatory and 
complex procedures had to be negotiated.
Although these chapters cover familiar concepts within the now well-
established discipline of medical ethics, the ALSPAC Committee was at 
the forefront of ethical thinking in regard to genetic epidemiology and 
longitudinal studies. How much the Committee’s work contributed to 
the current debates on these issues, evident in the abundance of journals 
and publications on the ethics of research, is debatable and references 
within this book have been limited to the few with obvious relevance. 
The Committee had to work from first principles and grapple with 
the real ethical dilemmas that emerged as the Study progressed and 
became ever more complex. Many of the policies arising from these 
xIx
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deliberations are considered standard practice within medical research 
now, others remain controversial. Nevertheless, these principles and 
policies have served ALSPAC well, with the integrity of the Study 
never compromised.
The final part of the book describes the broader remit of the 
Committee when deliberating on the ethical issues that arose when 
endeavouring to reduce attrition rates with appropriate incentives or 
collaborating with commercial companies. The Committee also had 
unique oversight of the whole of ALSPAC as it reviewed in detail all that 
was asked of participants. Finally, the wider influence of the Committee 
is discussed, not only in a formal advisory capacity for other institutions, 
such as a House of Lords Science and Technology Sub-Committee and 
the European Society of Human Genetics, but also as an exemplar for 
other longitudinal studies, a research methodology that has become 
increasingly popular since ALSPAC began. These interventions and 
the importance of the Committee’s work beyond that of protecting the 
Study participants have not been documented previously, although some 
references can be found scattered within the Committee minutes. The 
extensive influence of the Committee should provide weight to those 
considering the Committee’s work in the light of their own.
Personal perspective
In describing the early days of the Committee, a completely objective 
perspective was not possible as I have not been a detached observer. 
As a recent and thoroughly sleep-deprived mother, I joined Jean 
Golding’s Unit of Paediatric and Perinatal Epidemiology in 1988 as 
a medical coder when ALSPAC was being planned. As with all staff 
within ALSPAC in the early days, I had a variety of simultaneous roles, 
mainly related to my nursing background. In 1998, Jean asked me to 
complete the local NHS Research Ethics Committee form for approval 
for the first all-cohort research clinic, and so began my involvement 
with the ethical issues within ALSPAC. A year later, I was asked to 
take the minutes for the Committee, and soon after that, I became 
the Committee Secretary and then the ALSPAC Ethics Manager. For 
xx
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over 14 years I worked closely with the Committee, some members 
have become friends and I continue to work with Jean Golding. Other 
than verbatim quotes from recorded interviews and extracts from the 
Committee minutes, opinions and any errors remain my own.
There have been three main sources used when writing this 
document:
1. Minutes and accompanying documents of the Committee between 
its establishment in 1990 and July 2005, when the retirement of 
Jean Golding was formally acknowledged by the Committee. 
Ethical approval was given for the deposit of this material as a 
public resource in the University of Bristol ALSPAC Administrative 
Archive held by the Library’s Special Collections (Committee 
reference E201301, July 2015).
2. Papers during the same period from: Jean Golding; Michael 
Furmston, Chair of the Committee throughout this period; 
Elizabeth Mumford (née Roberts), Secretary of the Committee 
for the first 10 years; and myself, Secretary of the Committee for 
the following 14 years.
3. Brief oral histories recorded by me during 2012–13 from eight 
members of the Committee, as well as Professor Marcus Pembrey, 
ALSPAC’s Director of Genetics, who was central to the inclusion of 
genetics from the outset in ALSPAC’s design and provided essential 
information and advice to the Committee.
These documents have been indexed and will be archived along 
with the videotaped oral histories in the University of Bristol Special 
Collections as the ALSPAC Ethics Archive, a subset of the main 
ALSPAC Administrative Archive that provides a rich resource for 
further research into the origins and complex methodology of this 







The Avon Longitudinal Study of Parents and Children (ALSPAC) was part of a 
European consortium of longitudinal birth cohorts, designed by Jean Golding, 
who had extensive knowledge and experience of such studies from working on 
the previous UK national birth cohorts. It was an immensely ambitious study that 
uniquely included genetics in its methodology and was supported by a Steering 
Committee who believed, unlike many people, that Jean’s vision could be achieved. 
They also believed that it was vital for the Study to be beyond criticism not only 
scientifically, but also ethically, and promoted the novel concept of an ethics 
committee attached to the Study itself – the ALSPAC Ethics and Law Committee. To 
insist on such thorough and ongoing ethical review was exceptional at a time when 
research governance was minimal and ethical scrutiny not obligatory. ALSPAC’s 
frequent and detailed data collections from diverse sources (self-completion 
questionnaires, interviews, hands-on measurements, biological samples and 
environmental measures) provided a unique and complex resource for scientists 
of many disciplines but also created numerous ethical issues not encountered 
previously. It would be the Committee’s task to identify the principles and design 
the policies that would provide comprehensive protection of the Cohort throughout 
the Study.
The Avon Longitudinal Study of Parents and Children is known to 
the scientific community as ALSPAC and to the Study participants 
and public as ‘Children of the 90s’.1 ALSPAC was based in the UK 
city of Bristol and the surrounding area but was part of a multi-
centre European consortium (the European Study of Pregnancy 
and Childhood [ELSPAC]) (Golding, 1989a), which was initiated 
after a meeting in Moscow in 1985 convened by the World Health 
1
Organisation. Jean Golding was the initial Director of both ELSPAC 
and ALSPAC and brought with her a resolute belief in the value of 
longitudinal birth cohorts, based substantially on her previous work 
on the 1958 and 1970 UK national birth cohorts.2
The aims of ALSPAC were exceptionally ambitious: to identify the 
ways in which to optimise the health and development of children.3 
Not only were detailed and frequent data collections planned, but 
several innovative components were also included: to collect genetic 
data from the outset; to recruit women in pregnancy; and to collect 
data from both the mothers and their partners. George Davey Smith, 
Professor of Clinical Epidemiology, who took over from Jean Golding 
as Scientific Director of ALSPAC when she retired, has frequently 
talked about his first reaction to ALSPAC. In August 1989, he noticed 
a brief paragraph by Jean Golding in the back of the Lancet (Golding, 
1989b) describing ALSPAC and asking for potential collaborators to 
make contact. He considered the project an impossible undertaking, 
dismissed it out of hand and, not yet knowing Jean Golding personally, 
thought it sounded implausibly ambitious. If studying children was 
not ambitious enough, ALSPAC rapidly expanded to include adults 
and, to reflect this, in 1999, the meaning of the acronym ALSPAC 
was adapted from ‘Pregnancy and Childhood’ to the current ‘Parents 
and Children’.
From her experience with other longitudinal studies, Jean Golding 
knew of the difficulties of analysing and interpreting large longitudinal 
data sets that lack sufficient detail to obtain robust results. This, 
combined with a chance meeting in Athens in 1988 with Professor 
Marcus Pembrey (Overy et al, 2012, p 11), Professor of Paediatric 
Genetics at the Institute of Child Health in London, resulted in 
ALSPAC being designed to incorporate genetic data as well as the 
detailed and frequent physical, psychological, social, educational, 
environmental and biological measures originally planned. Marcus 
Pembrey reflected on the significance and context of this methodology 
when interviewed in 2013:
2
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“It was fairly clear that by 1988, it [the Human Genome Project4] 
was going to happen.… So, I knew that the big challenge – 
which no one really knew what the hell was going on – was 
these common diseases, the genetic component of asthma, 
allergy, diabetes, you name it.… It seemed a good plan.” (Marcus 
Pembrey, Oral History Interview, 2013)
A good plan indeed, also described as an “audacious plan”5 by the 
late Professor David Baum, the charismatic Head of the Department 
of Child Health at the University of Bristol at the time and a stalwart 
supporter of ALSPAC from the very beginning. David Baum was “a 
man who had a hundred ideas a day”, as described by his friend and 
colleague Dr Timothy Chambers, also interviewed in 2013, who 
went on to say:
“I don’t think David Baum had had a major focus on 
epidemiology … I think David came under the influence of 
Jean [Golding], quite rightly. David being David, once he was 
seized with something would then take the very big view … 
Jean had had the idea, it wouldn’t have taken much for David 
to be galvanised by it and to use his influence alongside hers to 
promote it.… Who could not be fired up with enthusiasm for 





The description of ALSPAC as audacious was baffling to Dr David 
Jewell, ALSPAC Ethics and Law Committee Chair from 2010 to 2013 
but a member of the Committee for 10 years previously, who admitted 
when interviewed that it took over a decade to understand why the 
Study could be considered audacious:
“I didn’t quite understand why [audacious], but it [ALSPAC] 
now seems both farsighted as well as everything else.… The 
genetics looked just about possible but a long way into the 
future and it now is becoming apparent that it has happened a 
lot quicker than anyone ever expected, so other studies now are 
trying to emulate what ALSPAC had built into its own ‘genes’ 
at the very beginning.” (David Jewell, Oral History Interview, 
2012)
The Study planned to enrol as many pregnant women as possible over 
a period of one year within the defined catchment area of three Avon 
Health Districts.6 Follow-up of these mothers, their Study children 
and their partners with detailed data collections was anticipated for 
at least seven years. As the Study progressed, so the design expanded. 
Over 14,000 mothers were recruited during 1990–92, a longer 
enrolment period than first anticipated, with data collected from 
five main sources: self-completion postal questionnaires; hands-on 
measurements; biological samples; third-party sources, such as hospital 
and educational records; and environmental monitoring, such as air 
quality. The longitudinal aspect of the Study became inestimable; 
seven years became lifelong and 650 of the children’s children have 
(as of August 2017) been recruited to a third-generational study. The 
mothers received four questionnaires during pregnancy and by the 
time Jean Golding retired, 80 different questionnaires had been sent 
to Study participants. These questionnaires could be up to 60 pages 
long. The hands-on measurements began with ‘Children in Focus’, 
involving approximately 1,400 children who attended research clinics, 
initially at the age of four months and then nine more times in their 
first five years. This expanded to annual half-day clinics for all Cohort 
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children from the age of seven to 13 years, with over 8,000 children 
seen at seven years and just over 6,000 at 13 years. Annual clinics 
overlapped as the Cohort comprised mothers whose births were due 
over a 21-month period. The collection of biological samples included 
placentas, blood, saliva, urine, hair, nails and teeth; DNA was extracted 
and cell lines eventually created, enabling infinite supplies of DNA. 
This has become a unique, internationally recognised resource used 
by thousands of collaborators from a multitude of disciplines.
There were no ethical committees in the UK specifically concerned 
with longitudinal studies at the time, despite the UK pioneering 
national birth cohorts in 1946, 1958 and 1970. So, in 1989, while 
ALSPAC was still being planned and piloted, the ALSPAC Steering 
Committee, which included David Baum, initiated an ethics advisory 
committee attached to the Study itself. As Elizabeth Mumford, lawyer 
and first Secretary of the ALSPAC Committee said:
“… it is ground-breaking that the founders of ALSPAC had this 
idea, not of submitting reluctantly to scrutiny, but actually asking 
for help and collaboration. That is the really outstanding thing 
about the beginning of this Committee: the sense that having 
an ethically ideal study was every bit as important as having a 
scientifically ideal study.” (History of ALSPAC c 1980–2000, 
Wellcome Witnesses to 20th Century Medicine, 2012, p 72)
This Committee had to grapple with the unfamiliar issues arising 
from not only an exceptionally long study (lifetimes in fact), but 
also enrolling participants in utero and the collection and utilisation 
of genetic data. Genetic issues had hardly been addressed previously 
in the context of population studies, in contrast to clinical genetics. 
There was little guidance: no other ethical committees within the 
University of Bristol (the University Ethics of Research Committee 
was only established in 2002), no academic department for ethics (the 
University Centre for Ethics in Medicine was established in 1998) 
and limited degrees of expertise or interest in the local National 
Health Service (NHS) Research Ethics Committees (LRECs). These 
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committees, based in each NHS Area Health Authority, were formally 
delegated the responsibility for ethical review of NHS research by 
the Department of Health, although guidelines making these NHS 
committees obligatory were not published until the year after the 
ALSPAC Committee was set up.7
The early years were taken up with formulating principles and 
establishing processes to ensure comprehensive protection of the 
ALSPAC participants. Consideration of the implications of enrolling 
participants from a local community was paramount. Not only would 
many of the participants know each other, but they might know some 
of the staff too. Quite a few ALSPAC staff were also participants, 
which complicated matters further. The guarantee of anonymity 
was essential to the Committee; a guarantee of mere confidentiality 
would not be adequate. Establishing participants’ trust in this respect 
was considered essential if attrition rates were to be kept low and data 
from questionnaires were to be credible. Yet, absolute and irreversible 
anonymity is not possible in a longitudinal study, not least because 
individuals’ data collected at sequential time points have to be linked. 
The Study participants were told ‘we shall be using two separate 
computers in this study, one to store personal identifiers and the other 
for survey results’.8 Computers were in their infancy; Jean Golding’s 
pre-computer ‘punchcards’ from her earlier epidemiological work 
were still to be found in her office and not just for historical interest. 
Innovative computing and administrative structures, now considered 
cumbersome, had to be designed by the ALSPAC Computing Manager 
to safeguard this guarantee as far as possible. This did not prevent the 
Committee having to reconsider this assurance time and time and 
time again when confronted by the real issues arising as the Study 
progressed, such as feedback to individuals of their test results or the 
protection of vulnerable children.
The Committee took into consideration not only the protection of 
Study participants, but also the protection of staff and of ALSPAC’s and 
the University’s reputation. The Committee rapidly became vital to the 
governance of ALSPAC as, in the early years, neither the University 
nor the LRECs had formalised their own governance procedures. As 
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Richard Ashcroft, Professor of Bioethics and one-time member of 
the Committee, said:
“… the Committee in my time were very clear about the need 
for ALSPAC not only to be ethically sound, but also to be seen 
to be ethically sound, and it took its advisory responsibilities 
very seriously. [Although] not involved in the day-to-day 
management … they are responsible if anything goes wrong.… 
When called upon to give advice about policy matters, it gave 
solid advice as far as I know and certainly hasn’t had any major 
[ethical] problems.” (Richard Ashcroft, Oral History Interview, 
2013)
To be ethically sound with no major calamities was quite a feat for 
such an audacious study. How much this was due to the solid advice 
of the ALSPAC Ethics and Law Committee is disputable, even among 
the Committee members themselves. However, Jean Golding remains 









Preliminaries and pioneers:  
framing the questions
The inspirational concept of an ethics and law committee attached to ALSPAC was 
initiated by a few key individuals at a time when there was a scarcity of guidelines 
and minimal formal governance and when research ethics committees were 
in their infancy. The appointment of lawyers as both Chair and Secretary to the 
Committee was crucial in providing sound legal advice for the pioneering work that 
was conducted without any framework for ethical practice in this type of genetic 
epidemiological research. Although the principle of anonymity was paramount, 
identifying the issues and formulating the questions to establish broader principles 
was necessary before policies could be established.
The ALSPAC Ethics and Law Committee was initiated in 1989 by the 
late Professor David Baum, founding member of the ALSPAC Steering 
Committee and, at the time, head of his newly established Institute 
of Child Health at the University of Bristol. The small ALSPAC 
Steering Committee (see Appendix 1) welcomed David Baum’s novel 
suggestion of an ethics committee attached to the Study itself. Included 
on the Steering Committee were two members of the Institute of 
Child Health in London: Catherine Peckham, Professor of Paediatric 
Epidemiology, who had a particular interest in, and experience of, 
working with birth cohort studies; and Marcus Pembrey, Professor of 
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Paediatric Genetics, whose vision for ALSPAC as a longitudinal genetic 
study cannot be underestimated. A population study that included 
studying the environmental and genetic interactions related to common 
diseases was entirely original.
All on the Steering Committee recognised that the genetic aspects 
of the Study in particular would have ethical implications that had 
not been considered in this context before. In the briefest of memos, 
‘Ethical considerations for the ALSPAC’ (see Figure 1), David Baum 
suggested that ALSPAC should have its own committee to ‘serve as 
guardians of the ethical principles’. Two principles were outlined:
Maintaining the absolute confidentiality of the data base and 
establishing the principle of non-attributability of the data to 
named families both now and in the future.
Similarly, establishing the absolute principle of non-attributability 
of the data relating to the mother and baby cell lines. (David 
Baum, memo, November 1989)
Although the inclusion of cell lines (used for the production of 
unlimited DNA) was an inspired and integral part of ALSPAC’s 
design, albeit raising significant ethical issues, it took until 1996 for 
Jean Golding and Marcus Pembrey to persuade any funders to support 
this aspect of the Study.
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So, the Ethics and Law Committee was established in April 1990, with 
Michael Furmston, Professor of Law at the University, as Chair, another 
lawyer, Elizabeth Mumford (née Roberts), a specialist in medical law, 
Figure 1: David Baum’s memo, November 1989
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as Secretary, plus a variety of experts from other disciplines (see Box 1) 
who were selected by Michael Furmston in consultation with David 
Baum. As Gordon Stirrat, Professor of Obstetrics and Gynaecology, 
a founding member of both the Steering and Ethics Committees, 
recalled “getting Michael involved was a stroke of genius because of 
his status and because of the fact he brought the law into it, which is 
so important. It was an ethics and law committee, wasn’t just an ethics 
committee”.1
It was another stroke of genius, but this time on Michael Furmston’s 
part, to get Elizabeth Mumford involved. As she explained, referring 
to herself:
“Michael was a brilliant lawyer and had an enormous range 
of knowledge but I think he thought it might be important 
to have somebody who had a particular interest and expertise 
in medical law and medical ethics. It was quite a new area of 
the law, which was rapidly developing at that point and still is, 
and I think he thought it interesting to have somebody who 
was probably fairly junior and who would go off and look up 
Michael Furmston
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the things that were necessary and fill in the details.” (Elizabeth 
Mumford, Oral History Interview, 2013)
Elizabeth Mumford, with her “good legal mind”, had done the 
Committee’s “groundwork” thoroughly, as related by Richard 
Ashcroft, the ethicist on the Committee at the time, who went on to 
describe the Committee’s approach to ethical issues:
“[The Committee was] not quite what I was used to in that it 
was legally driven, with both Michael Furmston and Elizabeth 
Mumford on the Committee … from the very beginning, with 
Alastair [Campbell, Professor of Medical Ethics] and myself only 
joining later … but it was quite different from a National Health 
Service ethics committee in that those committees tend to be 
very medically orientated and also were, and still are, advised 
not to think of themselves as giving legal advice. So, there were 
some quite important cultural differences.” (Richard Ashcroft, 
Oral History Interview, 2013)
As Richard Ashcroft inferred, there were cultural distinctions other 
than being legally driven, such as Study participants being included 
on the Committee and the Chair’s unique style. Although Michael 
Furmston’s expertise was in contract law, he was considered not only 
“wise”,2 but also a “wise choice”,3 generating much admiration and 
affection from many of the other Committee members. As Elizabeth 
Mumford described:
“… he is a man who is ‘larger than life’ in every way. He 
was twice dean of the Bristol law faculty, he was Pro Vice 
Chancellor, and eminent scholar in contract and commercial 
law, areas of law miles away from this one. He was a barrister, a 
practising barrister. He would lead the meetings in a style, which 
I suppose is reminiscent of the development of the common 
law, so he would do it by stories and anecdotes. Some of them 
were anecdotes about his own home life – quite a lot of them 
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were – but his home life was rather interesting as well. He had 
10 children plus about 22 dogs, and goats.… He was a postal 
chess champion. He was an expert on the American Civil War 
and on cricket.… But he was enthusiastic, he was warm, he was 
encouraging and he had a wonderful style of leading meetings. 
So, it made a very civilised, very enjoyable atmosphere in which 
to conduct some really very difficult business.”(History of 
ALSPAC c. 1980–2000, Wellcome Witnesses to 20th Century 
Medicine, 2012, p 74)
Box 1: ALSPAC Ethics and Law Committee: founding members
Professor Michael Furmston, Chair, Department of Law, University of Bristol
Professor David Baum, Institute of Child Health, University of Bristol
Professor Gordon Stirrat, Department of Obstetrics & Gynaecology, University of 
Bristol
Professor Peter Keen, Dean, Faculty of Medicine, University of Bristol
Professor Ursula King, Department of Theology, University of Bristol
Dr Iain Lister Cheese, Senior Medical Officer, Department of Health, London
Dr Timothy Chambers, Consultant Paediatrician, Southmead Hospital, Bristol
Mr David Hirschmann, Department of Philosophy, University of Bristol
Miss Elizabeth Roberts, Secretary, Department of Law, University of Bristol (to 
become Mrs Elizabeth Mumford in 1995)
Dr Jean Golding, Institute of Child Health, University of Bristol
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David Baum, Jean Golding and Gordon Stirrat were members of both 
the ALSPAC Steering Committee and the Ethics and Law Committee, 
and therefore provided a direct conduit between these Committees in 
the early years of ALSPAC when the complex practicalities of setting 
up the Study were being planned and implemented. As envisioned by 
David Baum, the Ethics and Law Committee was multidisciplinary. 
The range of expertise within the Committee allowed for a sound 
scientific grasp of most proposals by at least some members, who 
could then explain to the others if necessary. Jean Golding was always 
a vital source of information and scientific explanation too. In general, 
scientific review of projects was for the Scientific Advisory Committee, 
which had overall control of the projects that were undertaken. For this, 
they took advice from experts in the field, including other ALSPAC 
advisory committees, such as the Genetic Advisory Committee, thus 
securing the scientific integrity of the projects carried out. Although 
the Ethics and Law Committee tried not to review the science of 
proposals, they were inevitably concerned with their value as they 
had to balance this with the impact on participants in terms of time, 
inconvenience and risk. As David Jewell reflected when considering 
whether ethics committees should concern themselves with scientific 
review:
“… are the participants being asked to give up their time to 
answer a question that either has been answered already, or 
isn’t worth asking, or isn’t going to come to an answer because 
you are not going to get enough of them to participate? All of 
those are things [that] would be perfectly legitimate areas of 
concern for an ethics committee.” (David Jewell, Oral History 
Interview, 2012)
The input of Study participants to the Committee’s deliberations was of 
great importance. David Baum had suggested that participants should 
be on the Committee in 1989, but it was not until December 1994, 
when the Study children were between two and three years old, that 
the first Study mother (Mrs Sheila Bryer) joined the Committee. The 
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inclusion of Study mothers as “representative parents, able to reflect 
things that would actually bother other parents”,4 was incomprehensible 
to some other researchers who “even today [think] why on earth you 
could possibly want a lay person on the Committee?”.5 Yet, as another 
member of the Committee described, “This came through again and 
again, this was a shared enterprise: professionals, clinical professionals, 
health professional and lay people”.6
As Elizabeth Mumford (1999a) describes in her first paper on the 
Committee’s early work, there was little in English law relating to 
medical research and the guidance in international codes or from 
professional bodies was of little relevance to studies such as ALSPAC. 
Priorities when protecting human research subjects as stipulated by 
the Declaration of Helsinki (World Medical Association, 1964) are 
subtly different in epidemiology from those in clinical medicine. The 
guidelines of the Council for International Organizations of Medical 
Sciences (CIOMS, 1991), which did provide an ethical framework 
specifically for epidemiological research, were not published until 
after the Committee had been established. Therefore, the ALSPAC 
Committee’s pioneering work was conducted without a framework 
for ethical practice in this type of scientific research. The fundamental 
ethical policies were formulated mainly in the first few meetings of 
the Committee’s existence but evolved over many years as ethical 
issues arose and were brought before the Committee. This process 
was described by both Michael Furmston and Elizabeth Mumford as 
similar to the English legal system:
“The development of the rules was what I would regard as 
characteristic of English case law development, which [when] 
we had a particular problem, we kicked it around and came up 
with what we thought was the right solution.… And then if 
we got a similar problem, we would look back and see what 
we did last time and consider it in the light of that.” (Michael 
Furmston, Oral History Interview, 2012)
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“It was like our ‘constitution’, it’s not written but everyone 
knew … because there was a fairly high degree of consistency 
in the early days of Committee meetings, so we all knew we’d 
sat there, we’d gone through it, we’d come up with these 
conclusions and that’s what we referred to and when we started 
later on getting individual issues, so we said, ‘Well this is how 
we had discussed it, does it apply?’.… So, we couldn’t do this, 
wouldn’t do that, let’s refer to what we said, we’d go back to the 
minutes, go back to our own discussions, our own memories of 
our own discussions. So, it was like a constitution … We had 
this sort of loose structure, if you want to call it a ‘constitution’, 
and then we developed things incrementally so we didn’t look 
at … hypothetical cases, we looked at real cases and then we 
would build on those in the same way that the common law 
develops.” (Elizabeth Mumford, Oral History Interview, 2012)
Working without any relevant guidelines or formal governance 
structures in those early days, the Committee was not always consistent. 
Relying on the Committee members’ memories of ‘the rules’ rather 
than documenting policies was not foolproof, especially as the years 
rolled by and the Study became increasingly complex. It is difficult to 
discern if the lack of documentation was due to the ambiguous status 
of the Committee, which evolved from advisory to something more 
formal, or to the ad hoc nature of the Committee, which catalysed 
Tim Chambers’s resignation, as described in Chapter Two. Yet, some 
policies did appear in the minutes, such as the ones to protect the 
confidentiality of participants selected for sub-studies known as ‘the 
500 rule’7 (Mumford, 1999b). This rule was put in place to safeguard 
the anonymity of participants who were to be studied as part of 
subgroups selected on the basis of answers to questionnaires. It was 
decided that any subgroup identified for further study would have 
to be matched by at least an equal number of controls and that the 
total number would have to be at least 500. Other policies appeared 
in a variety of forms, including guidelines for specific groups of staff, 
such as interviewers visiting participants’ homes to help complete 
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questionnaires,8 or rules for data handling and processing.9 These 
seemingly haphazard arrangements were more robust than might 
be imagined and seemed to work well. The ethical principles, 
especially David Baum’s first principle of ‘non-attributability of the 
data to named families’ and the mechanism involved (known as the 
Ethical Divide, described in detail in Chapter Five) were part of the 
culture of all ALSPAC staff. As with the Ethics Committee, the low 
turnover (and initially relatively small number) of ALSPAC staff, 
who were renowned for their loyalty to Jean Golding and the Study, 
enabled the ethical principles and policies to be understood without 
formal documentation. This relaxed attitude to the crucial ethical 
underpinning of the Study would not be acceptable today and towards 
the end of Michael Furmston’s Chairmanship, policies began to be 
formally documented. At much the same time, the University also 
began to formalise their policies concerning the ethics of research.
Jean Golding, as Director of ALSPAC, attended, almost without 
exception, all the Committee meetings (up to 13 per year) in the first 
16 years (as did Michael Furmston) in order to provide information 
and listen to the Committee’s deliberations. When questioned about 
her role on the Committee by funding bodies and others, she was 
sometimes classified as an ‘observer’ or Michael Furmston was known 
to have said that she was not considered a ‘voting member’. This was 
hardly relevant as voting was never considered an appropriate way to 
make decisions during Michael Furmston’s 16 years as Chair. Her 
position on the Committee was crucial. It was taken on trust that she 
would bring to the Committee any relevant issues arising during the 
running of the Study, allowing the Committee to formulate consistent 
policies, even if not formally documented, on which the Study would 
continue. The Committee also took it on trust that not only she, but 
also the ALSPAC staff and collaborators, would act on the Committee’s 
advice. This did not always happen, as will be seen, but usually only 
due to error rather than conscious rebellion.
Most members of the Committee served for many years (see 
Appendix 2); some left when other work became onerous but returned 
to the Committee at a later date. The lengthy terms served were vital 
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to the culture and modus operandi. It enabled members to have a 
comprehensive grasp not only of what was asked of the participants, 
but also of the reasoning involved in constructing the ‘constitution’. 
It also contributed to the relaxed cohesion that developed within the 
Committee, allowing members’ discussions to be “formal but not 
hierarchical”,10 with conflicting views expressed without inhibitions. 
This longevity of service is frequently considered unacceptable now, 
with many bodies stipulating a limited term for membership or holding 
official committee positions such as chair or secretary, although the 
reasoning behind this remains obscure.
There was no formal training in ethics for Committee members 
in the first 16 years, which certainly surprised members of the 
Committee who joined later,11 although David Jewell explained that 
“It is not surprising in a way that other people weren’t able to say at 
the beginning ‘this is what we expect of you’ [as] it was only very 
slowly that I began to understand how the Committee worked”.12 
David Baum had tried to seek advice as early as May 1990, ‘particularly 
looking for problem areas which we may not as yet have addressed’,13 
when he approached Colin Normand, Chair of the British Paediatric 
Association Ethics Advisory Committee. Although Professor Normand 
indicated that his Committee ‘would be very interested to consider in 
a general way the implications of … longitudinal studies of this sort’, 
there is no evidence that this was taken any further.14 The University 
of Bristol Centre for Ethics in Medicine now provides training for 
NHS and University research ethics committees, as well as for other 
academic, health-care and legal professionals, using ALSPAC as an 
exemplar.15 The Centre was one of the first providers of such training 
courses in the UK but it was not established until 1998, many years after 
the ALSPAC Committee had been founded. This indicates the extent 
to which the Committee was exploring unfamiliar territory, having 
to formulate the appropriate questions to be asked and principles on 
which the Study should be run.
Terms of reference for the Committee were produced by Michael 
Furmston when pressed by Jean Golding’s successors at the very end 
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of his term as Chair. In contrast to the current 14-page document, 
he produced four brief items:
1. To consider the general principles which should govern the 
conduct of the study, in particular to formulate guidelines 
on the key questions of consent and confidentiality;
2. To keep this process under constant review;
3. To consider ethical and legal problems arising from the 
conduct of the study;
4. To consider other questions on which its advice is sought. 
(ALSPAC Ethics and Law Committee, ‘Terms of reference’, 
2006)
Despite this apparent administrative oversight, it seemed clear that 
protection of the participants in the broadest sense was the Committee’s 
paramount concern and, as David Baum had stated, ‘to serve as 
guardians of the ethical principles’. Perhaps not obvious to David Baum 
at the time, the Committee first had to identify the issues, formulate 
the pertinent questions and then establish the ethical principles.
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TWO
Informal or casual: an unusual style
Michael Furmston’s unusual style of conducting the meetings, with his warm 
informality and many entertaining and highly relevant anecdotes, did not detract 
from the Committee’s recognition of the importance of the work to be done. This 
generated a remarkable commitment in the Committee members, evident in the 
longevity of membership. With no terms of reference, defined status or formal 
documentation of policies (other than in the narrative minutes that detailed 
the essence of the discussions), the Committee today would not be considered 
acceptable, yet the calibre and conscientiousness of the members, with their 
considered contributions, produced effective governance and robust protection of 
the Study participants throughout.
The style of the ALSPAC Ethics and Law Committee under Michael 
Furmston’s leadership was particularly unusual, as recounted by 
those Committee members who had, in their professional capacities, 
considerable experience of university, National Health Service (NHS) 
or other committees. Michael Furmston himself remembers the 
meetings as being “not elaborately structured”, but with “serious, 
well-informed discussions” that were “interesting and intellectually 
demanding”.1 This was echoed by two founding members of the 
Committee, Tim Chambers, Consultant Paediatrician, who described 
the meetings as “immensely stimulating”,2 and Ian Lister Cheese, 
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Senior Medical Officer in the Department of Health, who pointed out 
“… the keenness, enthusiasm, the sense of duty and responsibility that 
all the members brought. There was that sense of something important 
to be done”.3 Richard Ashcroft remembered that “some of the 
discussions could be quite heated because difficult decisions were being 
made but it was always collegial”.4 The Committee’s modus operandi 
was set by Michael Furmston, who, as Jean Golding described, was 
“such a very warm, friendly, exciting and different personality that 
the whole Committee took on the role of being friendly and exciting 
and positive in its thinking”.5 Yet, his Chairmanship was:
“… deceptive, you could look at it and think ‘What on earth?’, 
it is all very informal and he’s not a very good Chairman, 
but actually, when you got into it, you saw his style was very 
authoritative, not authoritarian by any means, but he was 
absorbing everything, then, not the killer question, the critical 
question would come out.” (Tim Chambers, Oral History 
Interview, 2013)
David Jewell elaborated on this disarming technique:
“When Michael could see some glaring fallacy in what 
somebody [a visiting researcher or collaborator, not one of the 
Committee] was saying, he always used to say ‘Do you mind 
if I ask an idiot-boy question?’. And we [the Committee] 
learned by this stage that when he said this, he was going to say 
something completely devastating.” (David Jewell, Oral History 
Interview, 2012)
Michael Furmston’s anecdotal style was legendary too. As Elizabeth 
Mumford described:
“… he was like the common law, he was very anecdotal, he 
would say ‘Well this reminds me of such and such’ and if you 
were a busy person thinking ‘Oh please, get to the point’, you 
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might find this rather frustrating, but, actually, he would hone 
it down to the point. This story was there for a purpose.… 
He did it well but because it was this slightly roundabout way 
of coming at business, it could discourage some people, but I 
think it contributed to the friendliness of the Committee, and 
the fact we all felt comfortable with one another meant that 
we made better decisions.” (Elizabeth Mumford, Oral History 
Interview, 2013)
The “respectable sandwich lunch”6 may seem unimportant but it was 
thought that it contributed not only to people feeling comfortable, 
but also to people attending the meetings relatively consistently. Jean 
Golding recalled that “It was a committee people wanted to attend so 
it’s one of the few committees I’ve ever been on where the attendance 
was very high. We didn’t pay anybody. We provided a good lunch 
but that was it”.7
Richard Ashcroft, contrary to most others who emphasised the 
Committee’s informality, found his first few meetings:
“… quite intimidating actually, not in the sense that I wasn’t 
made welcome, because I was, but it was a quite formal 
committee, the personalities were quite formal, Jean is quite 
formal and Michael Furmston is quite formal, very lawyerly 
in an old-school way, quite charming when you get to know 
him but off-putting if you are not used to that sort of person 
and I wasn’t.” (Richard Ashcroft, Oral History Interview, 2013)
The Committee’s role as an advisory committee supporting Jean 
Golding was acknowledged by many, not least by Jean herself, although 
Elizabeth Mumford expressed some reservations:
“The feeling was we were friends sitting around the table. Jean 
was there. She was the Head of the Study, she wasn’t a member 
of the Committee, but she was there at all the meetings and the 
feeling was that we were helping her, that we were all working 
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together, maybe too much at times, maybe there was too much 
of a link and we felt that we were talking about us in the sense 
not as an ethics committee, but us in the sense of the Study. 
Maybe we should have been slightly more removed from it but 
I don’t think that blurred our judgement in any way.” (Elizabeth 
Mumford, Oral History Interview, 2013)
Perhaps what was not acknowledged or even noticed at that time was 
that although the male to female ratio in the Committee gradually 
became fairly even after the initial ratio of 7:3, the Committee was 
made up entirely of white, middle-class professionals. The feeling of 
‘friends sitting around a table’ might be due, in part, to the Committee 
comprising a broadly homogeneous group. David Baum’s vision of the 
Committee’s make-up was extensive but with no suggestion that it 
should be representative of the Cohort as such. He had suggested: ‘The 
appointment of a committee to represent the community’s views on 
the project as a whole.… Such committee to include representatives of 
certain groups: parents, community health councils, health, education 
and social services, and University representatives from the faculties 
of Law, Philosophy and Theology.’8
It took many years for these various groups to be represented on the 
Committee, and community health councils and social services never 
were. Minority ethnic groups were also not represented, but Bristol 
and the surrounding areas did not have large populations of minority 
ethnic groups. The 1991 UK Census reported that 4.1% of mothers 
with infants less than a year old described themselves as non-white 
(compared with 7.6% of mothers across the whole of the UK), with 
only 2.2% ALSPAC mothers described as such (Fraser et al, 2012).
Study participants
Despite David Baum’s far-sighted suggestion to include parents on 
the Committee when he initially outlined the composition of the 
Committee, Study mothers were only invited on to the Committee 
after four years and fathers not until 15 years after that, when they were 
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enrolled in their own right. Prior to this, data had been collected from 
partners only if mothers elected to pass on questionnaires to them. 
The mothers were selected at the suggestion of other Committee 
members who knew them and “thought this person would be good”.9 
Their importance and value was acknowledged by other Committee 
members and it seemed they integrated with few problems: “I 
remember how warmly they were welcomed and how comfortable 
it seemed to me they felt.… They were listened to and they didn’t 
generate resistance, we were of one mind”.10 Unfortunately, none 
were available for interview when Committee members were having 
their brief oral histories recorded, so the Study mothers’ recollections 
are not included here. Richard Ashcroft put into context their role 
as compared with NHS Research Ethics Committees, who also had 
lay members:
“So, in a typical ethics committee, you have lay members who 
are defined by being non-medical and non-university … whereas 
the parent members of the ALSPAC Committee had the direct 
experience of being involved … in this project.… So, in a way, 
they were more like representatives of the parent body and later 
of the children as well, where lay members on NHS Research 
Ethics Committees are not representative and they don’t have a 
specific relationship to any particular project…. In fact, if they 
did, it would be considered that they had a conflict of interests. 
So, there is an important difference actually. It was something I 
wondered about from time to time, whether the parent members 
… would be more interested in appearing knowledgeable and 
sensible to us than they would be in being good representative 
parents able to reflect the things that actually would bother 
other parents. I never saw a case where I thought ‘hang on a 
minute, you’ve crossed a line here, you are now one of us and 





The longevity of Committee members’ service and membership by 
invitation crucially contributed to the culture and functioning of the 
Committee, as Gordon Stirrat explained:
“The other quirky aspect of the Committee, which I don’t think 
would be allowed now … is the membership just persisted and 
persisted and persisted.… It wouldn’t be allowed today but, you 
see, when you had these people with their expertise and they 
became familiar with the Committee, it worked so well and the 
alternative of doing the bureaucratic thing of ‘Oh, we’ve got to 
change them every so often’, then some of that folk memory 
would be lost.… What we did … if we knew there was a need 
for someone else to come on to the Committee, we thought 
about it and approached people, we had some discussions and we 
invited people to come on. I don’t think we would be allowed 
to do that nowadays and, in some ways, that’s a shame because it 
worked well but, you see, no one trusts anyone to self-regulate 
nowadays.” (Gordon Stirrat, Oral History Interview, 2013)
Under Michael Furmston’s leadership, the endurance of membership, 
the friendliness and the lack of hierarchy enabled the Committee to 
create what one Committee member termed a ‘social ecosystem’, 
emphasising the power of such a system ‘as the whole [was] greater than 
the sum of its parts’. He went on to say ‘It was the relationship between 
longstanding members as individuals, beyond just their professional 
roles, which was so important … the relationship of the Committee 
to the institution(s) of which it was a part, especially being a vanguard 
in driving developments and the battles fought.’11
Despite, or because of, the anomalies of the Committee set-up, the 
Committee was judged to have worked well, albeit when judged by 
members of the Committee itself.
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Minutes
The Committee meeting minutes were also of an unusual style. 
Elizabeth Mumford, the first Committee Secretary and minute 
taker, had had experience taking minutes at “… an international 
committee and because there had been a room full of possibly almost 
100 delegates, all making points and all wanting their points to look 
good, I was fairly used to, not changing things, but certainly working 
things so they appeared in their best and clearest light on paper.”12 So, 
her minutes were, in her own words, “creative”, she would “fill in the 
gaps”, especially in relation to the law, and try to capture the sense of 
the discussion that would cover wide-ranging ethical issues. When 
the author took over as Secretary of the Committee, she took on this 
style of minutes. She soon discovered that the ‘irrelevant’ anecdotes, 
usually Michael Furmston’s, after meandering at length, would come 
right back to the point, as described previously, and so decided to 
take verbatim notes, which then took much time and effort to write 
up succinctly and coherently. As the Study became more and more 
complex, the author often referred to the previous minutes in her 
role as ALSPAC Ethics Manager. It was useful to be able to inform 
staff, collaborators or even Committee members how and why the 
Committee had come to their decisions and the development of their 
‘policies’ going right back to the beginning of the Study.
One Committee member spoke favourably of ‘the sense and 
narrative thread you [the author] bring to the minutes’13 when 
referring to the unusual style of minute taking, but they had not always 
been quite so appreciated. Tim Chambers cited the minutes, which 
tended not to be circulated in advance and were not formatted in the 
style usual for current research ethics committees, as one reason for 
his resignation after seven years on the Committee. His resignation 
letter to Jean Golding stated:
By this letter I am also tendering my resignation from the 
committee. My main reason is that the dates and venues of the 
meetings make it impossible for me to attend regularly.
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I have a subsidiary reason for resigning. The issues discussed 
by the committee are of the utmost importance and committee 
members have an accountability for the decisions of the group. I 
find that the ad hoc arrangements for the committee meetings, 
the variable punctuality and the haphazard minute taking are 
below the standards I have met in other ethics committees and 
I just wonder if they would bear scrutiny if they were held to 
account.
I apologise for writing in such a forthright way. It would 
probably have been better to speak to you in person and I 
will try to do so. Although I have headed this letter ‘Private 
& Confidential’ I have done so in order that you would see it 
first. I would be happy that its contents were divulged to other 
members of the committee if you thought it right.
I would like to wish ALSPAC the best for the future. It is an 
exciting and imaginative project. (Tim Chambers, letter to Jean 
Golding, June 1997)
When reflecting on this so many years later, Tim Chambers did not 
retract anything that he had written, but clarified that it was not 
the content of the minutes that concerned him, but that they were 
circulated on the day of the meeting, with a “sense that it was all rather 
cobbled together”.14 Elizabeth Mumford was quite open about how 
she usually wrote them on the day of the meeting but “hope[d] they 
were not misleading in any way. I put a lot of effort into them even 
if they were done at the last minute. It was high-intensity last-minute 
work”.15 Jean Golding expressed similar frustrations to Tim Chambers, 
“very often, I hadn’t taken appropriate notes during the meeting 
and needed [a] reminder as to what I should be doing, which wasn’t 
always there”.16 When the author became Committee Secretary, she 
frequently also only just managed to produce the minutes in time for 
the next meeting but would type up the ‘actions’ immediately after 
the meeting and thereby avoided Jean Golding’s exasperation.
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Despite Tim Chambers’s criticisms when he resigned, he expressed 
the feelings of many Committee members when he said that “It was 
fun, one sensed there were groundbreaking elements to it”, but he 
also described it as “an informal, rather agreeable club”.17 There 
were no terms of reference, formal rules for composition or rotation 
of membership; to a large extent, the effectiveness of the Committee 






Advisory to independent:  
a missed opportunity
The status of the Committee evolved over many years as the formalisation of the 
governance of medical research expanded locally, nationally and internationally. 
Whatever its official status, the Committee was unyielding in its determination 
to protect the Study participants and prevent the Study and University from 
disrepute. The necessity to submit ALSPAC studies to further ethical approvals 
from the local National Health Service (NHS) Research Ethics Committees (RECs), 
after the thorough and informed scrutiny of the ALSPAC Committee was debatable. 
The bureaucracy also became increasingly burdensome to many medical research 
studies, not just ALSPAC. When the ALSPAC Committee was registered as an 
Independent Review Board in the US, which provided internationally recognised 
independent status, dual approval by the NHS could have been revised. This 
would have been a sensible and timely change as it happened to coincide with 
the ALSPAC Committee being formally incorporated into the University of Bristol’s 
governance structure.
The ALSPAC Ethics and Law Committee’s initial status as an advisory 
committee to Jean Golding was confirmed by David Baum’s reassuring 
letter to the Chair of one of the NHS District Ethics Research 
Committees in January 1991, nine months after the establishment of 
the ALSPAC Committee:
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The ALSPAC Sub-Committee that advises on ethical and legal 
matters relating to the ALSPAC studies does not in any way serve 
as an alternative to the District Ethics Research Committee. It 
serves instead as a discussion group on the difficult and in many 
ways new problems that arise in relation to a study programme 
of the ALSPAC magnitude. (David Baum, letter to Denis Savage, 
January 1991)
The Government guidelines published only 10 days before this letter 
stated: ‘An LREC [Local Research Ethics Committee] must be 
consulted about any research proposal involving: NHS patients (i.e. 
subjects recruited by virtue of their past or present treatment by the 
NHS) … the use of, or potential access to, NHS premises or facilities.’1 
The recruitment procedure for some, but not all, ALSPAC participants 
did indeed involve the NHS, both staff and premises, as seen in Box 
2.2 Therefore, there was no question of the necessity of NHS Ethics 
Committees’ approvals at the beginning of the Study but continuing 
approval for research carried out by ALSPAC over the years was less 
clear. From the beginning, the ALSPAC Ethics and Law Committee 
provided thorough ethical scrutiny of ALSPAC as a whole, by lawyers 
and other appropriate professionals, while universities and the NHS 
took many years to establish effective governance, particularly for 
longitudinal epidemiological studies such as ALSPAC. Gordon Stirrat’s 
view was that “we should try to get away from putting things to the 
LRECs when it was possible. When we were not dealing directly with 
individuals as patients, we had no need to statutorily; therefore, we 
shouldn’t do so”.3 This view was shared by most of the Committee as 
not only did ALSPAC make no demands on NHS resources once it 
was up and running, but also many of the issues being considered by 
the ALSPAC Committee were of a non-medical nature and beyond 
the scope of the LRECs. As Elizabeth Mumford described:
“There was, I think, a slight sense of resentment that we had 
to go there [to the REC] as well as have our own [Ethics 
Committee]. The feeling was, ‘We are doing this, we are doing 
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this really well. Why should we have to send it away to somebody 
else who doesn’t know the Study as well, who is only looking at 
one little tiny piece of it?’.” (Elizabeth Mumford, Oral History 
Interview, 2013)
Box 2: Enrolment – ALSPAC protocol, seventh edition
Work prior to the start of enrolment in September 1990 had involved meetings with 
midwives and discussion with groups representing general practitioners as well as 
detailed discussion with obstetricians in the area. A variety of methods were used 
to engage the interest of eligible pregnant mothers:
• Posters were printed for display in a variety of different places – 
including chemist shops, libraries, mother and toddler groups, pre-school 
playgroups, general practitioner waiting-rooms, antenatal clinics and any 
other area where a mother was likely to be in early pregnancy.
• The poster displayed the logo of the study ‘Children of the Nineties’ and 
asked interested pregnant mothers to get in touch with the study team.
• ALSPAC staff approached eligible mothers when they attended for routine 
ultrasound examinations.
• The hospitals sent information [about the study] to the mothers with their 
booking information.
• The local community midwives when interviewing the mother for the first 
time discussed the study with her and gave her a card with which to send 
for further details.
• There was considerable local and national coverage in the press, radio 
and television.
• After delivery, ALSPAC staff approached eligible but non-enrolled mothers 
whilst they were in the maternity hospital.
Perhaps indicative of the informality of the Committee’s working 
processes, it was known by a variety of names throughout its existence: 
Ethics Committee4; Ethics and Law Advisory Committee5; Ethics 
and Law Sub-Committee6; Ethics and Law Committee7; and Law 
and Ethics Committee8. This appeared to be common practice; all 
three local NHS RECs referred to themselves differently at least twice 
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between 1990 and 1992.9 More recently, ALSPAC’s local REC has 
changed its name four times in four years10 – South West Central 
Bristol REC, South West 3 REC, North Somerset and South Bristol 
REC, and Central and South Bristol REC – but this is due to intense 
bureaucratic activity, quite the opposite of the informality of the early 
years of these committees.
After the first few meetings of the Committee, Jean Golding, 
not Michael Furmston, set the Committee agendas.11 The first 
meetings had been taken up with formulating the ground rules on 
confidentiality and consent, as proposed by Michael Furmston, but 
it was then necessary to respond to Jean Golding’s need for advice 
on the materials to be sent to participants. This included the initial 
information brochure and first questionnaires, one of which contained 
sensitive questions about sexual abuse in childhood. It made sense, 
as an advisory committee, for Jean Golding to set out the matters on 
which she needed advice. It was taken on trust that she would present 
the Committee with all relevant concerns and act on the advice given 
but, as Gordon Stirrat commented, “We wouldn’t have that trust 
nowadays, we wouldn’t be allowed to do that”.12 Similarly, Richard 
Ashcroft stated that “I don’t think it ever occurred to me that there 
would be something she would be keeping from us.… When you 





Jean Golding described how she set the agendas:
“Basically, I think I took everything … so things like new 
questionnaires were taken there, how we approached different 
aspects of contact with pregnant mothers, what we should 
do about refusals and the whole business of protection of the 
children was very important but also the protection of the 
Study from disrepute. So, all of that came into play, so I don’t 
think there was much I didn’t present to the Committee, which 
was why it was meeting so often.” (Jean Golding, Oral History 
Interview, 2012)
Protecting the Study from disrepute was integral to the Committee’s 
deliberations although rarely described in those terms. This was an 
important ethical matter as should the Study be publically declared or 
insinuated to be disreputable, participants would be likely to withdraw 
from the Study and the science would be devalued along with the data 
already contributed by all Study participants. Fewer participants would 
reduce the power of the statistical analyses as the vital longitudinal 
nature of the data from those participants would be limited. For the 
same reasons, the Committee took into consideration the likelihood 
of attrition rates being affected when reviewing aspects of the Study.
The initial advisory nature of the Committee was mentioned by 
nearly all the Committee members when interviewed: “We started as 
an informal, rather agreeable club helping Jean do her research” stated 
Tim Chambers when interviewed.14 Similarly, Michael Furmston 
thought that “It [ALSPAC] is a massive contribution she [Jean Golding] 
has made … everybody else was simply helping her really. Some of us 
helped quite well I think”.15 Richard Ashcroft elaborated:
“So, Jean definitely led but she wasn’t in the Chair and she was 
very clear about needing the advice of the Committee and 
wanting to get the best advice that she could get and she would 
respond to that advice positively. You never had a sense with 
her that she didn’t like the advice she was getting and she would 
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just go somewhere else until she got the advice she wanted. She 
took the Committee very seriously.” (Richard Ashcroft, Oral 
History Interview, 2013)
In 1997, the status of the Committee as advisory was once again 
confirmed when one member of the Committee raised the question 
of the relationship between the ALSPAC Committee and that of the 
LRECs. Was the Committee ultimately responsible for the ethical 
conduct of the Study, or had it responsibility as part of a chain, or 
was its responsibility merely to point out areas of concern, with final 
decision-making in the hands of the LRECs? That the question was 
asked at all indicates some confusion as to the status of the Committee. 
The Committee agreed that it was an advisory committee and that 
ultimate responsibility for decisions lay in the hands of the LRECs,16 
who seemed content at this time with the relatively informal system 
that had evolved and the ALSPAC updates that they received from 
Jean Golding.
For the LRECs to be considered to have ultimate responsibility for 
decisions was odd as they did not review the postal questionnaires, 
had only partial knowledge of the measurements that were carried out 
during the research (Children in Focus) clinics and, similarly, did not 
have comprehensive knowledge of all the other ALSPAC activities, 
such as home visits by the ‘interviewing team’ (for participants needing 
help with completing questionnaires). This lack of comprehensive 
review by the LRECs was of importance when considering ethical 
approvals of the many ALSPAC studies that involved secondary analysis 
only. ALSPAC was designed as a resource for the scientific community 
and encouraged local, national and international collaboration from 
‘scientists with bona fide projects of high scientific probity who have 
promised to abide by the study rules’.17 Many collaborators’ projects 
were concerned only with secondary analysis; they were not involved 
in the design or implementation of the data collection. The ALSPAC 
Ethics and Law Committee did not review these many requests to use 
data for secondary analyses as these were reviewed by the ALSPAC 
Scientific Advisory Committee, Genetics Advisory Committee or 
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other ALSPAC advisory committees. Michael Furmston, as Chair of 
the ALSPAC Ethics and Law Committee, provided a standard letter 
for these collaborators stating that the Committee had reviewed all 
primary data collections. This statement seemed to satisfy the funding 
bodies or whoever else needed evidence that the data had been 
ethically collected, stored and used. This assurance would not have 
been possible for the LRECs as they had not reviewed in detail all of 
ALSPAC’s many data collections.
Although the intention was for the ALSPAC Committee to review 
all primary data collections, a few sub-studies did not get ethical review. 
In February 1999, Jean Golding presented the Committee with an 
update of ALSPAC sub-studies.18 There were 18 sub-studies included 
on the list, of which the Committee had previously been informed of 
10. Many of these were not reviewed in detail and there were other 
sub-studies not included on the list of which the Committee were 
unaware. It appears that these were overlooked rather than the result 
of deliberate avoidance (as will be seen in Chapter Thirteen); ethical 
review was not, as yet, firmly established as part of the research process.
Many collaborators conducted sub-studies that did involve the 
collection of new or primary data. These studies recruited their 
participants through ALSPAC and not through the NHS and 
therefore did not conform to any of the stipulations requiring LREC 
approval. These new data would then be added to the ALSPAC 
database and become part of the main ALSPAC resource. Some 
sub-study collaborators had to gain ethical approval from their own 
institutions19 and queried the necessity to seek yet further approval 
from other probably less qualified committees such as the LRECs. Yet, 
other collaborating social scientists, including Richard Ashcroft, who 
resigned from the ALSPAC Committee due to a conflict of interest 
when he was about to conduct a study on participants’ perceptions 
of their ethical protection, believed that there was no statutory 
requirement to obtain ethical approval for social research projects 
(Kent et al, 2002). He and the other Study investigators nevertheless 
gained ethical approval from a local NHS REC as they felt that this 
was needed for the satisfactory protection of their participants.
36
PIONEERING ETHICS IN A LONGITUDINAL STUDY
Only one of ALSPAC’s many collaborators disputed the necessity for 
review by the ALSPAC Ethics and Law Committee. This collaborator 
questioned the ALSPAC Committee’s authority to decide whether 
analyses of cord blood could proceed as ethical approval had been 
obtained from the LREC. The LREC had confirmed that routine 
clinical specimens that would normally be discarded could be available 
for other usage as long as they were anonymised. This was not as 
stringent as ALSPAC’s guarantee to participants that no bio-sample 
analyses would take place without written consent. As the results of 
the laboratory analyses would eventually be linked to ALSPAC data, 
the Committee felt that the ALSPAC policy should apply even though 
the collaborator, who wanted these analyses conducted as a matter 
of urgency, was willing to wait for explicit consent before linkage 
took place.20
Institutional Review Board status
By 2002, the University of Bristol’s top-level Ethics of Research 
Committee had been established and this Committee’s oversight 
of the ALSPAC Ethics and Law Committee was confirmed when 
the ALSPAC Committee was registered as an Institutional Review 
Board (IRB) with the US Office of Human Research Protections.21 
Surprisingly, the registration took place without formal consultation 
with the Committee. One of ALSPAC’s collaborators thought that 
it would be useful as he was funded by an institution in the US and 
confirmation of IRB approval was necessary for this funding. This 
registration formally recognised the ability of the ALSPAC Committee 
to provide appropriate independent ethical review. This was useful for 
ALSPAC’s many collaborators from the US or others funded by US 
bodies, who frequently needed evidence that suitable review had taken 
place and IRB approval fulfilled the necessary official requirements. 
More importantly, this change in status for the ALSPAC Committee, 
now recognised as an independent committee and incorporated into 
the University’s governance structure, was a missed opportunity for 
the Committee. To be confirmed as an internationally recognised 
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independent committee and no longer merely advisory could have 
been the opportunity to discard the burdensome LREC approvals. 
Unfortunately, the Committee was not made aware of this change in 
status and therefore not able to consider the implications. Even if the 
ALSPAC Committee had recognised and taken this opportunity, it 
would have been a brief respite as in 2011, after Michael Furmston 
and Jean Golding had retired, the Department of Health stipulated 
that all studies involving the collection of bio-samples must have local 
NHS REC approval.22
The evolving importance and formalisation of the ethics of 
research, both within the university and in the NHS from 1990 when 
the Committee was set up, was bound to impact on the ALSPAC 
Ethics and Law Committee eventually. The opportunity to escape 
the increasingly bureaucratic LREC approvals, as detailed in the 
next chapter, was missed when its independent status as an IRB was 
authorised.
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FOUR
Bureaucratic battles: liaison with Local 
Research Ethics Committees
Any research that involved National Health Service (NHS) resources required 
Local Research Ethics Committee (LREC) approval but most of ALSPAC’s 
research had no impact on these resources. LREC approvals could have provided 
an extra level of protection for the Study participants but the LRECs seemed to 
be overwhelmed with the increasing amount of paperwork that they requested. 
It is well documented that their own bureaucratic processes became unethically 
onerous around the beginning of the millennium. At this time, ALSPAC was subject 
to untimely and inconsistent decisions by the LRECs, resulting in, for example, 
unnecessary (and costly) delays to the start of one clinic and prohibiting the use of 
genetic material from another. Throughout this period, the ALSPAC Ethics and Law 
Committee provided comprehensive ethical protection for the Study participants 
while endeavouring to negotiate a pragmatic working relationship with these local 
committees.
The ALSPAC catchment area covered three Distr ict Health 
Authorities, each with its own LREC: Bristol & Weston, Southmead 
and Frenchay. During the planning and piloting of ALSPAC, David 
Baum had written to the Chairs of these committees outlining the 
Study1 and this was followed by official application forms for ethical 
approval from Jean Golding.2 In those days (1989), the forms were 
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brief (two to four sides), designed with clinical trials in mind and 
mostly concerned with the use of drugs or radioactive materials. These 
LRECs gave their approval to the Study with only a few concerns: 
the use of NHS staff during recruitment and the sensitive handling of 
mothers who suffered stillbirths or miscarriages. They did request to see 
recruitment materials and questionnaires and wanted confirmation that 
the ALSPAC Ethics and Law Committee was an advisory committee 
only and not an alternative to the LRECs.
For many years, Jean Golding supplied the LRECs with considerable 
amounts of information without having to formally seek further ethical 
approval. During 1990, she sent the initial participant information 
sheets, letters and first questionnaires, followed in 1991 by 12 more 
questionnaires, including those to be sent to women who had 
miscarried, and the first ‘Children of the Nineties’ birthday card and 
newsletters. In 1992, a general update was sent informing the LRECs 
of: an extension to the enrolment dates; a list of bio-samples that would 
be analysed (only with written consent); the intention to look at 
medical records, including of the eligible mothers who had not enrolled 
(the latter not approved by one committee and abandoned); and the 
plan for a variety of sub-studies. Ethical approval of sub-studies was far 
from consistent. Some submitted their own separate applications to the 
LRECs but this was often only to one of the committees, for example, 
‘Indoor air pollution and lower respiratory illness in infancy’3 or ‘A 
population based study of neonatal cerebral ultrasound in the prediction 
of later impairment’4 (which was approved but not implemented as 
financial support was not forthcoming).
The application for the first ALSPAC research clinics, submitted 
to all three LRECs, entitled ‘Is screening for anaemia in the first two 
years of life worthwhile?’, contained the barest of details:
A 10% sample of the ALSPAC study will be asked to take part 
in this. They will be sent a letter which asked them to come 
to a clinic to be held at 6, 12 and 18 months of age. At the 
clinic the children will be given cognitive function tests, growth 
will be measured accurately and a 3-day dietary diary will be 
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administered to the mother. A heel prick will be used to take 
a small sample of blood from the baby provided the mother is 
happy with this. (Submission for ethical approval, Bristol and 
Weston LREC, April 1992)
This was the application for what was to become an exceptionally 
important ALSPAC sub-study, ‘Children in Focus’ (initially called 
‘The 10% club’). These children, numbering approximately 1,400, 
were invited to attend initially at the age of four months and then nine 
more times in their first five years. The measurements in these clinics 
ranged far wider than first envisaged in the infant anaemia study and 
included measurements of blood pressure, lung function, fitness, skin 
observations, allergy tests, dental observations and vision, hearing and 
language assessments, as well as environmental measures in the families’ 
homes and a parenting measure. These changes were not reviewed 
and approved by the LRECs prospectively.
Ethical approval from the LRECs continued to be informal and 
not entirely consistent for many years. Jean Golding regarded sending 
information about the Study as “a courtesy”.5 In 1993, she sent a report 
on the ‘Survey Development and Protocol’ with a covering letter that 
stated: ‘I trust that the study as set out in this document continues 
to meet with your approval’.6 Some extra information concerning 
change in blood-sampling methods was sent in 1994 and then similar 
survey reports were again sent in 1995 and 1997. Mostly, there was 
little response to these reports although there was considerable concern 
from the Chair of one committee about allergy (skin prick) tests at the 
final ‘Children in Focus’ clinic. Included in the correspondence about 
this issue was the request that a new proposal was submitted as it was in 
question ‘whether this additional test can be regarded as an extension 
of the original proposal to administer questions’.7 A proposal was duly 
submitted and approved ‘with the proviso that the information sheet 
states that you are looking at gene markers’.8 This was not the case 
and suggests that the LREC had not grasped the issues. The other 
two committees had no concerns, although the status of the approval 
was in question as the letter from one committee Secretary stated 
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that the Chair was ‘happy for you to continue the study in this way. 
If however you require formal approval, perhaps you would let me 
know’.9 Approval from the LRECs appeared to be optional; as Tim 
Chambers reflected, “they [the LRECs] were feeling their way”.10
The LRECs were aware that ALSPAC had its own ethics advisory 
committee as this was frequently mentioned in correspondence. It 
can be assumed that the LRECs were also aware of the nature of the 
work of the ALSPAC Committee, in that the Committee formulated 
ethical principles in the process of detailed and comprehensive review 
of all aspects of the Study.
By 1998, the planning for ‘Focus at 7’, the first half-day research 
clinic for all Study children (numbering over 8,000) was well underway. 
The ALSPAC Committee reviewed in detail the considerable number 
of relevant documents: protocols, invitation letters, participant 
information sheets, consent forms and so on. Policies such as 
divulging individual results were developed and clarified11 before a 
full application was subsequently submitted to the four LRECs (the 
original three had become four). This would be the case annually until 
2004, when the regulations changed allowing the necessity for only 
one LREC application. By this time, the relationship between the 
ALSPAC Committee and the LRECs had deteriorated. As Gordon 
Stirrat recalled:
“The relationship with the Local Research Ethics Committees, 
as they were, was really problematical and my recollection was 
that we decided, well, we probably didn’t need to go to them 
for most of the things.… But, regrettably, my view of the Local 
Research Ethics Committees was not high. I didn’t think the 
understanding, the quality of the people, some were good in 
their own fields but their understanding of ethics of research was 
partial … they really hadn’t a proper training.… They had no 
idea at all what was involved in an epidemiological longitudinal 
study.” (Gordon Stirrat, Oral History Interview, 2013)
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Towards the end of the 1990s, the work involved was substantial not 
only for the LREC members and administrators, but also for the 
NHS Trust Research and Development Departments, from whom 
approval was also necessary. One Trust required yet further review by a 
Paediatric Research & Development Peer Support Group. Considering 
the amount of work involved in reviewing aspects of the Study such 
as the research clinics, which had no impact on NHS resources, it is 
surprising that the LRECs were willing to undertake this work. In fact, 
for one LREC, it was quite the opposite; the review of an ALSPAC 
sub-study by another university’s Faculty Ethics Committee was not 
considered adequate and a formal LREC submission was requested.12
It is clear that any research that did involve NHS premises, staff or 
other resources required LREC approval but this was not the case 
for the vast majority of ALSPAC’s research. Apart from the expense 
involved in complying with the bureaucratic demands of LRECs, these 
demands were being questioned by many as being so extreme as to be 
unethical (Glasziou and Chalmers, 2004; Al-Shahi, 2005). The LRECs 
relevant to ALSPAC seemed to be overwhelmed with the paperwork. 
For example, on one occasion, there was baffling inconsistency of 
approvals by one LREC, which, when the discrepancy was pointed 
out, demonstrated determined inflexibility, as did the governing 
body, the Central Office for Research Ethics Committees (COREC). 
ALSPAC had submitted identical paperwork for the collection of blood 
samples from parents attending ALSPAC clinics with their children; 
one set of paperwork was submitted as an amendment to an already 
established clinic, the other as part of a new application for the next 
annual clinic. The paperwork for both submissions was reviewed at the 
same LREC meeting but, astonishingly, the amendment was approved 
with no ethical concerns while the same procedure for the new clinic 
was rejected. The reasons for the objection were equally baffling and 
showed little knowledge, not only of ALSPAC’s methodology, but 
also of their previous (or, in this case, simultaneous) approvals for 
identical procedures. The LREC members apparently felt ‘… that 
any proposed research involving this collection [of] DNA and Cell 
lines … should be subject to further ethical review by the Research 
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Ethics Committee’.13 This would mean that every new analysis of 
these samples would require a new submission to the LRECs. Jean 
Golding did not point out at this stage the inconsistency between 
approvals, but explained ALSPAC processes:
This request is not really feasible with this type of large, 
longitudinal, epidemiological study. Genotyping is carried out 
for certain collaborators, usually with a candidate gene in mind, 
after peer review and ethical approval from their institutions and 
the funding bodies. As with all data, secondary analyses will be 
conducted for years to come depending on developments and 
hypotheses generated within the scientific community. Some 
of the results of this analysis will be published, much won’t as it 
will not be relevant to the papers which are written. All analyses 
are only carried out after strict anonymisation (reversible as 
explained in the COREC form, Part B, Section 5) and we only 
allow analyses using genotype results by our own statisticians 
or occasionally on in-house stand-alone computers. We have 
been abstracting DNA from the cohort for seven years on this 
understanding with no objection from the cohort and with 
approval from the LRECs. (Letter to LREC Chair from Jean 
Golding, December 2004)
The restriction on this use of the ALSPAC genetic resource had 
severe consequences. While Jean Golding and Michael Furmston 
tried to persuade the LRECs to change their mind, taking blood from 
parents and children at this clinic had to be delayed. When it became 
obvious that the LREC would not see sense, ALSPAC agreed to their 
conditions so that they could collect and store blood and then attempt 
to overturn the decision at a later date. Eventually, after three years, 
the LREC decision was overturned with considerable effort from 
Professor George Davey Smith, who had, by then, succeeded Jean 
Golding as Director of ALSPAC.14
This was one of an extensive list of clashes with the LRECs that 
seemed to climax in 2004.15 It is not possible to determine how 
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Michael Furmston’s unusual approach was received by the Chair of 
an LREC at this time. One letter started ‘Let me speak in a frank and 
comradely fashion as Breznev said to Dubcek or vice versa’ but the 
substance of his correspondence was far from flippant, as can be seen.16
… the current process of gaining ethical approval from your 
committee does not accommodate the complexities of a large, 
well-established, longitudinal cohort such as ALSPAC. As you 
know, this will be the seventh annual ALSPAC clinic involving 
over one hundred staff and thousands of parents and children; 
we are obviously reluctant to postpone the start unless there are 
grave ethical concerns that need to be addressed.
He went on:
Let me come to the question of non-administrative amendments. 
You say in the fifth paragraph of your letter ‘The committee 
would like to express its concern that ALSPAC, with its wealth 
of research experience, appears reluctant to submit the relevant 
documentation for ethics approval, and we would welcome a 
commitment to do so in the future.’ Your committee must of 
course be aware that the ethical aspects of all these changes 
will continue to be considered by the ALSPAC Law & Ethics 
committee. It is not a question therefore of considering ethics 
approval but of how much paper we should send in your 
direction. It may well be that the members of your committee 
feel much more able to deal with the ethical problems than 
my committee but this view is not shared by my committee 
members. Of course, neither of us is wholly dispassionate in 
this respect. The problem I was trying to address in my previous 
letter was not so much ethics as timetable. Imagine the captain 
of a super-tanker who had to steer according to the guidance 
of your committee. What we wanted to do was to try to 
devise a working scheme, which would fit into the timetable 
requirements to which you are required to work.
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A further issue involved a sub-study that had already been reviewed 
and approved by the collaborators’ own institution as well as the 
ALSPAC Committee:
Much of the research being done by ALSPAC could be done 
by social scientists who would not go near your committee 
and would indeed be astonished that your committee members 
would have any particular expertise in the sort of work they are 
doing. If push comes to shove we may have to open up this can 
of worms but for the moment I am mindful of Pandora. As far 
as [this] … study is concerned, it has already been rigorously 
scrutinised by two committees and I was and still am anxious 
to avoid excessive delay and the generation of yet more paper.
As Gordon Stirrat related:
“Michael didn’t suffer fools gladly.… He went to see an Ethics 
Committee. I don’t think he helped by telling them exactly what 
he thought of them. Now, he had justification for doing so, but 
diplomatically it was not the thing to do and that caused a rift.”17
During the 1990s and 2000s, not only the understanding of the ethics 
of research, but also the processes involved to ensure the protection 
of research participants, underwent major developments. During this 
time, the LRECs’ requirements evolved from minimal retrospective 
information to demands for unmanageable quantities of documentation 
(both paper and electronic), resulting in untimely and inconsistent 
decisions. In parallel, the University was developing its own structures 
for understanding and dealing with ethical issues in research, although 
these did not impact on ALSPAC much during Jean Golding’s and 
Michael Furmston’s era. Throughout this period, the ALSPAC Ethics 
and Law Committee provided relative consistency and stability while 
trying to negotiate a pragmatic working relationship with the LRECs. 
It was almost certainly unique for the LRECs to have to accommodate 
46
PIONEERING ETHICS IN A LONGITUDINAL STUDY
the judgements of another better-qualified committee and, as Elizabeth 





Policy development:  
a case of case law
FIvE
Confidentiality and anonymity:  
a rod for their own backs
The guarantee to Study participants that their data would be anonymised, not just 
kept confidential, produced some highly innovative policies, such as the ‘Ethical 
Divide’. Although this enabled much of ALSPAC’s work to be carried out with robust 
protection of participants’ anonymity, issues continually arose requiring further 
thought and adjustment to the policies. Data access, especially issues of deductive 
disclosure and the misuse of data, were early concerns of the Committee. These 
became particularly problematic as time went on as there was increasing pressure 
by funding and government bodies to allow greater access to publicly funded data 
sets.
As David Baum stated when he first proposed an ALSPAC Ethics 
Committee, ‘establishing the absolute principle of non-attributability’1 
was considered of the utmost importance from the Study’s inception. 
Aspects of this principle and the wide-ranging implications for the 
infrastructure and running of the Study were discussed by the Committee 
throughout its existence. At the very first meeting in April 1990, Michael 
Furmston suggested that ‘Confidentiality’ was one of the two ‘general 
issues requiring most careful consideration’ by the Committee (the other 
being ‘Consent’). From this first discussion, the Committee returned 
to the theme time and time again, and strategies emerged. Participants’ 
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trust was considered essential if they were to answer questions honestly 
and supply the Study with sensitive information over many years. The 
importance of storing, processing and analysing data anonymously was 
considered of particular importance in a local study such as ALSPAC, 
where many staff knew participants personally and several staff were also 
members of the Cohort. Guarantees were made to the participants in the 
initial information leaflet that they were sent: ‘A very complicated set of 
procedures will ensure that no one will be able to link the information 
that you give us with your name’.2 In 1993, David Baum stated that 
this phrase ‘did not have to mean that it would be physically impossible 
to do so but could also indicate simply that no one would be allowed 
to do so’.3 However, even this interpretation of the guarantee could 
not be adhered to absolutely without hampering bona fide research, 
such as the selection of cases and controls for sub-studies. Although the 
leaflet had been reviewed and approved by the Committee, Elizabeth 
Mumford held that this phrase ‘came back again and again to haunt us’ 
(Overy et al, 2012, p 73) as it impacted on so many other ethical issues: 
child protection; the disclosure of individuals’ results; requests for help 
or other comments on questionnaires; and linkages to third-party data.
The ‘Ethical Divide’
Details concerning anonymity were available on request for Study 
participants in a letter (see Appendix 3), which described what came to 
be known by ALSPAC staff as the ‘Ethical Divide’. This was the process 
of keeping data anonymous. All ALSPAC staff were divided into two 
groups: ‘administrative’ staff and ‘research’ staff. The ‘administrative’ staff 
were allowed access to names and addresses, and for some teams, this had 
to include the limited data sets that they were collecting (for example 
data abstracted from hospital records or face-to-face measurements 
taken at the clinics) but they were unable to link to data sets from other 
sources. The ‘research’ staff, most of whom were statisticians, could link 
data sets from any sources but were prohibited from accessing names 
and addresses or other personal identifiers. Gordon Stirrat described 
this as the “golden rule: the policy by which we quarantined the data 
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so that those who were analysing it and those who were collecting 
it couldn’t contaminate one another”.4 This system, in itself, could 
not guarantee complete security as it was possible for someone with 
access to the research database to identify individuals with only a very 
few pieces of information if they wished to do so, for example, age of 
mother, number of children, occupation, type of housing or height. 
This is now known as ‘deductive disclosure’. All staff were required to 
sign a confidentiality form annually and every effort was made to embed 
a culture of absolute respect for the guarantees given to participants 
concerning their data but, ultimately, the prevention of deductive 
disclosure came down to the integrity of the staff. As time went on, 
collaborators or ALSPAC staff who both collected data and needed to 
analyse them using links to other data sets had to be accommodated. 
They were not allowed the central ALSPAC linkage number and were 
provided with only the specific data sets necessary for their research. 
There were also circumstances when it was necessary to cross the 
administration–research divide, not only when selecting participants 
for sub-studies from questionnaire answers, but also, for example, when 
identifying participants if they had withdrawn their consent for the use 
of their bio-samples. There were a limited number of named individuals 
permitted to do this, which, for many years, consisted of the ALSPAC 
computing manager and his assistant only.5
The ‘500 rule’
By 1991, a number of collaborators were interested in carrying out 
studies on particular subgroups of children, for example, children 
with severe speech impediments. Selection could be made from the 
mothers’ questionnaire answers but if the policy of not linking data 
to names was observed, further study of these individuals would not 
be possible. The Committee decided that controls should be selected 
and any fieldworkers meeting the Study participants would be blind 
to the individuals’ status (that is case or control).6 So, the policy on 
confidentiality began to evolve. In 1993, when the problem arose again, 
the Committee spent three meetings struggling with the issue,7 in 
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particular, the possibility of researchers being interested in a very small 
number of cases. This was when the ‘500 rule’ was established, which 
recommended that at least one control per case was selected with the 
total selected numbering at least 500; this arbitrary figure was considered 
adequate to protect confidentiality. In 1999, the (unwritten) rule was 
amended when a collaborator asked to conduct in-depth interviews 
with 300 girls (selected for high and low risk of engaging in anti-social 
behaviour). Conducting more than 300 interviews was not feasible 
due to limitations in funding. The Committee decided that the 500 
rule could be waived but only with specific project approval by the 
Committee. To waive an ethical rule due to financial considerations 
might be considered unprincipled but this was a pragmatic response that 
enabled the research to go ahead without, so the Committee believed, 
compromising the guarantee of anonymity given to the participants. 
It could be considered unethical to prevent important research being 
carried out by rigidly adhering to the arbitrary figure of 500. Other 
requests to waive ALSPAC’s ethical policies for financial reasons were 
not necessarily granted. One request that was denied was for the analysis 
of bio-samples without participant consent on the grounds that the 
enforced delay while consent was sought would threaten the job of a 
research assistant as there was not enough money to cover their salary.
Questionnaires
Prior to the first questionnaires being sent to participating mothers, 
the Committee discussed a variety of issues concerning young mothers 
(both under 16 and under 18), including:
… the practical matter of sending questionnaires to a home 
where it is possible that some or all family members are unaware 
of the girl’s pregnancy, or where the girl has not yet accepted 
the fact that she is pregnant or decided whether or not to keep 
the baby (both situations are prevalent among young mothers). 
(Appendix 4, ‘Young mothers’, by Elizabeth Mumford, 
submitted to Committee, November 1990)
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The Committee pragmatically suggested that all questionnaires should 
initially be sent in ‘innocuous-looking envelopes with no ALSPAC 
logo’.8
The guarantee not to link names with data again became an issue 
when participants added comments to their questionnaires anticipating 
a reply. ALSPAC’s solution to this was to ask participants to sign their 
comments if they wanted a reply. All self-completion questionnaires 
stated ‘N.B. Please remember we cannot reply to any comment 
unless you sign it’. In 2003, the Family Liaison Manger asked the 
Committee for clarification concerning unsigned comments on 
returned questionnaires. As documented in the minutes:
Linking of unsigned information to the study family was breaking 
the ALSPAC rules of confidentiality but in certain exceptional 
circumstances, e.g. ‘partner has died’, the information was 
acted on to make sure no further questionnaires were sent out. 
The committee agreed that common sense should be applied 
to information detailing change of circumstances. (Committee 
minutes, December 2003)
A protocol was drafted that was approved by the Committee at their 
next meeting.9 The wording on the back of the questionnaires was 
also changed very slightly at the recommendation of the Committee: 
‘Please remember we can’t reply to comments in this space unless you 
sign your full name’. As can be seen in Chapter Ten, this facet of the 
confidentiality guarantee created difficult decisions for the Committee, 
which spent much time over the years considering individual cases, 
which were not always resolved consistently.
Text data
In 2002, another related confidentiality issue came to the Committee’s 
attention: the processing of text data (that is hand-written comments) 
from self-completion questionnaires. These data (such as medications, 
types of accident, reasons for hospital admissions) were keyed into a 
53
CONFIDENTIALITY AND ANONYMITY
database without names attached. This did not necessarily make these 
data anonymous as dates or uncommon events made the data easily 
identifiable. It was recommended that names, places of residence and 
dates were removed, although the Committee allowed Jean Golding 
to use her judgement if collaborators needed to know, for example, 
places of residence in relation to certain diseases.10
Genetic data
Analysis of genetic data and the protection of participants’ anonymity 
was a concern that was resolved before ever being brought before the 
Committee. Genotyping was not carried out by ALSPAC as there 
were many laboratories, including commercial ones, better equipped 
to do this efficiently, which constantly updated their equipment and 
expertise as technology improved. Researchers receiving DNA for 
genotyping were required to return genotypes to ALSPAC for linkage 
to other data. They were not permitted to carry out further genotyping 
without permission from ALSPAC’s Genetic Advisory Committee and 
had to return remaining DNA once genotyping was complete. These 
genotypic data were returned to ALSPAC (very occasionally along 
with bio-sample residue) but, from the first analyses of genetic data in 
1997, were only linked to other ALSPAC data by ALSPAC statisticians 
who conducted the genetic analyses. Collaborators needing genetic 
analyses could either instruct the ALSPAC statisticians to do this or 
conduct the analyses themselves working on stand-alone machines 
within ALSPAC with the assistance of ALSPAC statisticians. This 
prevented them from being able to link to any other ALSPAC data 
sets without authorisation.
Data access
Access to ALSPAC data, even in anonymised form, was a concern for 
the Committee not just due to the risk of deductive disclosure, but 
also as it was considered possible for data to be misused if analysed and 
published irresponsibly, for example, if genes were analysed in relation to 
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race for political, not scientific, reasons. The Committee regarded it as 
their duty to prevent such misuse while recognising that it was vital that 
responsible collaborators were encouraged to access data and allowed to 
do so with the minimum of difficulties. Conditions for collaboration 
evolved from “gentlemanly guidelines”11 mostly concerned with the 
return of data to ALSPAC to more formal ‘Conditions for collaboration’ 
reviewed by the Committee in 1996.12 These covered: scientific 
approval; funding; ethical approval; additional data collection; data 
access and utilisation; publications; and accountability.
As time went on, there was increasing pressure by funding and 
government bodies to allow greater access to publicly funded data 
sets. Under close supervision by the Committee, who were concerned 
about breaches in anonymity and misuse of data, and after lengthy 
discussion in many meetings during 2005, ALSPAC deposited selected 
data sets with the UK Data Archive.13 This resource, supported by the 
Economic & Social Research Council, provides access for secondary 
analysis of large data sets to researchers and other academics mostly 
in the fields of economics and other social sciences.
The guarantee of anonymity was fundamental to ALSPAC’s design 
but it did generate complexities not anticipated at the beginning of 
the Study. The prevention of Study participants being identified by 
staff or collaborators was especially important in such a localised study. 
Irreversible anonymisation is not possible in longitudinal studies such 
as ALSPAC as the linking of sequential data from individuals is integral 
to the methodology. The highly innovative ‘Ethical Divide’ enabled 
much of ALSPAC’s work to be carried out with satisfactory protection 
of participants but issues arose repeatedly over the years, requiring 
further thought and adjustment to the policies. Constant vigilance was 
essential as this guarantee impacted on so many aspects of the Study, 
and the Committee had to spend much of its time finding solutions 




Informed consent:  
too much information
The complexities and practical considerations of aspects of consent (such as 
written, implied, informed, withdrawal, dual [parent and child], sole [child only] or 
assent) that covered all the many measures collected by ALSPAC, comprised much 
of the Committee’s workload throughout its existence. Of particular importance and 
originality, which was considered highly controversial at the time, was the strategy 
of ‘broad’ consent for the use of genetic material. This allowed for unspecified 
future research, not only on abstracted DNA, but also on ‘immortalised’ cell lines, 
which could be used to make more DNA far into the future. Participants’ trust in 
the investigators was recognised as crucial and, to this end, honest explanation of 
the research was necessary. Yet, too much information could be discouraging and 
balance in this respect was always the Committee’s aim.
The principle of informed consent was one of the fundamentals of the 
Ethics Committee’s ‘constitution’, as termed by Elizabeth Mumford. 
At the very first Committee meeting, Michael Furmston outlined 
what he felt were the central questions:
1. From whom should consent be sought? The mother? Her 
partner? Anyone else?
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2. To what should consent be given? General participation in 
the Study? The use of biological samples?
3. By what process should consent be obtained? ‘Opting in’ 
versus ‘opting out’. Will a written form suffice? How much 
explanation is necessary? (Committee minutes, April 1990)
From whom?
Mothers
Although the Committee’s minutes state ‘Naturally the mother should 
be asked to give consent to her own participation in the study’,1 
when the process of enrolment was described by Professor Golding 
at the same meeting, it was agreed that a consent form as such was 
not necessary:
Dr Golding explained that, as soon as a pregnancy became 
known to medical personnel, the doctor or midwife concerned 
would send the name of the pregnant woman to ALSPAC. A 
leaflet would then be sent to the mother, describing the project, 
and briefly stating what would take place (questionnaires, tissue 
samples). No actual ‘consent form’ was envisaged. Consent 
would be ‘implied’ if the parents did not specifically refuse to 
participate. (Committee minutes, May 1990)
It is doubtful that it would be acceptable now to enrol participants 
without written consent, although whether this would comprise a risk 
to patients is dubious. The return of self-completion questionnaires 
continues to be considered acceptable as ‘implied consent’. At that 
time, self-completion questionnaires and biological samples were the 
only suggested methods of data collection for ALSPAC, with written 




The Study design included mothers’ partners, whether they were the 
biological father or not, as Jean Golding recognised that their social 
influences were as important as the biological influences on the Study 
child. This was one of several unique features of ALSPAC. A leaflet 
circulated to potential funders and collaborators in 1989 outlining the 
Study stated that ‘it will be the first geographically-based population 
study involving the personalities, behaviour and attitudes of both 
mother and father’.2 The Committee therefore agreed that the partner 
would not necessarily be the putative father (that is assumed biological 
father), but be defined as ‘the person who was the mother’s partner at 
the time of first contact and to any subsequent partner who appeared 
during the course of the study’.3 This was an important decision, 
although it created some administrative complications as partners 
changed over time or questionnaires were written assuming partners 
were male when some partners were female. The mother was left to 
decide if she wanted her partner involved in the Study and the final 
version of the initial leaflet stated:
If you are living with a husband or partner, we would very much 
like to include them in the research. Partners can be an important 
influence on the health and development of a child. If you agree 
we will give you a questionnaire to pass on to him. His answers 
will, like yours, be confidential and he will be asked to return 
his questionnaire directly to us. The decision to include your 
partner in the study, however will be yours. (Initial information 
leaflet sent to participants)
Children
The children’s cooperation or assent for any procedure was always 
paramount but the Committee decided that from the age of 12, their 
signed consent for biological samples and certain other measurements 
was necessary along with parental consent. Although probably not 
58
PIONEERING ETHICS IN A LONGITUDINAL STUDY
legally binding, the Committee felt that this would provide a formal 
opportunity for the children not only to address any concerns they 
had to the researchers, but also to be informed of what would happen 
to their data.4 At 16 years old, sole consent from the Study child was 
considered acceptable by the Committee and although the law was not 
specific about young people with regards to research, this complied 
with the Family Law Reform Act 19695 as regards treatment: those 
who are 16 years old or above have the same legal ability to consent to 
any medical, surgical or dental treatment as anyone above 18, without 
consent from their parent or guardian.
Adults lacking capacity to consent
During the first year of the Committee meeting, adults considered by 
the Committee members to be lacking the capacity to consent due to 
‘mental handicap or mental or physical illness’ and ‘very young mothers 
who do not have the maturity to give consent’ were considered when 
Elizabeth Mumford presented a brief document outlining the legal 
position with these participants:
Presumably, it would still be of interest to have information 
about such women and this might be provided by their parents, 
guardians or other family members. The decision about whether 
a woman was capable of participating would ideally be made by 
the midwife/G.P. and following this, the questionnaires might be 
altered to eliminate those things which could not be answered 
by proxy (e.g. state of mind). (Appendix 4, ‘Young mothers’, by 
Elizabeth Mumford, submitted to Committee, November 1990)
The adaption of the questionnaires recommended by Elizabeth 
Mumford was endorsed by the Committee. The ALSPAC Family 
Liaison Team, known perhaps confusingly as ‘the interviewers’ for 
many years, who kept an ever-changing database of those participants 
who needed extra help or sensitive handling, administered the 
questionnaires. This would usually be by conducting a home visit 
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and either administering the questionnaires themselves or ensuring 
that the parents or guardians were comfortable in doing so, omitting 
inappropriate questions. It seems that it was simpler to keep this task 
within the Family Liaison Team without involving GPs or midwives.
To what and by what process?
Questionnaires and bio-samples
The Committee decided rapidly that if questionnaires were returned, 
whether by Study mother, partner or children (who started receiving 
their own postal questionnaires from the age of five), consent could 
be implied.6 In the early 1990s (before the introduction of the Human 
Tissue Act), there was no legal requirement to obtain informed consent 
to use biological samples from participants. However, the Committee 
were keen to ensure that bio-samples were only used with the consent 
of the mothers. The first bio-samples collected by ALSPAC were 
collected through the National Health Service (NHS) (for example 
antenatal blood, cord blood and placentas), with the NHS obtaining 
consent for therapeutic purposes only. The Committee were clear 
that this was not adequate for the non-therapeutic research purposes 
proposed by ALSPAC, so mothers were asked at a later date to sign a 
consent form to give ALSPAC permission to use them for research.7 
The first biological samples obtained by ALSPAC (not NHS) staff were 
taken at the Children in Focus clinics. Initially, these were heel-prick 
samples (at eight, 12 and 18 months old), but subsequently, venous 
blood samples were taken after the application of anaesthetic cream 
(EMLA cream). Consent from parents was recorded, although, in 
the early clinics, this was not in the format recommended nowadays. 
Nevertheless, ALSPAC was collecting consent from participants long 
before this became a legal requirement in 2006. The postal collection 
of the Cohort children’s milk teeth was taken as implied consent as 
parents would not have sent the teeth if they did not agree to their use.
Sampling of fathers’ blood was initially considered too sensitive 
to be acceptable because of potential paternity issues. The issue was 
discussed in the first year of the Committee’s existence at the request 
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of the Steering Committee (identified in the Ethics Committee 
minutes as the ‘Scientific Group’). Although there was ‘significant 
interest in assessing the genetic contribution of the child’s father’, both 
Committees expressed concern. The Ethics Committee minutes state:
There is a significant proportion (not less than 5% and probably 
between 10–30%) of fathers who raise children not biologically 
their own. Inevitably some men within that group are not 
aware that the child is not their own, others would be unwilling 
to share this information with anyone else, even as part of a 
confidential study. The mere fact of asking for paternal samples 
might be seen as threatening and could prompt some mothers 
to withdraw from the study altogether. Hence, the Committee 
agreed with the conclusion reached by the Scientific Group, 
that prudential consideration probably outweighed the scientific 
merit of the exercise. (Committee minutes, September 1990)
It was not until 1996 that this decision was overturned and the Ethics 
Committee agreed to the collection of partners’ saliva through the 
post for genetic studies as ‘there have been interesting findings lately 
about patterns of inheritance, suggesting that children inherit things 
differently from their mothers and their fathers’.8 The Committee 
thought that written consent would not be necessary ‘as there was no 
bodily intervention being carried out by study personnel’.9 Although 
this implied that there could therefore be no legal accusations of battery, 
it did not comply with the Committee’s previous insistence that written 
consent must be obtained before analysis of any bio-samples. Despite 
the Committee’s recommendation, others in ALSPAC took a more 
cautious view and written consent forms were included in the postal 
packs, making it quite clear that the samples were for genetic analyses. 
This very simple consent form was sent with a brief Question & 
Answer information sheet (see Boxes 3 and 4), which had been seen 
and approved by the Committee. This set a remarkable precedent for 
genetic research on population-based studies like ALSPAC as only very 
broad or ‘blanket consent’ was obtained. Any genetic analyses could 
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be conducted without informing the participants of the nature of the 
research and without obtaining further consent. Although this is now 
standard practice in genomic research, both at the time and for many 
years afterwards, it was considered controversial (Caulfield et al, 2003).
Box 3: Participant information sheet (partner’s mouthwash)
Some questions and answers
Q: I can understand why you want to study the genes of my child, but why of me 
and my partner?
A: You and your partner are also very important to the study because so little is 
known about the health and well-being of young men and women – and how to 
improve things for them in the future.
Q: Surely DNA is only used for looking at criminals or deciding who is the father 
of a child?
A: Well, that is certainly what hits the headlines and the DNA can be used for those 
purposes. That is not the aim of the study though. We are interested in your partner 
regardless of whether he is the father of the study child or not. Of course we are 
interested too in the DNA of those partners who are the fathers of the Children of 
the 90s, as we are interested in the ways in which abilities and healthiness are 
inherited.
Q: What are the most exciting questions that you think the DNA will help solve?
A: The whole question of asthma and allergies. We know that whole families can 
be affected, but other children, and their parents, can suddenly become allergic 
or develop asthma out of the blue. But why? Partly it is by contact with something 
like pets or air pollution, but many people are also in contact with these things and 
do not develop asthma. The secret lies in finding out what the protective genes are. 
Discovery of which the protective genes are may show us all how to stop asthma 
occurring.
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Box 4: Partner mouthwash consent form





I am happy to give this mouthwash to the Children of the Nineties in order for 
research to be carried out into the genetic causes of health and illness.
I understand that the results will never be linked to my name or that of any of my 
family.
Signed………………………………………..  Date………………….
1. FULL NAME (capital letters please)
………………………………………………………………………………………..
2. Your date of birth
1 9
3. Your relationship to the study child (please tick one)
Biological father  
Male partner  
Female partner  
Thank you so much
Please put this consent form in the return envelope with the mouthwash.
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INFORMED CONSENT
By 1999, the Committee reviewed a more extensive information sheet 
written by Marcus Pembrey for parents who wished to have more 
information about the genetic aspects of the Study,10 and by 2001, 
for the Focus at 9 clinics, information sheets were available for both 
children and parents.
How much explanation is necessary?
When the Committee met for only the second time in May 1990, 
another fundamental of Elizabeth Mumford’s ‘constitution’ was 
discussed. This concerned information for participants and the 
minutes state that the ‘educative process was the most crucial element 
in securing a balance between the study’s success in maximising both 
the number of participants and subsequent participant satisfaction’.11 
This may seem beyond the remit of the Committee but maximising 
participant numbers was crucial for the scientific validity of the Study. 
If numbers were not adequate, the data given by participants would be 
wasted and this would be unethical if avoidable. Participant satisfaction 
also needed to be considered when weighing up the risks and benefits 
of whatever the participants were being asked to do and could be 
considered a relevant judgement for the Committee. Although not 
explicitly stated at that meeting, the Participant Information Sheets 
(PIS) were also considered an integral part of the process of gaining 
informed consent. This was quite a new concept and beyond any 
legal requirement.
The Committee endeavoured to review every consent form and 
PIS before implementation; during the first 16 years, nearly 200 of 
these documents came to the Committee. Many aspects had to be 
considered, from the tone and readability (as the average reading age 
of the general population was well below that of the researchers who 
created the documents), to the amount of information given, with 
special attention as to the age of the participants. Separate information 
sheets were frequently produced for adults and children. Too much 
information was considered as detrimental as too little information. In 
a longitudinal study such as ALSPAC, there was an accumulation of 
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knowledge by the participants over many years and it was thought by 
the Committee that an excess of information could be discouraging.
Other aspects of consent
Although Michael Furmston and the Committee focused on consent 
for questionnaires and biological samples in the early Committee 
meetings, over the following years, other issues around consent took 
up much of the Committee’s time.
Withdrawal of consent
Withdrawal of consent had to be considered by the Committee from 
early on, although, as with other ALSPAC policies, it was not formally 
documented until long after Jean Golding had retired. In May 1992, 
the Committee were asked to consider:
Could the information collected before the women’s withdrawal 
from the study be used?… Mr Hirschmann pointed out that 
there might be two types of ‘drop-outs’; those who were simply 
tired of participating and those who regretted their choice to 
take part. Professor Furmston suggested that if there were any 
specific requests to have material collected in the past destroyed 
on withdrawal from the study, then such a request ought to be 
met. (Committee minutes, May 1992)
It is not clear if the ‘material’ referred to bio-samples or other data. 
Bio-samples could be and were on occasions destroyed but the 
withdrawal of information already processed, analysed and published 
was not possible. The following year, the Committee decided that:
… the onus was on the woman to indicate if the withdrawal was 
intended to be retrospective as well as prospective. However, 
as a matter of good practice all those who communicated their 
intention to withdraw personally should be asked whether it 
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was because of some specific incident or problem. (Committee 
minutes, August 1993)
It was not suggested that this personal contact would be an opportunity 
to establish if the withdrawal was for retrospective as well as prospective 
data, presumably because of the difficulties of withdrawing data from 
ALSPAC’s ‘built files’ (processed data, including summary statistics). 
By 2003, Michael Furmston decided that Study children ‘should not 
be able to opt out retrospectively; it was sufficient that consent had 
been obtained at the time’.12 Throughout Jean Golding’s and Michael 
Furmston’s time on the Committee, requests to withdraw from the 
Study were dealt with on a case-by-case basis by the Family Liaison 
Team, with very occasional referral to the Committee. The emphasis 
was always that ‘children wanting to withdraw from the study should 
not only be enthusiastically thanked for all they had done with emphasis 
on how important their contribution had been, but also given easy 
opportunities to re-join if and when they changed their minds’.13
Gift clause
In 2002, Jean Golding had asked ‘if a child wanted their samples to 
be destroyed was ALSPAC obliged to comply?’.14 Elizabeth Mumford 
thought that there was no clear answer as to who owned bio-
samples and it was suggested by another Committee member (John 
Henderson) that perhaps the bio-samples could be considered a gift 
to the researchers. This was not enacted upon at the time. It was not 
until a Local Research Ethics Committee (LREC) made the same 
suggestion that a clause was added to the bio-sample consent forms 
two years after it had first been suggested. This stated, ‘I understand 
that donated blood will be considered a gift but I will have the right 
to withdraw permission for analysis’. Analysis or testing of the sample 
itself could be prohibited and the sample destroyed but any results from 
the sample that had been used in previous analyses and publications 
could not be withdrawn.
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Proxy consent
As time went on, protocols had to be drawn up to cover obtaining 
consent from children arriving in clinics with adults other than 
parents or guardians (such as grandparents) or accompanied by other 
minors (such as older siblings), and, by 2003, when the children 
were approaching their teenage years, arriving by themselves. This 
had implications not only for consent, but also for chaperoning, as 
the Committee advised that any session involving physical contact 
(for example anthropometry, which included head, arm, waist and 
hip circumference measurements) should be chaperoned either by 
the parent or another member of staff. This was for the protection 
of both the child and the member of staff conducting the measures. 
The protocol tried to ensure that the process was as easy as possible 
for the parents without compromising the consent process. The 
consent forms and information sheets would be sent in advance to 
be signed by the parent or guardian, or another form was included 
giving the person who would be attending with the Study child the 
authority to sign on their behalf. If the Study child arrived without the 
relevant forms, there was a process to try to obtain verbal consent on 
the phone, which was witnessed by a second member of staff. If the 
parents could not be contacted, the tests were not carried out. There 
was some concern that staff were unable to be certain of the identity 
of the person they were talking to on the phone but it was pointed 
out that checks on identity were not made at the clinics either15 and 
no further stipulations were made.
Other consents
As the Study and technology developed, the Committee reviewed and 
approved other consent processes: photos of Study children could be 
included on the ALSPAC web site only with parental consent (and 
without surnames attached)16 and reminders of clinic visits could be 
sent by text to mobile phones or by email, again, only with parental 
consent.17 The Committee’s consideration of the issues involved 
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in obtaining informed consent was hugely time-consuming but 
surprisingly not because of the policy of broad consent for genetic 
material, controversial as it was or rapidly became as other studies 
started conducting similar genetic research. This aspect of consent was 
accepted within ALSPAC as sensible, pragmatic and ethical. Central 
to this was the Study participants’ trust in the Study investigators; the 
Committee had an acute awareness of this trust and an unwavering 
commitment to nurture it in the Cohort. It was the Committee’s wish 
to see all documentation for participants, especially consent forms 
and accompanying information sheets, that took up so much time 
as the Study became increasingly complex with substantial numbers 
of sub-studies built in. As recognised by others (O’Neill, 2003), the 
appropriate balance between too much and too little information 
had to be found.
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SEvEN
Child protection: an observational study?
The principle of non-intervention that was inherent in the design of ALSPAC was 
soon challenged as child protection and other individual concerns were raised. 
These concerns arose when Study families were visited at home, attended ALSPAC 
research clinics or imparted worrying information when answering questions in 
interviews or questionnaires. The Committee reviewed many cases individually, and 
from these genuine cases, pragmatic guidelines and protocols evolved.
The design criteria for the European Longitudinal Study of Pregnancy 
and Childhood (ELSPAC), the consortium to which ALSPAC 
belonged, stated: ‘The Study is observational and should aim to 
intervene as little as possible in the normal course of the pregnancy and 
childhood’.1 Absolute non-intervention was ethically problematic but 
many of the research questions that were to be asked were specifically 
included to establish if interventions were appropriate or necessary.
Family Liaison Team
Some guidelines on intervention were established rapidly in the first 
few months of ALSPAC’s instigation. The ALSPAC ‘interviewers’, later 
to be renamed the Family Liaison Team, visited participants’ homes to 
help with the completion of questionnaires and needed some guidance 
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if concerned about participants. Their instructions, almost certainly 
written by their manager, stated: ‘If you come across a situation that 
worries you, e.g. child abuse, report back to the office. It is not breaking 
confidentiality’.2 Presumably, this was not considered to be breaking 
confidentiality as the information remained within the Study team. 
These instructions were reviewed by the Committee, who expanded 
on confidentiality and stated that the interviewer should ‘report it to 
the office but not to anyone else (except of course in the case of an 
emergency when, for example, an ambulance may be immediately 
necessary)’.3 In further discussion, guidelines for Jean Golding (in 
other words, ‘the office’) were set out:
It was decided that certain problems ought to be referred … 
to Professor Baum or some other medical doctor connected to 
the study.… the study bore no responsibility to investigate or 
deal with many of the potential problems … property or drug-
related criminal activity, revelations about HIV infection.… 
Although such matters might cause concern, the importance 
of maintaining confidentiality was felt to override the desire to 
intervene. However … there were certain limited situations in 
which it would be wrong for the study to be held to a policy of 
non-intervention: for example, if a child were actually abused in 
the presence of the interviewer. The committee decided that it 
would not wish to provide a precise list of instances in which Dr 
Golding should pass on such information: she agreed to discuss 
sample cases with the group as they arose, in order that the policy 
might be reviewed. (Committee minutes, September 1990)
Two cases were duly brought to the Committee by Jean Golding in 
1995; in both cases, the Committee decided that the policy of non-
intervention was appropriate but this was not always to be the case. 
The first case in May 1995 was described in the minutes:
An interviewer had expressed concern about a child who 
demonstrated autistic-type behaviour and whose mother did not 
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acknowledge that there was any problem. She wondered whether 
someone ought to be notified especially if early intervention 
might improve the child’s prospects.
Professor Baum was of the opinion that early intervention 
might not make much difference; he added that the situation 
was not the same as that involving a life-threatening condition. 
Mr Hirschmann wondered whether the problem would be likely 
to be discovered anyway, for example by the child’s G.P. It was 
noted that ALSPAC itself does not have the mechanisms to help. 
Dr Chambers remarked that to notify the G.P. or health visitor 
would be to place the difficult burden on them of interfering 
when their assistance had not been sought. The general view was 
not to intervene; however, Mrs Bryer asked how the interviewers 
would react to such a decision. (Committee minutes, May 1995)
The answer to the question put by Mrs Bryer, the first Study mother 
to join the Committee, is not known, but only a few months later, 
a very similar concern from another of the interviewers was put to 
the Committee:
During a home visit to a three-year old child, one of the 
interviewers formed the impression that the child was 
developmentally delayed and wondered if the child might have a 
hearing problem. There was no indication from the mother that 
she had noticed any problems. In the absence of Professor Baum, 
Dr Emond was consulted. He thought that early intervention 
might be of some benefit to such a child and suggested that the 
health visitor be contacted.
The committee found this case similar to that reported in the 
minutes of 1 May 1995 and decided that the approach taken 
then ought to be applied here. ALSPAC’s policy in general is 
not to intervene; mothers should not be asked whether they 
have noticed problems detected by the interviewer. The Health 
Service ought to be examining this child in the ordinary course 
of events and problems would likely be detected at that point 
71
CHILD PROTECTION
(although Mr Hirschmann wondered how many children 
are actually seen at 3½.) It was also felt by the committee 
that interviewers needed to be briefed on ALSPAC’s policy. 
(Committee minutes, October 1995)
Research clinics
The procedure for staff concerned about children evolved and 
became more formalised with the establishment of the ‘Focus at 7’ 
research clinic, where up to 8,300 children were seen over a two-
year period. The Committee approved the following statement: ‘If 
a tester has serious concerns about a child’s health and safety, he/she 
will communicate with the clinic manager, the paediatrician in charge 
or study director in confidence and the issue may then be taken to 
an appropriate authority and/or the ALSPAC Ethics Committee to 
decide on action.’4  By the eight-year clinic, this was expanded further:
If abuse is suspected (sexual abuse or unacceptable physical 
force used against the child), the child will be told that the 
information may be passed on to someone who can help him 
or her. If the information given by the child is ambiguous, the 
member of staff will attempt to clarify what the child has said. 
After the session, the member of staff will write down … his 
or her concerns about the child, without using the child’s name 
or any other identifier.… The report without identifier will be 
passed to Professor Jean Golding, who will then consult with 
Dr Alan Emond as appropriate. If they decide to take it further, 
they will approach … [the] team leader for details which will 
identify the child. (Committee minutes, June 2000)
Alan Emond was a community paediatrician and close collaborator 
of ALSPAC, who decided that intervention was necessary on a 
few occasions and the parents and social workers were contacted. 
This illustrates, once again, how confidentiality was paramount 
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and participants’ identities were protected unless not doing so was 
considered absolutely necessary.
Psychologists’ sessions
By the 10-year clinic, a formal policy was reviewed and approved by 
the Committee5 but this proved inadequate for the types of disturbing 
problems that the staff were coming across in one particular clinic 
session. These sessions were conducted by ALSPAC psychologists 
and included questions on friendships and peer groups, bullying, 
antisocial activities and depression. Some concerns were presented 
to the Committee:
• A child being bullied at school, to and from school, 
including an attempted strangulation, who feels that the 
school is not doing anything to help them, and scored 
highly on the depression scale.
• A child disclosing that they do not have any friends, feeling 
very isolated, and do not feel they can talk to anyone at 
school when they are attacked and again scoring highly on 
the depression scale.
• A child with special needs, who presented themselves as 
rather immature who disclosed that their friends set fire 
to things and are encouraging them to take part, and that 
he intends to make a petrol gun and use it. (Committee 
papers, May 2002)
The staff were restricted to recommending that the child talks to a 
parent or teacher or phones Childline (a free 24-hour counselling 
service for children run by the National Society for the Prevention 
of Cruelty to Children). After considerable discussion and redrafting, 
the policy was extended and clarified to include a section specifically 
for the psychology team (see Box 5). This made clear that if the child 
requested help, their consent was needed for a member of staff to 
contact their parents before their school or any other body could be 
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approached. If this consent was not obtained and the staff member 
remained concerned that the child was at risk, the child would be 
told that someone else would have to be informed and the process of 
anonymous referral described earlier would be instigated.
Box 5: Section from the ALSPAC Child Protection Policy
The Psychology Team
• In the rare cases where the child may want to speak in more detail about 
their problems. Please say ‘I’m sorry I’m not able to help you now. But 
would you like us to ring somebody at home to talk about this?’
 ◊ If the child does request help it is vital that you find out who they 
want us to contact at home; mother, father, carer.
 ◊ Then clarify with the child that it would be ok for us to contact the 
nominated person.
 ◊ At the end of the session check again with the child that it is ok to 
contact their parents and ask them to let their parents know that 
someone from Children of the Nineties will phone them.
 ◊ If the child declines this help, explain that we cannot contact the 
school or anyone else without first informing their parents/carers.
• Skip any potentially upsetting parts of the session.
• If you have concerns that the child may be taking part in behaviours that 
may risk their health in the future, please pass this information on to 
the Head of Team, as with any concerns you may have over the child’s 
welfare. (Committee papers, July 2002)
The policy was reviewed regularly by the Committee with 
consideration to different concerns, such as self-harm or suicidal 
thoughts,6 psychotic symptoms7 or general unease by the staff over 
the level of intervention.8 ALSPAC’s non-interventionist position was 
observed unless there was evidence that a child was a serious danger 
to themselves or others.
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Questionnaires
Information that might cause concern from questionnaires was 
treated differently, although this was not included formally in a child 
protection policy until 2007. The Committee had decided in 2003 
that ‘ALSPAC did not have a duty of care should “alarming” answers 
be given’.9 The Child Protection Policy of 2007, co-authored by 
Elizabeth Mumford, stated:
Data from postal questionnaires and computerised questionnaires 
completed at the clinics may not be analysed for many years; 
it takes two years for a complete data set to be collected. 
Information from these sources, which may in other 
circumstances cause concern, is never used for any sort of 
intervention. (Child Protection Policy, July 2007)
Although clearly designed as an observational non-interventionist 
study, it was established from the very beginning that there were 
circumstances when intervention was necessary. The Committee 
were asked to consider the ethical implications of intervention or 
non-intervention time and time again over the years. During this 
time, ALSPAC policy formed, although it was not comprehensively 




Disclosure of individual results: foreseen 
feedback and incidental findings
The Committee’s general position of non-disclosure of individual participants’ 
results was soon challenged. On many occasions, they had to review matters 
concerning the discovery of treatable conditions either foreseen (such as anaemia 
when analysing blood for haemoglobin levels) or unexpected if something unusual 
was detected (such as a possible tumour), now known as an ‘incidental finding’. 
After extensive deliberations, their policy was eventually determined: before the 
disclosure of individual results, data must give clear, unequivocal evidence of 
an existing or future health problem, and the health problem identified must be 
amenable to treatment of proven benefit. Other cohort studies established since 
ALSPAC have not always come to the same conclusion.
The discovery of a treatable condition or disease can be ethically 
problematic for an observational study. This was acknowledged in 
the very first meeting of the ALSPAC Ethics and Law Committee in 
April 1990 when it considered:
Should ALSPAC practice be to always/sometimes/never notify 
them [participants] (e.g. if a treatable disease is discovered?) 
… one view would suggest an obligation to … inform [the 
participant] at once, [although] it was possible to argue that 
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chances were high that any such problem would already have 
been diagnosed in the ordinary clinical fashion. Problems were 
more likely to arise in the context of genetic abnormalities, 
where information gained from the study (and possibly otherwise 
unavailable to the participants) might be of assistance in deciding 
whether or not to have any more children. (Committee minutes, 
April 1990)
Although divulging individual results for a variety of tests was 
discussed at great length by the Committee on many occasions, genetic 
abnormalities were never discussed again. The Committee did review 
an information sheet in 1999 which ‘emphasised that no one would be 
given any results of the genetic tests, whatever they might be. ALSPAC 
was interested in populations rather than individuals and most of the 
tests being carried out were in areas that were at present insufficiently 
understood to provide any meaningful information on an individual 
level.’1  So, although the collection and utilisation of genetic data in 
the context of a population study was a research methodology not 
used before, the disclosure of individual genetic results took up little 
of the Committee’s time, unlike the many other non-genetic results.
Feedback of individuals’ results was also a concern for the Parents 
Advisory Group that met in May 1990.2 This parent group did not feel 
that non-intervention was justified on the grounds of confidentiality in 
the case of a significant medical problem and wanted assurance that the 
participant’s GP would be notified. The discovery of a ‘treatable disease’ 
was a near certainty with some common conditions such as anaemia 
when testing for haemoglobin levels, while other rare or unexpected 
conditions were possible but unlikely to be uncovered. An ALSPAC 
policy concerning the latter, now termed incidental findings, was not 
considered for some years; initially, the Committee had to decide on 
how to deal with predictable discoveries.
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Foreseen feedback
Within eight months of their first meeting, the Committee were asked 
by Jean Golding to decide if disclosure of results was an ethical necessity 
for an environmental sub-study that intended to measure a variety of 
indoor air pollutants. These measurements were being made in order 
to determine the impact on individuals’ health. The sub-study was 
funded by the Department of the Environment, whose usual practice 
was to disclose all results to participants when undertaking these 
types of studies. The Committee, when first discussing the sub-study, 
thought that the results should only be divulged if the pollutant levels 
were known to be dangerous.3 The Department of the Environment 
determined a threshold above which there should be intervention 
‘although we have no evidence to suggest that the level of the 
pollutant found in the home is detrimental to health, the level found 
was unusually high and it would therefore be prudent to investigate 
the cause and take steps to reduce the concentration of the pollutant 
e.g. by increasing ventilation.’4 The ALSPAC Committee approved 
disclosure above this threshold despite this being contradictory to 
their initial conclusion that the pollutant level must be known to 
be dangerous. A similar conclusion was reached when another sub-
study on radon was reviewed at around the same time. The National 
Radiological Protection Board, a non-departmental government body 
that conducted research and provided information, advice and services 
around radiological protection, had statutory thresholds for action to 
be taken. The Committee agreed that parents should be told if their 
homes had radon levels exceeding this threshold, ‘although there was 
some question about what the “danger level” actually was’.5
By 1994, the policy was clarified, as can be seen in a letter from 
Jean Golding to a collaborator interested in lead levels in children: 
‘… it is totally against the policy of the ALSPAC study to divulge 
results of any tests to mothers unless there is unequivocal evidence 
that without intervention, harm will come to the child’.6 In the UK, 
there was no screening or legal threshold for intervention, unlike in 
the US.7 The Committee discussed what parents should be told about 
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their children’s lead levels and decided, ‘… in keeping with previous 
decisions of this nature, to inform parents that they would be told if 
they had very high levels of lead, levels at which present knowledge 
would clearly indicate the importance of intervention’.8 The threshold 
was determined by the collaborator.
Several years later, in yet another sub-study, it was decided that 
the measurements of electromagnetic fields within homes should 
be disclosed on request despite the association with ill health being 
unknown. The collaborator attended the Committee, as documented 
in the minutes:
[The collaborator] was of the view that participants should be 
told their electric field measurements if they asked. There was, 
of course, the further issue of whether this information should 
be provided even if it was not requested. ([The collaborator] 
indicated that if his own house had a high rating, he would 
choose to have it re-wired.) Perhaps study participants should 
be given this option.
Professor Golding pointed out that it was the usual study 
policy not to provide results. The significance of various 
numbers and what their correlation might be to ill health was 
at present unknown. However, it was decided that there was 
no sufficiently strong ethical reason not to provide the actual 
numbers if requested to do so. The engineer might then add 
that the significance of the numbers was unknown. (Committee 
minutes, January 1998)
The various decisions to divulge results were not entirely consistent 
and did not always comply with the ALSPAC policy clearly defined 
by Jean Golding in 1994 that results should not be divulged unless 
there was ‘unequivocal evidence that without intervention, harm will 
come to the child’. Although the Committee was finding its way, it 
seems surprising that, particularly with environmental measures, they 
were persuaded to ignore their own policy on occasions.
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Another early decision to divulge results came after lengthy 
discussions by the Committee concerning a proposed sub-study that 
involved an ultrasound scan of the newborn baby’s head.9 The clinical 
significance of many brain irregularities was unclear but it was decided 
that ‘a list be made of abnormalities which could clearly be diagnosed 
and particularly of those where early intervention would be to the 
child’s benefit. In such cases, both medical staff and parents should be 
notified of the existence of the problem.’10  As the Committee had 
other concerns about this sub-study (the appropriate time to ask for 
consent and the response of the parents to the testing), a pilot study 
was suggested. This was duly conducted and the results reported to 
the Committee.11 Eventually, the sub-study was approved, including 
the limited disclosure of individual results, but the study was not 
implemented as financial support was not forthcoming. This decision 
to divulge results was consistent with the yet-undocumented policy 
as diagnosis and early intervention would be to the child’s benefit.
Low haemoglobin indicating anaemia was the first test result that the 
Committee agreed should be reported to the participant’s GP, although 
it was decided that it was preferable for ALSPAC not to make direct 
contact with the GP. Participants would be issued with letters to be 
given to their GPs if they so wished, a practice that was to become 
commonplace in ALSPAC when individual results were to be divulged. 
When the Committee was first informed of the sub-study ‘Is screening 
for anaemia in the first two years of life worthwhile?’, they rejected any 
intervention as it was thought that ‘… it would be more contrary to the 
spirit of ALSPAC if results were divulged to parents  especially when 
the precise medical significance of mild, but asymptomatic, anaemia 
was not known (and was in fact the question being investigated by the 
study).’12  A few months later, when the issue of infant anaemia was 
discussed again, the Committee reversed its decision. It was decided 
that low haemoglobin results should be disclosed if it would warrant 
further investigation in a clinical situation but also that care must 
be taken not to give the impression that a clinical service was being 
offered.13 This was an important point that was to be emphasised over 
and over again by the Committee over the coming years: participants 
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should not be given the impression that ALSPAC clinics provided 
a health check. Jean Golding, in consultation with Alan Emond, 
Community Paediatrician and ALSPAC collaborator, decided on the 
haemoglobin threshold warranting disclosure. During these discussions, 
there was concern that the blood would not be analysed until the end 
of the sub-study at least 18 months later (although, in fact, analysis 
of the blood immediately after sampling rapidly became possible). 
The delay to analyses for a variety of reasons, such as the ‘batching’ of 
laboratory tests, and the subsequent implications on the disclosure of 
results were discussed on occasion but no obvious solution was found.
The infant anaemia sub-study rapidly developed into the ‘Children in 
Focus’ sub-study, incorporating a much wider range of measurements. 
This 10% sample of the cohort children, numbering approximately 
1,400, were invited to attend a research clinic, initially at the age of 
four months and then nine more times in their first five years. Details 
of the measurements can be found on the ALSPAC website14 and a 
summary is given in Figure 2. Each measurement was considered by 
the Committee before the clinics began, to decide if results should be 
divulged. Expert collaborators were consulted to determine if there 
were clinically significant thresholds with effective available treatments. 
For example, if specific defects were found during the vision tests, 
immediate referral for treatment by the collaborating ophthalmologist 
was offered.15 In the unlikely event of very high plasma cholesterol 
levels indicating familial hypercholesterolemia being found, referral 
to the collaborating clinician was suggested16 but, in this case, the 
Committee decided not to intervene as treatment at this age was 
uncharted and such intervention was likely to cause unnecessary 
stress.17
Informing parents of their children’s blood pressure results was 
another early decision by the Committee that would conflict with 
the Study policy when eventually documented; specifically, results 
should not be divulged unless there is unequivocal evidence that 
without intervention, harm will come to the child. The information 
sheet reviewed by the Committee for the first Children in Focus clinic 
stated: ‘If we find that the blood pressure is unexpectedly high, we will 
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tell you about this so that you can seek appropriate medical advice’.18 
The threshold for such an intervention was established on the advice 
of an expert, which ‘fits in broadly with British Hypertension Society 
guidelines’19 and was based on mild hypertension in young adults. Six 
years later, when plans were being made to invite the whole cohort 
to the seven-year clinic, the Committee were made aware that there 
were no reliable norms for this age group and that ALSPAC would 
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be establishing baselines. Nevertheless, the Committee recommended 
that ‘the parent be advised to take their child to the G.P. for re-testing, 
explaining that there were a variety of reasons for elevated blood 
pressure, including anxiety’.20
Defective hearing, as with anaemia, was a test result that the 
Committee initially decided should not be revealed at the Children 
in Focus clinics but was later retracted. This was due to concerns 
expressed by both parents and clinic staff once the clinic was up and 
running. The Committee’s first discussion when informed of the 
proposed tests described the dilemma:
The study planned to look at the problem of otitis media with 
effusion. It was estimated that 30% of children would be found 
to be abnormal in the average winter screening. The aim of the 
study was to discover whether, over time, the treatment or non-
treatment of this condition would affect the linguistic ability of 
the child. There were two complicating factors: first treatment 
of all those discovered to have the condition would prevent the 
purpose of the study being fulfilled as there was no control group. 
However, in addition, there was some doubt about the efficacy 
of existing treatments. Furthermore, treatment is frequently 
not carried out until there have been several episodes of otitis 
media but those screening the children for the study would not 
know their past history. (Committee minutes, December 1991)
It was important that the treatment on offer was not fully evidence-
based and there were questions as to its efficacy; had it been known 
to be an effective treatment, withholding treatment would almost 
certainly have been considered unethical.
The matter was left unresolved until further discussion when 
the Children in Focus clinics were about to begin. The participant 
information sheets were reviewed and the Committee advised: ‘to 
make very clear … that some results … would not be reported back to 
the parents [as] some parents might otherwise be misled into thinking 
that their babies’ ears, etc. had been “checked” and found healthy’.21 
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Once the children were attending the clinic and the hearing tests were 
under way, the staff reported that: ‘More and more parents are putting 
pressure on the staff for hearing test results and are gradually getting 
more annoyed by the lack of response from us.’ 22 Some parents of 
children who had poor results from the hearing tests had been told by 
their health visitor that the child’s hearing was fine and any behavioural 
problems were due to something else. In one extreme case, the child 
was being recommended for a special school. In consultation with 
the paediatric audiologist who was collaborating with ALSPAC and 
advising on the hearing tests, it was decided to give parents the results 
of the hearing tests, including if the child’s hearing was within normal 
limits.23 By the seven-year clinic (when the frequency of temporary 
hearing loss due to glue ear is much reduced), the Committee was 
consulted and only those parents of children showing deficient hearing 
were given the results.24 The letters stated that their child’s hearing 
‘… was not within normal limits and advisable to have another test 
done. This will probably be done at school but if you have any concern 
please ask your G.P., school nurse or health visitor to refer your child 
to the Child Hearing Centre.’25
The confusion around the development of the policy for disclosing 
individual results was acknowledged by the Committee during the 
planning of the seven-year clinic when the Committee discussed which 
results should be revealed to parents:
It was decided that whatever our former policy had been in this 
area, it was open to us to review and change that policy. The 
committee chose to maintain the policy of giving test results (if 
available) to parents where there were ‘clear health implications’ 
involved. It was not necessary to limit this to situations where 
‘efficacious interventions’ might be possible. (Committee 
minutes, March 1998)
At this stage, the Committee again decided that it was not necessary 
to have ‘unequivocal evidence that without intervention, harm will 
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come to the child’, as stated by Jean Golding in 199426 and eventually 
incorporated into the documented policy.
Incidental findings
Incidental findings were discussed by the Committee on a number 
of occasions. The first, in 1998, was in relation to brain MRI scans 
proposed to be conducted on a subset of ALSPAC children at the 
Institute of Child Health in London. The minutes stated that:
It was the policy of the Institute of Child Health to contact 
parents in any case in which a problem was identified in a scan.… 
The committee were happy to uphold this policy. However, it 
was felt important to give parents proper advance notification. 
They ought to be told … of the (fairly remote) possibility that 
something abnormal might be detected and divulged to them. 
(Committee minutes, September 1998)
A few years later, a senior member of the clinic staff, prompted by a 
parent’s query, asked the Committee for guidelines should anything 
suspicious be noticed on a DXA scan:
J.G. showed the committee an example of the DXA scan of the 
skeleton and lungs that a child is given at the Focus at 9 clinic 
and asked the committee to consider the action that should be 
taken if something unusual should been seen, for example a 
tumour. J.H. identified two problems: i) a staff member, and ii) 
a parent, noticing something out of the ordinary. M.F. presented 
a further scenario: a parent contacts ALSPAC sometime after the 
clinic asking why we hadn’t noticed a particular abnormality. 
After some discussion it was decided that the parents should be 
informed that the clinic staff are not trained to spot abnormalities 
but if they did notice something odd or if the parents had 
concerns they should take the scan to their G.P. who would 
be able to follow it up if necessary. J.G. would draft a letter 
85
DISCLOSURE OF INDIVIDUAL RESULTS
to the G.P. to be given to the parents in those circumstances. 
(Committee minutes and draft letter, February 2001)
When a suspected tumour was seen on a DXA scan the following 
year, Jean Golding immediately showed the scan to the Community 
Paediatrician, who referred it to a consultant radiographer, who 
advised further referral to an oncologist.27 The parent and GP were 
also informed and when Jean Golding reported her actions to the 
Committee, they ‘commended the procedures and the speed with 
which they had been implemented’.28 At about the same time, another 
incidental finding (a raised white blood cell count, possibly indicating 
leukaemia) was referred to an expert, who thought that the result much 
more likely indicated the start of an infection, not leukaemia, and 
intervention was not advised.29 This approach of (anonymous) referrals 
to appropriate experts who then decided if intervention was necessary 
was eventually incorporated into (informal) policy by Jean Golding.
David Jewell reflected on the Disclosure of Results Policy that was 
eventually documented, though some time after Michael Furmston 
and Jean Golding had retired:
“What emerged from this was the need to have a general policy 
about disclosure of information from research. That policy … 
was written by Gordon Stirrat and we have since revised it and 
it has become very interesting because we have had numerous 
conversations since with other people involved in different 
studies where they struggle with the same issue and we worry, 
at least I worry, because we’ve taken a minimalist position, that 
the default which everybody has agreed in ALSPAC is that we 
should as a general rule not inform people of abnormal findings 
unless certain specific conditions are met, which is different 
from a general position which other people adopt, which is in 
general you would inform them.” (David Jewell, Oral History 
Interview, 2012)
86
PIONEERING ETHICS IN A LONGITUDINAL STUDY
ALSPAC was not, in fact, nearly as minimalistic as some other studies, 
such as UK Biobank (the large national longitudinal study set up in 
2006): ‘Apart from providing you with the results of some standard 
measurements made during [your] visit, none of your results will be 
given to you or your doctors (even if the results do not seem to be 
normal)’.30
The ALSPAC policy that was eventually drawn up31 was quite clear 
as to when individual results should be divulged, and included:
• that an item of data gives clear, unequivocal information of an 
existing or future health problem; and
• that the health problem identified is amenable to treatment of 
proven benefit.
It took many years, with some contradictory decisions, before the 
Committee could establish how it should come to consistent decisions 
on the disclosure of individual results that were not ‘contrary to the 
spirit of ALSPAC’.
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NINE
Disclosure of individual results: 
participants’ requests
On occasions, the Committee had to review requests for individual results from 
Study participants, clinicians and lawyers. They thought it prudent to review all 
such requests as it was for them to decide if, and under what circumstances, 
information should be disclosed and, in doing so, whether to break the guarantee 
to keep data anonymous. The risk of the guarantee of anonymity being broken 
was that this could soon become widely known in such a localised study and the 
vital trust of the participants in the investigators would be diminished. Despite 
considerable pressure at times to release results and with conflicting legal 
opinions, the Committee never felt that an individual’s circumstances warranted 
the disclosure of the information requested.
Over the years, the ALSPAC Ethics and Law Committee were asked 
to consider many issues relating to the disclosure of individual Study 
participants’ results. Other than the feedback decided in advance 
or the discovery of an unusual treatable condition, as described in 
chapter Eight, some participants (or lawyers or clinicians acting on 
their behalf) requested results to specific tests, such as the disclosure 
of paternity status.
The disclosure of individual results broke the guarantee of anonymity 
made to participants as names would necessarily have to be linked to 
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the results (apart from a few results that were obtained in participants’ 
presence and given to them on the spot, such as heights and weights) 
and the Committee was particularly reluctant to do this unless it 
was considered absolutely essential. At one time, the University’s 
Information Rights Officer suggested that any participant’s requests 
for individual data should be allowed. This suggestion was not made 
directly to ALSPAC, but was in answer to a question during a training 
seminar provided by the University Governance Team.1 Elizabeth 
Mumford (an expert on medical law) was consulted and felt that 
the Information Rights Officer’s suggestion was unsound and the 
Committee chose to ignore it. This is indicative of the tension that 
built up between the ALSPAC Committee and the higher levels of 
University Governance, which only became established long after the 
ALSPAC Committee had been in place.
Individual requests for data were dealt with on a case-by-case basis 
by the Committee. The first request for release of questionnaire data 
came from a solicitor representing an unmarried pregnant participant 
whose partner had died suddenly. She was anxious to ensure that 
he was declared the father of her unborn child. The partner had 
completed a questionnaire that included a question on paternity. After 
considered advice from Elizabeth Mumford (see Box 6), breaking the 
code was rejected.
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Box 6: Personal reflections (not formal legal opinion) of Elizabeth Mumford regarding 
release of questionnaire data (Letter to Jean Golding, November 1992, embargoed)
I see no reason why the solicitor should not formally be told by us that the father 
filled in an ALSPAC questionnaire. He might also be told that 98.?% of respondents 
answered the question about paternity in the affirmative. Both of these facts would 
provide additional supporting evidence. However, I would be reluctant to hand over 
the actual questionnaire.
1) Respecting the man’s confidences
There is certainly no reason to divulge the answers to any questions other than that 
about paternity. There is a 98% certainty that this man gave a positive answer to 
the paternity question. But if he did not, then I would be extremely unhappy about 
disclosing that very private admission to anyone, including the mother.
2) Preserving the integrity of the study
Once we have disclosed information in these albeit very sympathetic circumstances, 
then there is no way in which we can rely on the argument that the code is 
‘unbreakable’. We would have broken our promise to a participant and this would 
challenge our credibility in agreeing to respect confidences.
Conclusion
If the court deemed the answer to the paternity question essential to its decision, 
then it could direct the questionnaire to be produced under subpoena and we would 
of course be obliged to comply. (It must be added that courts are very reluctant to 
insist on the disclosure of confidential information in this way.) However, I suspect 
that the answer to the paternity question will be either (a) unnecessary or (b) 
inconclusive in any case. Hence, to break our code, just in case it might be of help, 
would seem unjustifiable.
Some participants occasionally requested access to their own completed 
questionnaires for a variety of reasons. One mother asked for access 
in order to provide documentary evidence in a court case in which 
she was alleging abuse of her child. The minutes stated:
90
PIONEERING ETHICS IN A LONGITUDINAL STUDY
… the Committee recognised that the information was ‘hers’, 
however, to offer her access to it was to acknowledge that the 
study could link questionnaires [to participants’ names].… the 
Committee recommended that the mother be sent a blank copy 
of the relevant questionnaire and be told that a system had been 
devised in order to make unwarranted access to information 
impossible; therefore we might not be able to retrieve the 
information for her.… it was to be pointed out to her that her 
own questionnaires were unlikely to add any support to her legal 
case. This it was hoped would dissuade her from further attempts 
to obtain her responses. (Committee minutes, September 1997)
Another request was made by a clinical psychologist on behalf of 
a Study mother. The results of her child’s psychological tests were 
requested as the child was possibly suffering from the effects of lead 
poisoning. The Committee again declined to disclose results (although 
they said that they would reconsider their decision if there were clinical 
reasons for releasing the data)2:
D.J. was unclear of the assurances that had been given to ALSPAC 
parents concerning confidentiality and thought that the parents 
might, although perhaps not in law, be entitled to access data. 
J.G. explained that although it was technically possible to link 
data, the parents had been assured that this would not happen. 
There may be rare circumstances when it would be necessary (if, 
for example, a blood sample showed the child had leukaemia). 
M.F. said that it was the task of this committee to decide if 
circumstances justified breaking confidentiality. He felt that 
this particular case did not warrant such action as the clinicians 
on the committee (J.H. & D.J.) felt it was unlikely to make 
any difference to the clinical management of the child. The 
committee did have to think in terms of justifying their decision 
in court although it was unlikely to come to that. M.F. thought 
a court would be likely to uphold the committee’s decision. 
(Committee minutes, February 2001)
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This was one of many occasions when the possibility of having to 
justify the Committee’s decision in court was mentioned. Michael 
Furmston and Elizabeth Mumford always had the utmost confidence 
that the Committee’s decisions would be upheld.
Further examples of requests for the disclosure of results, also 
declined, were for serial heights:
J.G. explained to the committee that the request was for two 
different types of data; i) heights from the self-completion 
questionnaires (data only fed back under exceptional 
circumstances and despite previous requests the committee as yet 
had not approved such action), and ii) Focus@7 measurements 
which had been fed back at the time. Both types of data would 
be difficult to retrieve and would involve breaking of ALSPAC’s 
self-imposed rules. M.F. thought the latter was a good reason to 
refuse the mother’s request and suggested J.G. explained that she 
had been guided by the ethics committee. D.J. thought it was 
unlikely to make any difference clinically if the exact heights 
and dates were known but suggested that the mother was told 
that the committee would review the request again if it came 
from a doctor. (Committee minutes, July 2001)
Yet another request again indicates how the Committee, although 
consistently determined to protect the data given to them in 
confidence, recognised the need to review each request on merit as 
there may be exceptional circumstances when confidentiality may 
have to be broken:
K.B. told the committee that a request had been received from 
a study mother … whose son is possibly suffering from cerebral 
palsy. She wanted to know her son’s Apgar scores (score which 
estimates the physical health of a child at birth). ALSPAC has 
abstracted this information from the medical records. The 
committee were sympathetic to the mother’s request but felt they 
should not set the precedent of revealing information abstracted 
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from medical records to parents or others. They suggested that 
J.G. replies to the mother explaining the committee’s position 
and suggesting the child’s neurologist writes to the hospital 
concerned, asking for the Apgar scores and any other relevant 
information. (Committee minutes, September 2003)
Jean Golding wrote to the Study mother as suggested and included the 
name of the hospital consultant and hospital contact details.
The ALSPAC Committee’s policy on the disclosure of results 
demonstrates the discord that evolved between the ALSPAC 
Committee and the University’s Ethics of Research Committee 
(ERC). This Committee was established in 2002, with some 
uncertainty initially as to the formal relationship between it and 
the ALSPAC Committee. Eventually, the governance structure was 
confirmed and the ALSPAC Committee was answerable to the ERC 
(through another committee – the Faculty Ethics Committee). As 
Gordon Stirrat recalled:
“They [the ERC] felt that there were things that we were 
deciding and then giving opinions on that we weren’t competent 
to decide … and more things should be passed up to them. 
The area in which we had the biggest dust-up with them was 
about providing results, individual results.… That caused quite 
a lot of problems because [the ERC] had lay members on the 
Committee, who were lawyers, who felt that, in this time of 
individualism and human rights, these data were owned by the 
individuals and therefore the individuals should have access to 
them.” (Gordon Stirrat, Oral History Interview, 2013)
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Despite this conflict of legal opinions and considerable pressure at times 
to release results, the ALSPAC Committee maintained its position 
as the preservation of the guarantee of anonymity was considered so 
crucial to ALSPAC. Nevertheless, the Committee also thought it right 
to review all such requests and decide if, and under what circumstances, 
the code should be broken. Frequently, after examining the requests, 
the Committee came to the conclusion that divulging the information 
requested would not affect the outcome that the participant was 
seeking. The Committee never had to justify their decision in court, 
but both Michael Furmston and Elizabeth Mumford were aware that 
this was a possibility and would have been prepared to do so.
Gordon Stirrat
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TEN
Participants’ problems:  
people not policies
Individuals’ problems that were brought to the Committee’s attention vividly 
illustrated the range of impacts that the Study had on participants but, more 
significantly, frequently brought up the issue of breaking ALSPAC’s guarantee 
of anonymity. There were some occasions when, for compassionate reasons, the 
Committee decided that the guarantee should be broken but there were risks 
in doing so. If it became widely known within the Cohort that the code would 
be broken on occasions, trust would be jeopardised. The participants’ carefully 
nurtured trust in the research team was critical. Lack of trust was likely to not only 
increase the attrition rate, but also produce less honest answers in questionnaires, 
thus jeopardising the scientific value of the Study. As the risks were different in 
each participant’s case, the Committee felt it essential to review each one on a 
case-by-case basis.
On occasions, the ALSPAC Ethics and Law Committee had to review 
individual participant issues unrelated to their data or test results, such 
as requests for help, complaints about the Study processes or concerns 
by field workers over participants’ mental state. The Committee’s 
deliberations over these individual cases made them aware of the 
range of impacts that the Study had on the lives of individuals, which 
were not always obvious. It became increasingly important for the 
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Committee to have this participant perspective and the Study mothers 
on the Committee were vital in this respect too. Once again, the 
guarantee made to Study participants in the initial information leaflet 
that ‘no one will be able to link the information that you give us with 
your name’1 caused the Committee considerable anguish, particularly 
concerning some individual requests for help. Although the leaflet had 
been reviewed and approved by the Committee, Elizabeth Mumford 
held that this phrase ‘came back again and again to haunt us’ (Overy 
et al, 2012, p 75), as stated in Chapter Five.
Requests for help
As ALSPAC was designed and conducted as an observational study 
with minimal interventions, any individual interventions had to 
be ethically compelling and approved by the Committee before 
implementation. ALSPAC had a responsibility to participants should 
they become distressed by aspects of participation in the Study, such 
as by asking potentially disturbing questions either in questionnaires 
or at face-to-face interviews, which may require intervention. 
Practices evolved to deal with such situations, for example, helpline 
Elizabeth Mumford
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numbers and information about relevant organisations were made 
easily and discreetly available at clinics or included at the end of postal 
questionnaires. Volunteers who manned the ALSPAC participant 
phone ‘hotline’ were trained to give out similar information. These 
arrangements were also used when direct requests for help were made 
that were not necessarily related to distress arising from participation 
in the Study.
The Committee could be rigid in their denial of help if it involved 
breaking the guarantee of anonymity. The rationale for this was that 
in a local population such as ALSPAC, it might become common 
knowledge that ALSPAC was prepared to break the code for a variety 
of reasons, including providing help. This might open the floodgates to 
requests for help but, more importantly, it might jeopardise participants’ 
trust in the researchers.
One request for help to complete questionnaires was made by a 
12-year-old sibling of a Study child, whose first language was not 
English. This was denied as she had made the request on a questionnaire 
but had signed only her first name.2 Although stated clearly on the 
questionnaire that a signature was necessary if a response was required, 
it seemed harsh to assume that a 12-year-old would understand 
ALSPAC’s requirement for a full signature.
On other occasions, the code was allowed to be broken. One 
Study mother had given consent for tests to be carried out on her 
placenta providing that the placenta was eventually returned to her. 
The Committee decided to allow the code to be broken in order to 
be able to identify the placenta and return the unused portion. This 
was despite, as documented in the minutes, ‘the concern that other 
participants, if they discovered that the code could be broken, might 
fear that the anonymity promised to them might be jeopardised’.3 On 
another occasion, a questionnaire was received with a signature on 
it but no text in the space provided. The participant had not signed 
any previous questionnaires, indicating that she did not think that a 
signature was required when completing the questionnaires. Within 
the questionnaire itself, she had indicated that she had been raped by 
her father. It was not clear to the Committee if the signature was a 
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mistake or she was asking for help. The Committee decided that she 
should be contacted asking if she had wanted a response. If this was 
the case, help could be offered in the usual way, such as supplying 
appropriate contact numbers to support agencies.4 To break the code 
when it was so unclear that help was being requested seemed somewhat 
inconsistent with the refusal of help for a young girl who had neglected 
to sign her full name.
Other requests for help were more direct; on one occasion, the 
Committee reviewed a letter that came to Jean Golding from a child 
(see Figure 3):
The committee felt that a letter should be written in reply 
which assumed that the parents would be likely to read it. The 
letter should explain that the tests carried out at clinics would 
not necessarily discover all health problems and that it would 
be appropriate for the child to be seen by her G.P. J.G. would 
suggest that the child showed the letter to her parents ‘in case 
they didn’t realise how worried she had been’. J.G. would also 
suggest that the child might be able to talk to someone else 
about her concerns (another relative, teacher, school nurse) and 
would include the Child Line telephone number. (Committee 
minutes, October 2000)
A letter was duly written and reviewed by the Committee, who 
considered it ‘an excellent response’.
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Another case was referred to Elizabeth Mumford by Jean Golding’s 
Personal Assistant, presumably for legal advice:
… whilst Jean was away, we had a call from a mother in the study 
(record of telephone call attached). Whilst this could have waited 
for JG’s return, their plight was featured on the local TV news 
earlier this week. Jean wondered if you could advise her on what 
to do. Apparently, this family escaped … [their homeland] a few 
years ago as political refugees. They are scared to return as the 
… authorities have videotape showing the parents taking part in 
demonstrations against the State. The Home Office want them 
Figure 3: Letter to Jean Golding from a Study Child
Dear Gean Golding, I visit Children of the ninetys every year now, and you have done 
all these tests and there is nothing rong with me but since a year ago I felt sick every 
day and I still feel sick today but my Mum and Dad does not believe me can you 




to go back saying that now there is a change of government it 
will be safe for them. However the parents argue that they will 
be detained and interrogated over their participation in these 
demos (as most of the changes are ‘cosmetic’ rather than real) and 
that the children will be taken away and put in orphanages. The 
mother said she would rather give her children up for adoption 
in the UK than end up in an orphanage…. They have 28 days 
to leave the country. The youngest child is 3 and one of the first 
babies born in the ALSPAC study. As you can see she wonders 
what effects the ‘deportation’ may have on him. I guess what 
she really wants is evidence that the move will have a negative 
effect on her son to use as ammunition against the Home Office 
ruling. (Letter to Elizabeth Mumford from Yazmin Iles-Caven, 
September 1994)
This is one of the more harrowing of participants’ stories but, 
unfortunately, there is no record of the advice given by Elizabeth 
Mumford or the response from Jean Golding.
Partner issues
The ALSPAC fathers or partners were not initially enrolled in their 
own right as they were contacted through the Study mothers. ALSPAC 
relied on the mothers to pass on the self-completion questionnaires 
to their partners but ALSPAC was unable to ascertain if this actually 
happened and were not able to send reminders. Although subsequently 
regarded as a family study, with many fathers formally enrolled and 
invited to clinics, during the first years of the Study, some fathers were 
not fully engaged, as is reflected in the response to questionnaires, 
which having initially been approximately 10,000, dropped to around 
3,650 by the time the children were 11. At this time, 7,500 Study 
mothers were responding to questionnaires. Some fathers were eager 
to participate but this could be difficult for partners who had separated 
from the Study mother and were living apart. It was ethically easier 
if the break-up was amicable and mothers continued to forward the 
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‘Partners’ Questionnaires’ and provide information about the child’s 
clinic visits but more difficult if the couple were antagonistic. By 
1997, the Committee was asked by Jean Golding to consider couples 
living apart. Until this time, contact had been through the mother but 
the Committee was asked to consider if this should change to reflect 
different family structures. They decided that the mothers should be 
asked through a newsletter article to supply the names (and presumably 
contact details) of their partners if separated, although a search through 
the archived newsletters could find no evidence that this had happened. 
This is not the only case when a Committee request for an article to 
be published in a newsletter did not materialise. The minutes record 
that, ‘As to fathers who had written in themselves, it was feared that 
to accept their offer to participate might run the risk of alienating 
the mothers if their permission was not sought first’.5 This proved to 
be true when, a few months later, the Committee were informed of 
‘the case of a father whose Study participant wife had left him and 
who had written in to ALSPAC asking to be sent questionnaires. A 
subsequent angry letter had been received from the wife, asking “How 
dare you think of involving him?”’.6
At another Committee meeting, it was reported that ‘one woman 
had requested that her husband not be told that the placenta had been 
taken to be used in the study’.7 This was not problematic as fathers were 
not normally informed of the retention of placentas, but it indicates 
the complexities of family dynamics, not always anticipated.
Abuse of clinic staff
Abuse of clinic staff was rare but did occasionally occur. An incident 
involving a Study father becoming abusive to ALSPAC clinic staff was 
documented by one of the staff involved: ‘Man entered office, stopped 
outside clinic room door. Looked in window. Called out “How much 
******* longer? Not hanging about much ******* longer.” Tried 
the door, locked. Shouted out “Don’t smile at me. I’ll slap your face.” 
Walked out of office towards reception.’8
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This incident resulted in changes to clinic procedures being drafted 
by the Clinic Manager:
• To exclude this family from further testing. [Named staff 
member] to draft a letter for them and circulate it to the 
rest of the group for comments. [Named collaborator] to 
be consulted before it is sent.
• Head of Security to be asked whether they or the police 
should be called for help if needed. (His response was that 
if the incident is serious enough to need the police anyway, 
or there is no immediate response from University Security, 
dial 999. Otherwise phone Security.) The Security number 
to be placed next to each phone.
• If the receptionist feels threatened by a parent she should 
quietly leave the reception area; the children are the 
responsibility of the parent who is with them. She should 
join the other member(s) of staff and seek help from them 
(and Security if necessary).
• A meeting of receptionists should be called to discuss the 
handling of any future such incidents.
• Reception staff to remind parents of the likely length of the 
test, and to make clear that both parents are welcome to be 
present. Tester to repeat this welcome to the father/partner.
• No other changes to be made to staffing or to home visits. 
These were discussed but no decisions made other than 
to think hard about other studies needing home visits. 
The general rule was reiterated – that the address to be 
visited and the estimated return time should be left with a 
responsible person who would raise the alarm if the tester 
failed to return.
• Those being required to do home visits need security 
training before they begin, using the experience, and 
imagination, of those who have already done them. 
(Incident Report by Clinic Manager, 1st April 1996)
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The document was seen by the Committee, who ‘felt it [the document] 
wholly appropriate’.9 It was not converted into a formalised policy, 
but it provided useful clinic guidelines.
Child’s death
Another dilemma that the Committee encountered came after a Study 
child’s death following an asthma attack aged nine. It was suggested 
to the Committee that it might be scientifically valuable to link the 
post-mortem results with the mass of longitudinal data that ALSPAC 
had collected on the child’s respiratory health and lung function. If 
something important was to emerge from such linkage and the results 
published, it would be extremely difficult to keep the identity of the 
child anonymous as such deaths are so rare. Linking an individual’s 
results in this way was not the usual ALSPAC policy and the Committee 
felt that it would weaken ALSPAC’s customary position. The chance 
of discovering a vital ‘key’ was considered minimal by the respiratory 
paediatrician who sat on the Committee and the linkage was not 
approved. Instead, it was suggested that a study looking at the factors 
associated with severe asthma could be carried out; if all asthmatics 
needing either intensive care or frequent hospital admissions were 
selected, then the deceased child’s identity could be concealed.10 This 
seemed an imaginative proposal for allowing something positive to 
come out of the tragedy but has not yet been implemented.
Miscarriage
The Committee had been made aware within their first year of meeting 
that researchers were interested in both the environmental conditions 
and psychological aftermath of miscarriage. They had reviewed 
letters to be sent to mothers who had miscarried,11 ensuring that 
they were written with sensitivity. Six months later, other researchers 
had proposed investigating electromagnetic forces possibly associated 
with miscarriage. Jean Golding informed the Committee that 95% of 
those who had suffered miscarriage were prepared to continue in the 
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Study.12 The Committee were then asked to consider an individual 
case: a participant had miscarried and her mother had contacted 
ALSPAC requesting no further contact. The Committee discussed if 
the daughter should be ‘asked her views on the matter’. It was decided 
that it would be best to contact the participant’s health visitor before 
contact was made.13 It is not known if this particular participant was 
contacted, but it illustrates the importance that the Committee gave 
to each individual participant’s involvement in the Study.
Guarantee of anonymity
Some of the individual issues that were brought to the Committee’s 
attention were straightforward requests for help that did not 
compromise the guarantee of anonymity, such as the child’s letter 
to Jean Golding or abusive behaviour in the clinic. Other requests, 
though, again brought up the issue of breaking the code and, with it, 
the Committee’s self-imposed rules. Michael Furmston believed ‘that 
it was the task of this committee to decide if circumstances justified 
breaking confidentiality’14 and Jean Golding therefore brought to the 
Committee any case that required this decision. There were some 
discrepancies in the Committee’s decisions, sometimes agreeing to 
break the guarantee of anonymity, albeit for compassionate reasons, 
and sometimes strictly sticking to the guarantee, however harsh. 
Consistency in this decision-making could perhaps have been achieved 
if there had been a more formal risk assessment should the guarantee 
of anonymity be broken. The fear was that if it became widely known 
within the Cohort that the code could be broken and under some 
circumstances would be, trust would be jeopardised. This was likely 
to both increase the attrition rate and produce less honest answers in 
the self-completion questionnaires. The risks of these outcomes were 
different in each participant’s case and a consistent assessment of risk 
with guidelines as to when the code should be broken might have 
prevented the Committee, as Elizabeth Mumford described, being 
haunted by the guarantee of anonymity.
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External databases: anonymous linkage
Linkage to external or third-party databases was an important aspect of ALSPAC’s 
methodology, but although consent on an opt-out basis was acceptable when 
ALSPAC began, this became inadequate over time as the ethical issues involved in 
medical research became more prominent and processes for more comprehensive 
protection of patients developed. This was exemplified by the creation by the 
Government of the Patients Information Advisory Group (PIAG), which could 
decide if National Health Service (NHS) records could be accessed by researchers 
without patients’ specific opt-in consent. Informed opt-in consent from ALSPAC 
participants for linkage to health, education and other third-party databases, as 
established now within ALSPAC, would perhaps have gone a long way to alleviating 
the ethical issues that challenged the Committee on a number of occasions.
Some ALSPAC statisticians linked ALSPAC data to publicly available 
databases, such as Indices of Multiple Deprivation (the deprivation 
level of the neighbourhood) or the proximity of power lines to homes. 
These linkages did not pose ethical problems as they did not require 
consent from the participants and were publicly available. Linkage 
to other third-party data was less straightforward and did require 
consideration by the Committee.
105
Health records
From the very beginning, health data were made available to ALSPAC 
from local NHS databases. Linkage to the ‘Child Health’ database 
(used extensively by Health Visitors) was integral to the methodology 
of ALSPAC and ethical approval was not considered necessary. As 
has been described previously, scrutiny by ethics committees was 
somewhat relaxed in 1990. The database was checked weekly and used 
to identify stillbirths and perinatal and infant deaths, thus preventing 
any inappropriate communications with recently bereaved mothers. 
Enrolled mothers who had delivered safely were sent congratulatory 
cards.
The database used by midwives was validated by ALSPAC against 
the paper records and proved to be both inaccurate and inadequate 
for ALSPAC purposes, so the paper records were used for abstracting 
obstetric data. Obtaining information from medical records was 
mentioned in two of the three initial applications to the Local Research 
Ethics Committees (LRECs): ‘Objective measures of child health (e.g. 
medical history) and development (e.g. HV [Health Visitor] screening) 
will be used wherever possible or appropriate. Data on specific medical 
problems will be ascertained from medical records’. On one of these 
two forms, an additional handwritten clause followed the typed text: 
‘after parental consent has been obtained’.1 The consent obtained 
was ‘opt-out’, which was quite accepted by the LRECs at the time; 
previously, much epidemiological research using health records gained 
no consent at all and participants were not aware that their records 
were being viewed. The wording giving ALSPAC participants the 
option to opt out was far from clear. The initial leaflet to participants 
concerning enrolment, which was reviewed and amended by the 
ALSPAC Committee, contained brief information concerning linkage 
to hospital and other health records:
We will know how your pregnancy progresses from the hospital 
records, and details of your baby and how he or she develops 
from the child health records. These will not give us enough 
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information on you and your baby though, and we will be 
sending you questionnaires asking for details. (Initial Participant 
Information Booklet)
On the following page, there was an option to opt out, although it 
was not clear that this applied to health records: ‘Unless you tell us 
that you definitely don’t want to take part, we will be sending you 
a questionnaire in a few days time. Other questionnaires will follow 
in the next few months’. This information giving Study mothers the 
option to opt out has been exaggerated by some over the years. The 
published ‘Cohort Profile’ of the ALSPAC mothers (Fraser et al, 2012) 
states: ‘The information sheets given to the women in pregnancy 
stated that data from medical records would be abstracted, unless she 
specifically indicated that she did not want this to occur’.
In 1992, the Committee were reminded of the opt-out consent 
when they considered (and rejected) accessing the medical records of 
women who had miscarried prior to joining the Study:
Some of the progress of study participants will be tracked 
through a study of their hospital records. Participants are told 
in the initial brochure that researchers will use such records as a 
source of information; thus it is presumed that if they agree to 
participate, they have consented to what would otherwise be a 
breach of confidence on the part of the hospital.
The question presently arising is whether ALSPAC may have 
access to the records of those women who miscarried prior 
to joining the study, particularly in order to examine the sort 
of help such women are given. It would seem insensitive to 
approach them at that time to ask explicit consent. However, 
the Committee was of the view that, as these women had done 
nothing to imply consent, to ask for their records would mean 




The Committee, including the two lawyers, seemed clear that a possible 
breach of confidence when accessing records would be on the part 
of the hospital, not ALSPAC, even if ‘induced’ by ALSPAC. As time 
went on, there was widespread and increasing concern nationally 
about consent (or lack of it) to access medical records for research 
purposes, which culminated in the formation of the PIAG by the 
Department of Health in 2001. This powerful Committee could 
authorise the common law duty of confidentiality to be set aside in 
specific circumstances for research purposes, specifically allowing NHS 
records to be accessed by researchers without patients’ consent. During 
its existence, PIAG created considerable difficulties for public health 
researchers and epidemiologists, for example, it took 18 months to 
obtain a decision from PIAG for one major research project within 
the same University department as ALSPAC (Department of Social 
Medicine). As stated by a departmental colleague when a description 
of this process was published in the Journal for Medical Ethics (Metcalfe 
et al, 2008): ‘Such delays pose near insurmountable difficulties to grant 
funded research, and in our case £560 000 of public and charitable 
money was spent on research staff while a large part of their work was 
prohibited until the third year of a three year grant.’
ALSPAC continued to collect data from medical records on the 
initial opt-out consent, without objection from the local maternity 
hospitals and without exemption from PIAG.
The team of ALSPAC staff, mostly nurses and/or midwives, who 
abstracted data from medical records was fully aware of the wording 
in the initial information leaflet. They were concerned that the 
information was somewhat misleading and that many ALSPAC 
mothers would not realise that their medical records were being, or 
had been, accessed by ALSPAC. The team felt strongly that it was 
unacceptable to access records if the women had withdrawn from 
the Study during pregnancy but not if they had withdrawn at a later 
date as, by this time, it was quite possible that their data could already 
have been abstracted. Surprisingly, even to the author, who was 
supervising this team at the time, this matter was not referred to the 
Ethics Committee. The data abstractors came to their own conclusion 
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regarding the ethics of their work and did not collect data from the 
medical records of those mothers who had refused in pregnancy.
In 1993, the Ethics Committee was asked to advise on another matter 
relating to medical records, which tied in with their deliberations 
concerning identifying mothers through their questionnaire data:
The committee was asked whether it would be acceptable to 
check doctor’s notes (e.g. about early bleeding in pregnancy) 
and to compare these with the mothers’ responses in the 
questionnaires. This was felt to be acceptable, as it involved 
putting information into the computer rather than taking it 
out. (Committee minutes, August 1993)
It is unclear from the minutes exactly what process was approved by 
the Committee but it is assumed that the linkage was carried out 
anonymously in accordance with the usual principles of the Ethical 
Divide, as described in Chapter Five.
Office for National Statistics
The Office for National Statistics (ONS), a non-ministerial government 
department, provided information to ALSPAC concerning mothers 
who developed cancer or who had died. ALSPAC had supplied a list of 
participating mothers to the ONS without referral to the Committee. 
This release of ALSPAC participants’ identities only became an issue 
later regarding linkage to education data. Consent from participants 
to access the data was not necessary until 2005, when the ONS asked 
ALSPAC to endeavour to obtain consent from the Study mothers. 
If participants did not reply, the ONS would supply ALSPAC with 
data under ‘Section 6o Support’. This was an exemption clause in the 
Health and Social Care Act allowing NHS data to be used without 
signed consent. The consent form was carefully worded to cover 
consent for both Study mothers and Study children ‘to follow up my 
health status and keep in touch with my child/children and me’. This 
form was approved by the Committee, who were impressed with the 
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breadth of the consent.2 The Committee encouraged broad consent, 
feeling that it was best not to overload participants with frequent 
requests if it could be avoided.
Education records
It appears that the Committee’s awareness of ALSPAC’s access to 
educational data, specifically school entry and Standard Assessment 
Tests (SAT) results from the National Pupil Database, happened quite 
arbitrarily. They knew ALSPAC collected data through schools as 
they had reviewed questionnaires sent to teachers and head teachers 
concerning various aspects of the school environment and ethos, as well 
as data on individual children.3 They only became aware of the other 
educational data sources when the Committee was asked to advise 
on the age that a child could give consent for linkage to educational 
records. Parents had been asked at the Focus at 7 clinic to consent to 
ALSPAC linking their child’s education records to ALSPAC data and 
one parent had refused to consent to linkage after the child reached 10 
years old unless their child had given consent themselves. The lawyers 
on the Committee advised that the law was unclear on this matter. It 
was also observed that the Data Protection Act 1998 was ‘confusing, 
particularly concerning epidemiology and public health’. Although 
‘there was a general agreement within the committee that it would 
be better to involve the children soon rather than leave it until they 
were older’,4 there does not seem to have been any further action on 
gaining consent from the children themselves. The Committee rather 
vaguely recommended that the children should be consulted at the 
Focus at 10 clinic some years away.
The following year, the Committee again discussed consent for 
linkage to educational records. Jean Golding explained that over 3,000 
Study families had not attended the Focus at 7 clinic and consent had 
therefore not been obtained. She suggested writing to these 3,000 
families to inform them that the educational data would be used unless 
they objected (opt-out consent). Most of the Committee felt that this 
was not adequate and it was suggested that the participants should be 
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written to in the first instance asking for signed consent. If they did 
not reply, they should be contacted by phone. The Chair asked that 
the Committee review the process again after these steps had been 
taken, by which time, the numbers involved, he presumed, would be 
considerably reduced.5 This advice was not acted upon immediately 
and after a further nine months, another issue concerning these data 
emerged. This time, it was the ALSPAC statisticians who felt that the 
wording of the consent form was vague and they were uncertain how 
they could use these data.
This exemplifies the way in which ALSPAC operated at its best: staff 
anxieties about ethical issues were taken seriously and the issues were 
brought to the attention of the Committee. In this instance, it meant 
that the consent form was viewed by the Committee, who, surprised 
that it had been approved, asked to see the minutes of the meeting 
that had dealt with the consent form and any supporting papers.6 
These did not materialise as the Committee had not been asked to 
review the form. At the time the Focus at 7 clinic was set up, ethical 
review of such paperwork had regrettably not become embedded in 
the ALSPAC clinic procedures. The consent form was confusing and 
would almost certainly have been amended had the Committee seen 
it before it was put into use. Not only did it serve a dual purpose – (1) 
consent for linkage to educational records and (2) consent for linkage 
to medical records – but it also contained a phrase unlikely to have 
been approved by the Committee: ‘This permission will remain valid 
until my child becomes 16’. Some Committee members thought that 
the wording of the form implied that consent was being asked for any 
medical record that the school held (see Box 7).
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Box 7: Focus at 7 consent for health and educational records presented to the 
Committee in March 2003
Consent
FOCUS AT 7
I understand that the Children of the 90s study may be contacting
a) my child’s school, and
b) may look at his/her medical records.
(delete if either not applicable)
I understand that any information will be kept in the strictest confidence, and will 
be used only for producing statistical information. This permission will remain valid 
until my child becomes 16.
If I should change my mind at any point I will be free to do so.
Signed……………………………………………… Date ………………….
Your name in full …………………………………………………
I.D. ………………………………………………………………………
Relationship to child ……………………………….
Once again, the Committee recommended written consent to be 
obtained using a new form that kept consent for educational and 
medical linkage quite separate. Although Jean Golding said that she 
would concentrate on the education consent and would draft a new 
form and circulate it to Committee members before the next meeting, 
this did not happen. Instead, Professor Dieter Wolke, ALSPAC Head of 
Psychology, attended a subsequent Committee meeting describing how 
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scientifically important it was to link these educational data with other 
ALSPAC data. Jean Golding then described the difficulty and expense 
involved in gaining written consent from all parents and, as ALSPAC 
anonymised all data before links were made, written consent was not 
required under the Data Protection Act. Eventually, the Committee 
were persuaded, mostly on pragmatic grounds (in this instance, the 
expense involved) to inform participants of ALSPAC’s intention to link 
to educational records through the regular ALSPAC newsletter with 
a clear option to opt out.7 On this occasion, the Committee did take 
financial considerations into account, although it is questionable as to 
whether this should influence their decisions. Michael Furmston had 
been known to say that it should not, yet if important scientific research 
was impossible to undertake due to stringent Committee rulings when 
alternative ethical strategies could be implemented, this could also be 
considered unethical. The Committee reviewed articles for both the 
participants’ newsletter and the newsletter for professionals, which was 
sent regularly to local health and educational professionals, as well as 
ALSPAC collaborators.8 The latter was published but it seems that 
the article for the participants’ newsletter was not, although it is not 
clear why. It is highly likely that this was an oversight rather than a 
deliberate refusal to comply with the Committee’s advice, but it does 
suggest that follow-up of the Committee’s advice could or should 
have been more effective.
In 2003–04, there was a confusing episode concerning access to 
educational data. It is unclear if this was an example of i) inconsistency 
in the Committee’s decision-making or ii) their determination to 
protect ALSPAC participants. One of ALSPAC’s collaborator’s projects 
involved identifying if and when developmental impairments in the 
Cohort children had been suspected and diagnosed. This included 
identifying ALSPAC children with special educational needs through 
Bristol City Council (BCC). The Council were unwilling to release 
information unless it was confirmed that the child was part of the 
ALSPAC cohort and a ‘Fair Processing Letter’ sent. This letter gave the 
participants an opportunity to opt out of the research and not allow 
educational details to be passed on to ALSPAC. The Committee would 
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not allow ALSPAC to give a list of ALSPAC participants to the BCC 
as this was considered confidential information: ‘Michael Furmston 
felt that the issue of trust, whether in the BCC or another institution 
was irrelevant; the ALSPAC participants had given information on the 
understanding that it was confidential and therefore their names and 
addresses should not be revealed.’9  The Committee were reminded 
by Jean Golding that a list of participants had been sent to another 
external organisation, the ONS, with the Committee’s permission in 
order that ALSPAC could be informed of cases of cancer and deaths. 
If the Committee had sanctioned the release of participants’ identifiers 
to the ONS, it would have been quite inconsistent not to allow the 
release of similar information to the BCC. There is no evidence in the 
Committee minutes that they had ever been asked about the release of 
identifiers to the ONS and so it is more likely that they were taking a 
principled position on the guarantees of confidentiality that had been 
made to the Cohort. The impasse with the BCC was resolved by 
liaison with the Department for Education and Skills (DfES), who had 
most of the information required by the collaborator. The lists were 
matched through an independent third party (the Fischer Trust) that 
the DfES used under similar circumstances. This solution had been 
suggested to the BCC but they had rejected the suggestion. This was 
another pragmatic solution by the Committee that went some way 
to meeting their concerns, although the list of ALSPAC participants 
did have to be released to a third party (the Fischer Trust), which they 
had initially categorically ruled out.
Linkage to external or third-party databases was an important aspect 
of ALSPAC’s methodology, as noted in the initial ethical application 
forms to the LRECs and information booklet for Study mothers. 
Consent on an opt-out basis for linkage to health data was acceptable 
at that time but this gradually came to be considered inadequate. The 
Committee, as always, dealt with ethical issues as they emerged during 
the running of the Study but there was inconsistency in their decision-
making. Although the release of the list of ALSPAC participants’ 
identities to the ONS was not sanctioned by the Committee, when 
they were made aware of it, they seemed unconcerned. When a similar 
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process was required, albeit to a local, not national, organisation (the 
BCC), much concern was expressed. The compromise eventually 
agreed upon used an independent third party to match lists, which 
inevitably involved the release of the identities of the ALSPAC 
Cohort anyway. With hindsight, informed consent from participants 
for comprehensive linkage to health, education or other third-party 
databases would have gone a long way to alleviating the ethical issues 








Retention of the Cohort: 
incentives or inducements
Keeping attrition rates low was crucial to the scientific value of ALSPAC and 
has contributed to its outstanding success and international recognition. The 
Committee supported ALSPAC staff in their constant endeavour to this end by 
keeping the Study participants informed, engaged and enthusiastic. This was 
achieved by cultivating media coverage, including publicising scientific papers, 
issuing regular participant newsletters, creating the Discovery Club for the Study 
children and, where necessary, sensitive contact with individual Study participants. 
Reimbursements for time and inconvenience were given, as were small rewards for 
participation in the Study. When the rewards were assessed, the fine line between 
incentives and inducements had to be negotiated. The Committee considered 
that inappropriate rewards could make the cohort devalue the Study rather than 
increase their appreciation of it. They believed that altruism should always be 
emphasised as this was a powerful motivator for Study participants.
As with all cohort studies, keeping attrition rates low is crucial to 
the scientific merit of ALSPAC as it maximises statistical power and 
minimises bias. Although not stated explicitly, this was considered 
an ethical matter, certainly by Jean Golding. Should participants 
withdraw from the Study, data already contributed by all Study 
participants would be devalued. Fewer participants would reduce 
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the power of the statistical analyses as the vital longitudinal nature 
of these data would be limited. Keeping attrition rates low creates 
particular challenges in longitudinal studies as cohort participants 
are frequently studied for decades or throughout their whole lives. 
Members of the ALSPAC Ethics and Law Committee were acutely 
aware of this fundamental issue and it influenced almost every aspect 
of their work. Broad concepts were endorsed, such as the importance 
of establishing participants’ trust in the researchers, protecting them 
from being overly burdened and ensuring that all written information 
was easy to read for both children and adults with a wide range of 
abilities and education. That said, the regular newsletters that were 
sent to the participants and considered vital to the retention of the 
Cohort were not reviewed by the Committee before publication. Of 
course, members of the Committee who were Study mothers did 
see the parents’ newsletters, but on no occasion did they bring to the 
Committee’s attention any concerns.
Local and national media coverage, as well as more direct feedback 
of published results, was considered equally important in keeping the 
Cohort engaged and enthusiastic. The Committee rarely influenced 
the media coverage but were aware that adverse publicity or 
breaches in confidentiality in such a localised population could have 
disastrous effects on Cohort retention rates. This led to great care 
and consideration when their attention was brought to individual 
participants’ requests or problems, as described in Chapter Ten. All 
these strategies were recognised as an effective method of reducing 
attrition rates by encouraging participants’ identification with the Study 
and their understanding of the importance of their contributions.
ALSPAC employed a team of staff (the Family Liaison Team), 
initially to ensure enrolment rates were high and then specifically to 
keep attrition rates low. The Committee were aware of most aspects 
of their work, including prioritising the more vulnerable participants 
and thus keeping involved those who might easily have abandoned 
the Study due to temporary or permanent stresses (such as illiteracy, 
mental or physical illness, bereavement, multiple births, large families, 
or poverty). Ethical issues that arose from this aspect of the Team’s 
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work have mostly been described elsewhere, in particular, the child 
protection issues described in Chapter Seven. The Public Relations 
Team worked alongside the Family Liaison Team and was equally 
dedicated to keeping attrition rates low. This team was responsible 
not only for publicity and media liaison, but also for the newsletters. 
Both teams were acutely aware of attrition rates, as were the more 
senior staff involved with the annual Focus Clinics.
Incentives
Out of the determination to keep the Cohort participants involved and 
enthusiastic, in recognition of their time and effort dedicated to the 
Study and to make them feel valued and appreciated, small gifts were 
offered after attendance at the clinics. These would be inexpensive 
toys such as ‘stretchy men’ for the children or pens with the Children 
of the 90s logo for the adults. Although not documented anywhere, it 
seems that it was understood that gifts should not be disproportionate: 
if obtaining the gift was the reason for participating in that aspect of 
the Study, it was likely that the gift had been misjudged and could 
be considered unethical. There are subtle distinctions between 
reimbursements, incentives and inducements that the Committee 
had to tackle more frequently, both as the Cohort children got older 
and as the nature of the data collections became more complex. 
Reimbursements for travel may seem straightforward but, for example, 
when taxis from participants’ homes to the clinic (which could be 
20–30 miles away) or train fares and overnight hotel accommodation 
in London were on offer, could these be judged as inducements? In 
both these cases, these reimbursements were judged to be ethical and 
not regarded as inducements, and were approved by the Committee.
The Committee was not usually involved in deciding what 
these gifts should be; it was assumed that the staff who made these 
decisions would discern what was appropriate, in that the gifts 
were not disproportionate or coercive, but specific incentives were 
occasionally brought to the Committee’s attention. On one occasion, 
the Committee was asked to consider the reward for a sub-study that 
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involved 200 children wearing activity monitors for one week during 
each season of the year. The Committee was asked if it would be 
acceptable to give the participants a token for a ‘Four Seasons Pizza’; 
a popular pizza at the time with toppings representative of each season 
on each quarter of the pizza. Due to the increasing concern by health 
professionals and others about the levels of obesity in the population, 
the Committee understandably felt that tokens for pizzas would give 
the wrong message; tokens for activities (swimming, skating, bowling) 
were discussed but it was thought that these rewards might influence 
the results. Eventually, the collaborator was asked to use ‘neutral’ 
rewards, for example, CDs or cinema tickets.1
More problematic for the Committee was the disclosure of clinical 
results. Although clinical results were generally not disclosed except 
under the strictest of criteria (see Chapters Eight and Nine), on-the-
spot results of certain clinical measures, such as heights and weights, 
were disclosed to participants. In fact, the children attending the Focus 
Clinics were provided with booklets in which to document specific 
measures (see Figures 4 and 5). Clinic staff reported these booklets to 
be popular and as enhancing the clinic experience for the children. 
Positive experience in the clinics not only encouraged the children to 
attend future clinics, but, if they discussed their experience with their 
peer group, many of whom would also be Cohort members, could 
also positively affect clinic attendance rates. There is some evidence 
that one clinic, which was not much enjoyed by participants, had 
considerably lower attendance rates due to this informal information 
exchange. The seven-year clinic was attended by 8,297 children. This 
dropped to 7,487 at the eight-year clinic and recovered to 7,725 at 
the nine-year clinic. The clinic for eight year olds involved much 
time spent on measuring intellectual abilities (IQ, attention, executive 
function, speech and language) and ascertaining behaviour, attitudes 
and non-verbal skills (friendships, bullying, anti-social activities, 
gender behaviour, self-image, non-verbal accuracy), leaving little 
time for physical measures. The only physical measure was a bronchial 
challenge, which involved inhaling methacholine, inducing a reduction 
in lung function that was not considered pleasant. The Committee, 
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alongside others planning the subsequent clinics, tried to ensure that 
there was a good balance between physical and psychological measures; 
this was not always easy as it was ALSPAC collaborators’ interests 
and financial contributions that largely dictated the measures to be 
implemented at the clinics.
Figure 4: Example page from Focus at 7 booklet
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The Discovery Club
Another highly successful and popular method of keeping the Study 
children engaged with the Study and therefore attrition rates low was 
the ‘Discovery Club’, which was instigated in 2000 when the children 
were eight to nine years old. Once enrolled in the Club (by returning 
a form included in the newsletter or at a later date online), the children 
would receive a membership card, badge, folder, newsletters and the 
opportunity to enter many competitions. They were also entered into a 
monthly prize draw for returning questionnaires. The Committee were 
told about the Club and shown the form, which made it quite clear 
that there would be a prize draw, but, surprisingly perhaps considering 
their major objections a few years later, no objections were made. The 
Committee’s only concern was that it might attract more girls than 
boys.2 This proved to be the case, with approximately 500 more girls 
Figure 5: Example page from Focus at 7 booklet
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enrolling in the Club (53% girls and 47% boys). The Club encouraged 
much active participation by the children, such as: sending in photos 
and news; taking part in swimming galas, charity bike rides or football 
tournaments; playing online games; and entering competitions. There 
was substantial emphasis on the latter and, at one time, a monthly 
competition was instigated for such things as the funniest joke or best 
name for the laboratory’s DNA robots. There were impressive prizes 
available, including a helicopter ride, a week-long course at the local 
science centre culminating in making a film and tickets for various 
music and other events. The ALSPAC staff ensured substantial media 
coverage and cultivated good working relationships with the local 
media, such as arranging for the children’s weather pictures to appear 
on the local television news.
The Discovery Club continued beyond Jean Golding’s retirement 
but in the six years up until then, it rarely came to the Committee’s 
attention. Once, Jean Golding presented a ‘fact finder’ booklet that 
she thought could be sent via the Discovery Club and used as an aide 
memoire to help the children fill out their questionnaires; it was not 
intended to be returned. The Committee had many criticisms (too 
dry, too culturally specific) and although Jean Golding said that she 
would redraft it, it was abandoned. On another occasion, when the 
Committee were discussing the problematic issue of gaining informed 
consent for immortalised cell lines, it was ‘agreed that the Discovery 
Club should be used to inform the children about DNA and the many 
issues involved; confidentiality should be re-emphasised’.3 This would 
have reached most children still actively participating in ALSPAC, with 
over 8,000 enrolled in the Discovery Club.
The Discovery Club was brought to the attention of the Committee 
one further time concerning bicycle helmets. The Club had advertised 
‘Bristol Biggest Bike Ride’, a non-competitive cycling event that 300 
Study families had said they would like to join representing Children of 
the 90s. The team organising this had negotiated a discount on cycle 
helmets from a firm approved by both the Royal College of Paediatrics 
& Child Health and the Royal College of Surgeons and wanted to offer 
them to the Study families at the discounted price. The Committee 
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approved this after checking that ALSPAC would not be liable if a 
child was injured but also noting that there was some evidence that 
helmets did not make cycling safer. T-shirts with the Children of the 
90s logo were issued to the families and the event was covered by the 
local media – another example of highly successful promotion of the 
Study through the Discovery Club by the Public Relations Team.4
The prize draw
As the children became older and their lives busier, response rates to 
questionnaires and clinic attendance levels understandably dropped, 
with concern by some staff that this would be exacerbated by the 
frequency of postal questionnaires that it was necessary to send at 
times. As with the clinics, much of the information collected by 
questionnaires was dictated and funded by collaborators. In 2005, the 
Committee reviewed a request from the Public Relations Team to 
consider a prize draw for children completing questionnaires. This 
was towards the end of Jean Golding’s and Michael Furmston’s era and 
the Publicity Team consisted of relatively new staff members. Perhaps 
unknown to them and certainly forgotten by any others who might 
have known (Jean Golding, the author and the Study mothers on the 
Committee), a monthly prize draw of £25 had been implemented in 
October 1997 for participants returning questionnaires. This had not 
been referred to the Committee. The winners’ names were published 
in the newsletter and this incentive was still being implemented in 
May 1999, although it is uncertain as to how long it continued. 
When consulted in 2005, the Committee were unambiguously against 
implementing a prize draw and even less enthusiastic when asked to 
consider ‘Fundraiser Discount Books’ (books of tokens) a few months 
later, as can be seen in the minutes:
The committee reviewed the draft invitation to enter a prize 
draw. This had been suggested by the ALSPAC publicity team, 
as they thought it might improve the response rate from study 
children who were about to receive several questionnaires in 
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quick succession. H.B. thought this was unlikely to increase 
the response rate and most of the committee felt it might have 
negative repercussions as the cohort were used to being informed 
that their participation was an important contribution to science. 
(Committee minutes, May 2005)
The committee reviewed the Discount Books, a suggested 
alternative to book tokens that are given to study participants 
at the clinics currently. Several members were concerned about 
the time limits on the vouchers, as from their own experience, 
they did not feel good if they did not use vouchers within the 
deadlines. Many of the committee members were not happy 
about the general impression of the books and felt that, as with 
the prize draw discussed recently, altruism should be emphasised. 
Some of the committee thought that the nature of these rewards 
is vital; the wrong sort of rewards can make the cohort devalue 
the study rather than increase their appreciation of it. The 
committee felt that book and CD tokens are more appropriate 
gifts. (Committee minutes, July 2005)
The ALSPAC prize draw illustrates the Committee’s ineffectiveness at 
times as they relied on Jean Golding to bring issues to their attention 
and if this did not take place, as with the early implementation of a 
prize draw, important consideration of the ethical implications was not 
only bypassed, but also not assimilated into the ethos of ALSPAC staff.
The Committee supported ALSPAC staff in their constant endeavour 
to keep attrition rates low by keeping the Study participants engaged 
and enthusiastic. The Family Liaison and Public Relations Teams used 
a variety of methods to achieve this, such as newsletters, the Discovery 
Club, publicising scientific papers and other media coverage, not all of 
which were reviewed by the Committee. Incentives were sometimes 
reviewed by the Committee to ensure that they were proportionate and 
appropriate but these judgements were mostly made by ALSPAC staff. 
The emphasis on altruism was always considered an equally important 
aspect of retaining the Cohort as any of the other methods employed.
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Commercial collaborations:  
selling our souls
Collaboration with commercial companies, as long as there were strict rules about 
publication without veto, was standard practice within universities when ALSPAC 
was founded and not considered controversial by Jean Golding or her many advisory 
committees. There were few objections from the Study participants, who were 
made aware through the newsletters of these collaborations, as well as donations, 
both financial or in kind, from mostly local companies. Throughout the 1990s, 
there was increasing pressure from the large research funders, such as the Medical 
Research Council (MRC), to provide ‘open access’ to data and thus increase 
collaboration with commercial companies. This did concern the Committee as it 
raised the possibility of ALSPAC not only losing control of data, but also breaking 
guarantees given to the participants. After the Committee met with representatives 
of the MRC and explained the ethical issues involved, no changes were required 
and collaborating with commercial companies continued as before.
Jean Golding and the ALSPAC Steering Committee always regarded 
collaboration with commercial companies as acceptable if the 
companies did not influence any publications coming out of the 
sponsored research. This position was not due to the lack of core 
funding that ALSPAC had to endure in the early days as, long before 
ALSPAC was set up, Jean Golding accepted financial support from 
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commercial companies on this principled basis. Even during the final 
planning and piloting stage of ALSPAC, she had to be firm with one 
large international pharmaceutical company who disputed her results 
when they showed that the company’s product was associated with 
childhood cancer (Golding et al, 1992). Commercial collaborations 
continued with ALSPAC from its beginning, mostly harmoniously, 
without being specifically brought to the attention of the Study 
participants or Ethics and Law Committee. Funding for research on 
this basis was well established within universities and Jean Golding did 
not regard it as controversial.
Endorsements by commercial companies came to the attention of 
the Committee in 1995 when a small supermarket chain expressed 
interest in subsidising the cost of producing the ALSPAC newsletter. 
Jean Golding informed the Committee that ‘sponsors had supported 
the study for some time, but the issue of having a sponsor’s name 
included on something that was sent to the parents might … appear to 
compromise the independence or integrity of the study’. None on the 
Committee had any particular objection to this particular supermarket 
but ‘Professor Baum said that he would strongly oppose the use of 
certain sponsors, such as producers of baby milk formula.… It was 
generally felt that, if possible, it would be better to include the name 
of several sponsors rather than just one.’1  At the time, there was a 
prominent campaign to boycott one multinational producer of formula 
milk (Nestlé) as they were seen to be responsible for causing infant 
illness and death in poor communities, particularly in the developing 
world, by promoting bottle feeding and discouraging breastfeeding. 
This boycott continues today. In the previous year, Jean Golding had 
included in the regular newsletter that was sent to Study participants 
a brief item on ALSPAC’s relationship with commercial companies. 
It was included in a section entitled ‘Your comments’:
One mother felt that if answers are being given to ‘outside 
organisations’ parents should give their formal consent. First of 
all let us assure you that we never give any commercial company 
the actual information that you have given us.
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We do, however receive money from various companies who 
are anxious to know whether their products are safe. From the 
information you have given us on the questionnaires we are 
able to look at various commonly used things, from electrical 
appliances to foods, medicines and drinks.
If we find something worrying we will warn the company, 
but however helpful the money they had given us, this will not 
stop us from publishing the results. (ALSPAC parents newsletter, 
Spring 1994)
Sponsors’ names and logos were not attached, as such, to any documents 
distributed to participants. Recognition of sponsors’ contributions was 
acknowledged in participants’ newsletters from January 1999 without 
involvement of the Committee. A simple list of 20 sponsors and the 
following statement was published: ‘As we go to press the companies 
listed here have either sponsored a child or given us goods and services 
in kind’.2 Sponsoring a child did not infer sponsorship of an individual 
participant, but meant that the company donated a sum that would 
cover the cost of a clinic visit.3
In 2000, another locally based company (Mail Marketing) 
approached Jean Golding offering to provide a liaison service between 
ALSPAC and commercial companies. They had suggested that some 
companies would pay ALSPAC to endorse their product with a logo 
indicating ALSPAC’s approval of the product. She sought advice 
from the Committee, who expressed their reservations: ‘respectable 
companies may not be as respectable as they initially seemed and it 
was vital [that] ALSPAC was not associated with harming children’s 
health’. The Study mother on the Committee ‘felt that ALSPAC’s 
independence from commercial companies was of importance and 
valued by the study parents’.4 It was agreed that representatives from 
Mail Marketing should be invited to the Committee to discuss their 
proposal but the company, having initially accepted, then postponed 
and eventually did not take up ALSPAC’s offer. Collaboration with 
commercial companies seemed to be becoming an issue as, around 
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the same time, it was again featured in the newsletter (see Box 8), 
triggered by a participant’s concern.
Box 8: ALSPAC study participants newsletter article
You ask us
I heard that the data might be sold to companies like Coca Cola. Please tell me if 
this is the case or not.
All the information collected as part of Children of the 90s belongs to the University 
of Bristol and is kept confidential. We do, however, accept some money from 
companies such as Coca Cola to look at the data. Research like this always carries 
a contract that says we will publish results regardless of whether the company is 
pleased with them or not. This is precisely the case with Coca Cola, the old British 
Gas (looking at the safety of gas cooking), SmithKline Beecham (looking at the 
safety of paracetamol), Dreamland (looking at the safety of electric blankets) and 
so on. Any results will be published and summarised in our newsletters. (ALSPAC 
parents newsletter No 19, 2000)
It became apparent that this article should have been worded more 
carefully as it was open to misinterpretation. Two thoroughly 
conscientious Study mothers, both of whom had completed every 
ALSPAC questionnaire that they had ever been sent, wrote to Jean 
Golding demanding to be withdrawn from the Study: ‘I was disgusted 
… [that] you pass information on to other companies. I understand it 
was confidential for your research only. I feel I have been betray [sic] by 
this as a breach of confidentiality’, and ‘you insist its All Confidential. 
What a lot of bull’.5 Jean Golding replied to both mothers personally, 
as she did to many participants who wrote to her, explaining that 
confidential information is never passed on to commercial companies 
and offering to talk to them on the phone or meet face to face if 
preferred. It is not clear if these mothers were persuaded to remain 
in the Study, but it did emphasise the importance of the guarantee of 
confidentiality and to the strong feelings aroused at the possibility of 
commercial companies obtaining personal data.
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Medical Research Council terms and conditions of grant
The issue of collaborations with commercial companies became even 
more pressing for the Committee in 2000 after a successful ‘site visit’ 
to ALSPAC by the Medical Research Council (MRC) and Wellcome 
Trust, when further substantial core funding (£5 million) for a five-
year period was achieved. Jean Golding and Marcus Pembrey had first 
secured funding from these bodies in 1996. The two funding bodies 
stipulated substantial changes to several aspects of ALSPAC, including 
key changes to the Scientific Advisory Committee, so as to include 
both funders and representatives from industry. There was also much 
perceived pressure from the funders for ‘open access’ to data and 
encouragement to engage with commercial companies, particularly 
‘pharmaceutical companies concerning genetics’.6 This did worry the 
Committee, who even considered asking the Vice Chancellor to get 
involved as ‘the strict ALSPAC protocol concerning genetic analysis 
and refusal to sell biological samples to commercial companies may 
come under pressure particularly as ALSPAC will be setting up a cell-
line bank with MRC funding’.7 The Vice Chancellor’s involvement 
was considered appropriate as all ALSPAC bio-samples (and data) were 
owned by the University.
By December of that year, Jean Golding had received from the 
MRC the terms and conditions of ‘Strategic Grants awarded under 
the DNA collections initiative 2000’. Included in the document were 
a number of points. Those of most concern to the Committee were:
2. All DNA Collections in the initiative are funded on the 
understanding that they are to be managed as shared national 
resources, and must be made readily available to collaborators.…
3. Consent must be obtained from sample donors to allow the 
samples and associated data to be used for a range of genetic 
projects. Donors should be aware that samples will be part 
of a shared resource for use by scientists other than the team 
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collecting them, and that this might include scientists from 
commercial companies….
5. Commercial access. All requests for access by commercial 
companies should be referred to the MRC and the MRC 
should approve the terms and conditions under which such 
access is granted. No single company will be given exclusive 
access to samples collected under this initiative. Under no 
circumstances can the samples be sold for profit, although 
recovery of reasonable costs is acceptable. (Committee papers, 
December 2000)
Jean Golding sought advice from the Committee, as recorded in the 
minutes of December 2000:
The MRC document ‘Terms and Conditions of Awards’ was 
reviewed. J.G. informed the committee that the MRC would 
not give ALSPAC a grant until their conditions had been 
agreed…. She was concerned that point 2 implied collaborating 
with scientists whose probity was not necessarily assured and 
in view of the MRC’s particular interest in pharmaceutical 
companies, she emphasised the need for ALSPAC to somehow 
distance itself from that position. She reminded the committee 
that ALSPAC has a strict protocol concerning the analysis of 
DNA; collaborators feedback DNA results, which are linked 
and analysed in our offices by ALSPAC statisticians working 
closely with the collaborators.
The committee agreed that the conditions were unsatisfactory 
particularly as they went against the guarantees we had already 
given to our study parents and the MRC needed to be informed 
of that. It was suggested that the MRC might have to change 
its terms and conditions in the near future depending on the 
recommendations from the House of Lords select committee. 
(Committee minutes, December 2000)
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ALSPAC seemed to be in some difficulty now; core funding was, 
of course, essential for the continuation of the Study, especially as 
the funding was for the creation of cell lines (immortalised DNA), 
yet to comply with the terms and conditions would be breaking the 
guarantees given to participants when they had signed the consent 
forms. The Committee chose to invite representatives from the 
MRC to attend the Committee in order to discuss the dilemma. 
This involved much preparation, with several lengthy meetings to 
prepare ALSPAC’s case. At the meeting in May 2001, attended by 
Dr Catherine Moody, MRC Programme Manager, ‘responsible’ for 
ALSPAC, and Dr Frances Rawle, MRC Strategic Projects Manager, 
responsible for the development and coordination of strategy related 
to DNA collections, Michael Furmston expressed the Committee’s 
general unease at the suggestion that commercial companies would 
have access to ALSPAC data. Jean Golding explained how ALSPAC 
maintained control of genetic data: genotyping was carried out by 
collaborators but linkage to other ALSPAC data and statistical analyses 
were carried out by ALSPAC statisticians or by collaborators working 
in-house with these statisticians. Commercial companies had not been 
interested in collaborating on this basis. The Committee’s anxieties 
seemed completely unfounded as the MRC representatives reassured 
the Committee that ‘… the conditions were written for newly funded 
studies and not necessarily relevant to ALSPAC. The guidelines stated 
the principles but were open to intelligent interpretation. Dr Moody 
stated that ALSPAC’s procedure for peer review and ethical approval 
were entirely reasonable.’8
It is possible that a quick phone call could have resolved these issues 
satisfactorily but it is more likely that the painstaking preparation9 
and detailed analysis of ALSPAC’s position by Michael Furmston, 
Jean Golding and Marcus Pembrey, plus the contributions from the 
Study mothers and other Committee members, left little room for any 
other response from the MRC.10 The Committee was asked to adapt 
the terms and conditions to suit ALSPAC and, eventually, the MRC 
adapted its guidelines to accommodate longitudinal epidemiological 
studies (MRC, 2005).
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Genetic Knowledge Park
In 2001, the Committee reviewed another ambitious attempt to 
secure funding in collaboration with other Bristol scientists from two 
government departments seeking bids for a ‘Genetic Knowledge Park’. 
This proposed ‘cyber-park’ was intended not only to facilitate research, 
but also to disseminate information to the National Health Service 
(NHS) and the general public. The strength of the Bristol bid was 
seen as ALSPAC’s emphasis on health, not disease, and its progressive 
approach to the ethics of genetic research, as seen by the existence of 
the Committee and the involvement of parents in ethical decisions.11 
Crucially for the Committee, the Genetics Park would ‘help local and 
national researchers, both academic and commercial, harness this unique 
national resource to discover the determinants of common diseases’.12 
When asked by one of the Study mothers on the Committee if this 
would include drug companies, Jean Golding thought that it probably 
would but emphasised that the ‘ALSPAC protocol dictated all research 
using our data had to be of academic value and not conducted for profit 
only’.13 The bid failed but was seen as a worthwhile exercise as it had 
generated useful contacts both within the University and externally.14
Phenome scan
By 2002, Jean Golding, Marcus Pembrey and Richard Jones (ALSPAC 
Head of Biological Collections) had designed a highly original method 
of using ALSPAC data, which they thought might be of great interest 
to commercial companies. This was the ‘phenome scan’, which was 
described as ‘a new approach to genotype/phenotype association 
studies … in which dense phenotypic information in human cohorts 
is scanned for associations with individual genetic variants’ (Jones et 
al, 2005, p 264). As explained to the Committee when Jean Golding 
first presented them with the concept:
This resource will enable specified genes to be related to any 
number of chosen variables (medical, psychological or social) in 
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order to identify statistical significance. For example, if a gene 
was identified with high cholesterol, ALSPAC could identify 
other associations and enable drug manufactures to take these 
into account when considering side effects or other benefits of 
a drug to lower cholesterol. (Committee minutes, 26 February 
2002)
At a subsequent meeting, Jean Golding explained the necessity for the 
involvement of commercial companies as ‘they could do biological 
tests but could not make population links; ALSPAC did not have the 
genetic knowledge necessary, or the finances, to independently gain 
that knowledge’.15
The Committee spent several meetings discussing detailed aspects 
of this proposal, including financial arrangements, review process, 
publication policy, data management and intellectual property rights, 
but of most concern to the Committee was how the participants would 
respond to this suggestion and how it should be presented to them. 
There was perceived to be a subtle distinction between ‘allowing access 
to’ and ‘selling data’ and it was suggested that money from commercial 
companies could be called ‘sponsorship’, or ‘investment’ rather than 
‘payment’ and that ALSPAC ‘charged for’ rather than ‘sold’ companies 
data. Several members of the Committee felt that the Study parents 
might be anxious that their data was being exploited for commercial 
purposes or shareholder profits.16
A few months later, Richard Jones produced a thorough and clear 
explanation of the phenome scan, the involvement of commercial 
companies and, importantly, how this would add value to ALSPAC’s 
research endeavours (see Appendix 5). This was presented to the Clinic 
Team Leaders as it was thought that they would have some idea as to 
how Study participants would react to the idea:
Funding from pharmaceutical companies – in the public interest 
or selling our souls? Richard Jones has written the document 
that follows. He would like feedback from ALSPAC staff and 
is particularly interested in our views of the parents’ possible 
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reactions. Please read it before the meeting and give the subject some 
thought. Richard will join us during the discussion. (ALSPAC 
Clinic Team Leaders meeting, June 2002)
It is not known how the staff responded to the article but no 
amendments were made before it was reviewed by the Committee, 
who suggested that it needed to be shortened and adapted for Study 
parents. It seems that this did not happen, but 10 months later, a brief 
article was published in the participants’ newsletter asking what they 
felt about ALSPAC working with drug companies (see Figure 6). 
This was shown to the Committee after it had been published with 
no opportunity for the Committee to amend it but Jean Golding did 
say that their comments would be noted for a follow-up article.17 She 
twice again referred to a follow-up article – a few months later18 and 
the following year19 – yet, it seems that another article did not appear. 
It is not known for certain why the follow-up article did not appear. 
It could have been overlooked or might have been because after 4,000 
newsletters had been sent,20 Jean Golding had had no responses to the 
first article. Eventually, one response was received that was shown to the 
Committee: ‘Please let Professor Golding know I trust her judgement 
re funding from drug companies. Do what you need to do’.21
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This is another example of the actions arising from the Committee’s 
discussions not materialising, although another newsletter article 
would have made little difference as no pharmaceutical companies 
ever expressed interest in collaborating with ALSPAC in this way. 
The phenome scan has been used to a limited extent, mostly by Jean 
Golding, who has published research using this methodology (Jones 
et al, 2005). Collaboration with commercial companies continued as 
it had done from the beginning, with strict rules about publication 
without veto and donations, financial or in kind, being acknowledged 
in the newsletters with a simple list of donors.
Figure 6: Participants’ newsletter article
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FOURTEEN
Comprehensive oversight: undocumented 
and unacknowledged
The Committee reviewed all data collections within ALSPAC, giving them a broad 
perspective of the Study as a whole. Other than Jean Golding, few recognised 
the importance of such all-encompassing oversight. This provided significant 
support not only for her, but also for the protection of the participants (always the 
Committee’s foremost priority). None of the other ALSPAC advisory committees 
were aware of the detail of all that was being asked of Study participants, whether 
by questionnaire or in research clinics, not only in whole-cohort studies, but also in 
pilot studies and sub-studies, of which there were many. When the Local Research 
Ethics Committee (LREC) expressed concern about the amount that participants 
were being asked to do, with the possibility of preventing the implementation of 
some sub-studies, it was the ALSPAC Ethics and Law Committee who shaped Jean’s 
robust and effective response to the LREC. Questioned by one ALSPAC Committee 
member of the necessity of reviewing studies in so much detail, Michael Furmston 
was clear that it was only by this attention to detail that the Committee was able to 
effectively fulfil its function.
The review of data collection proposals was central to the ALSPAC 
Ethics and Law Committee’s unstated remit. As the extent and range 
of data collected by ALSPAC increased, so did the Committee’s 
workload. On occasions when planning for a particularly intense 
period of data collection, such as a new research clinic, the Committee 
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would meet four or five times within a period of six weeks. For most 
of the Committee, who gave up their time voluntarily and fitted the 
Committee’s work around busy professional schedules, this was too 
much. One long-standing member of the Committee, David Jewell, 
felt that he “didn’t really understand how this was an ethics committee 
since it seemed to be spending an awful lot of time lost in detail and 
very little time thinking about higher principles”.1 This was dismissed 
sympathetically but swiftly by the Chair with ‘the devil is in the detail’2 
and, as recalled by David Jewell, “that it was only by attention to detail 
that we could exercise our function properly”.3
Collaborating scientists who wished to have new data collected 
submitted their proposals to the Committee. Some were asked to 
attend Committee meetings to provide further explanation but it 
could be difficult for those not based locally to be in Bristol for a brief 
attendance at a Committee meeting. Irritatingly for the Committee, 
they found themselves asking collaborators for almost identical changes 
to a variety of different documents over the years, such as including 
a confidentiality clause on information sheets. It would have been 
beneficial to apply a more formalised pre-submission review by 
someone knowledgeable of the Committee’s requirements to minimise 
these repetitive specifications. Jean Golding did view most paperwork 
before submission, as did the author in her capacity as Committee 
Secretary from 1999, but formalised and consistent pre-submission 
review took some years to evolve. Templates for documents such as 
information sheets or consent forms were not practical with such 
a variety of data collections within ALSPAC. The National Health 
Service (NHS) LRECs did introduce templates for documents such 
as consent forms but ALSPAC struggled to make use of them when 
applying for ethical approval to these committees as they were not 
designed for local, longitudinal population studies. Follow-up of 
the Committee’s recommendations was not formalised either; the 
Committee assumed that Jean Golding would ensure that they were 
carried out, which, apart from occasional oversights documented 
elsewhere, they were.
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The Committee was acutely aware of the demands being asked of 
the Cohort participants and continually assessed the value of the project 
against the burden on participants. They would consider whether it 
was possible to conduct the research on another population as the 
efficient infrastructure of ALSPAC could easily be exploited. The 
Scientific Advisory Committee, who reviewed research before it came 
to the Ethics Committee, took this factor into consideration also, so 
it was only occasionally that the Ethics Committee rejected research 
on these grounds, such as with a proposed sub-study of children with 
cerebral palsy: “this research did not necessarily need to make use of 
ALSPAC data or participants. The 36 children with cerebral palsy 
were already known to the health service and the additional controls 
could be drawn from the population at large”.4
Pilot studies
Pilot studies were an important aspect of ALSPAC’s methodology and 
the Committee were given results if relevant to their review. On other 
occasions, if the Committee was concerned about a particular measure 
or set of questions, it would ask for a pilot study to be conducted 
and postpone their decision until the results were known. As early 
as their third meeting in July 1990, the Committee asked for a pilot 
on a questionnaire containing sensitive questions about participants’ 
early sexual experiences. This resulted in a warning being included 
in the questionnaire immediately before this set of questions as the 
pilot participants were disturbed by the questions coming ‘out of the 
blue’. For this first pilot study, it was suggested that before the pregnant 
(non-ALSPAC) mothers were approached, ‘approval from the Ethics 
Committee be sought’.5 This referred to the LREC as the ALSPAC 
Committee regarded itself as an advisory committee at that time. It 
appears that such approval was not obtained.
ALSPAC pilot studies continued to be conducted without ethical 
approval from any committee, including the ALSPAC Committee, 
who frequently only knew of them if results were presented. As the 
LRECs became more established and formalised, it was stipulated that 
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pilot studies had to be approved before they were implemented. The 
ALSPAC Committee chose to ignore these requirements, believing that 
approval from the LRECs was not mandatory, although they continued 
to seek ethical approval from these NHS committees for the annual 
research clinics.6 As described in Chapter Four, the bureaucracy and 
length of time to gain LREC approval was becoming difficult for all 
medical researchers, not just ALSPAC. If, as the Committee members 
believed, LREC approval was not obligatory, it was justifiable for 
the pilot studies not to be subjected to the LRECs for approval. It 
would be less contentious if all pilot studies had been reviewed by the 
Committee, but as this was not the case, it left staff and participants 
involved in a few pilot studies somewhat vulnerable.
Questionnaires
Understanding the longitudinal changes taking place within the cohort 
was crucial to this type of epidemiological research and successive 
questionnaires would often have the same questions included. The 
Committee evolved a system of being alerted to those questions 
repeated from previous questionnaires and not needing to be reviewed 
again. However, they did insist on seeing the whole questionnaire 
to ensure that the length and layout were appropriate, for example, 
questions on self-harm or bullying were not placed at the end of the 
questionnaire as this could leave participants feeling unduly negative. 
It was a persistent challenge to find the balance between scientists’ 
requirements for thorough and comprehensive longitudinal data 
without overburdening participants with lengthy and repetitive 
questionnaires, thus risking a rise in attrition rates.
Research clinics
Review of the annual research clinics (Focus Clinics) constituted much 
of the Committee’s workload. The implementation of these clinics 
was a considerable administrative achievement, with overlapping 
clinics as the cohort were born over a two-year period. Over 8,000 
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children attended the seven years clinic, with over 6,000 attending 
the 12 and 13 years clinics. It was a considerable achievement for the 
Ethics Committee too, who, on occasions, had to meet many times 
over a period of weeks in order to review all protocols, information 
sheets, consent forms, letters of invitation, reminders and letters to GPs.
Blood samples
The method of taking blood from children attending the Children in 
Focus clinics came under scrutiny as, in the early 1990s, there was:
… considerable pressure to transfer blood testing from the group 
of procedures designated to pose ‘no risk’ into the ‘low risk’ 
category. Although such a proposal had recently been rejected 
by the BPA [British Paediatric Association] … other ethics 
committees had been considering whether it was in the interests 
of healthy children to be given blood tests for the purpose of 
research. (Committee minutes, May 1992)
The ‘pressure’ referred to in the minutes came from guidelines issued 
by not only the BPA in 1992 (BPA, 1992), but also both the Royal 
College of Physicians in 1990 (RCP, 1990) and the Medical Research 
Council in 1991 (MRC, 1991).
By 1994, when the ‘Children in Focus’ were approaching two 
years old, the Committee were asked to consider blood sampling by 
venepuncture rather than heel pricks, which had been the method used 
at previous clinics. There was lengthy discussion about the potential 
distress caused when taking blood by various methods: heel prick, 
finger prick or venepuncture. A pilot study was conducted to assess 
if distress could be minimised or eliminated during venepuncture, as 
discussed by Elizabeth Mumford (1999a). Members of the Committee 
watched the testing in progress and agreed to permit venepuncture 
using anaesthetic cream and a fine butterfly needle, with only one 
attempt to obtain blood and, most importantly, the assent of the child. 
This, plus the addition of a ‘Postman Pat’ or similar video that was 
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viewed during the procedure, worked remarkably well. At the final 
‘Children in Focus’ clinic when the children were approximately five 
years old and venepuncture had been used at two previous clinics, 81% 
of parents gave permission for venepuncture, with samples obtained 
from 82% of these (that is 66% of the attendees).7
Sub-studies
It was only in the last month of Michael Furmston’s 16-year period 
as Chair of the Ethics Committee that formal terms of reference for 
the Committee were formulated. These were minimal (see Chapter 
One) and gave no indication of the Committee’s commitment to 
reviewing the details of data collection. Slightly more indication of 
the Committee’s broader remit had been documented within the web-
based protocol in 20018 (see Box 9) but the stated ‘detailed scrutiny 
of all aspects of the study’, including the ‘Ethics of Nested Studies’ 
(sub-studies), evolved over time.
Box 9: The ALSPAC Ethics and Law Committee
The ALSPAC Ethics and Law Committee was set up in 1989 before the study 
children were born and while many pilot studies were being conducted in order to 
advise on the ethical and legal aspects of the study. This independent committee, 
chaired by a lawyer, has broad membership: medical ethicist, two study mothers, 
legal medical expert, philosopher, paediatrician, GP, child psychiatrist, head 
teacher and school health nurse. The Committee meets every month and insists on 
rigorous and detailed scrutiny of all aspects of the study. This includes:
• Data: Questionnaires, Hands-on Measurements and Biological Samples.
• Confidentiality and Anonymity.
• Consent and Assent.
• Ethics of Nested Studies.
• Individual Feedback: Prospective and Retrospective.
• Child Protection, Staff Protection and Data Protection.
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Although Jean Golding’s intention was for the Committee to review 
all sub-studies involving new data collections, this was not always the 
case. An update of sub-studies was presented to the Committee in 
19999 but not all had been reviewed in detail prior to the start of the 
studies (nitrogen oxide and carbon monoxide studies, stepfamilies 
study and an alcohol and breastfeeding study). Two months earlier, 
Jean Golding had received a letter from one of the LREC Chairs 
expressing concern at the intensity of the data collection:
… the Committee [LREC] has become increasingly concerned 
that consent given to the initial longitudinal study has been 
extrapolated to the continuation of that study, and that the 
involvement of the subjects had become increasingly intense. 
The subjects, having invested considerable time in the on-going 
study in its previous forms may feel more obliged to continue 
participation than would otherwise be the case.
Of even greater concern is the use of the same population of 
subjects in satellite projects, the database of which appears to be 
given or sold to other researchers so that the subject population 
can be contacted again and involved in yet further studies, 
disruption of school, and time off work for the parent. Despite 
assurances, it does take an effort of will to refuse to participate 
in such studies.
If the index subjects of all these diverse studies are the same 
in each case, over-exposure to research is taking place. If the 
controls of such studies are the same in more than one satellite 
study it is probable that over-exposure is taking place. The 
Committee needs assurance that persuasion, even coercion, 
however politely applied, is not being exerted unethically to 
make these studies, albeit valuable possible. We realise that the 
information gathered on this subject population is extremely 
valuable and it would be far more inconvenient to gather such a 
wealth of data on any other subject population. Yet, the interests 
of the subject must be considered before and above the interests 
of the research. (Committee papers, December 1998)
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Jean Golding showed the ALSPAC Committee the letter and a robust 
response was formulated:
• Response rates are still high (78% of those invited attended the 
Focus at 7 clinics).
• Postal invitations do not pressurise participants in the way that a 
face-to-face interview or telephone call might.
• Pilot studies were conducted in order to ascertain how participants 
would respond to further testing.
• Participants are only selected if they had not taken part in a previous 
sub-study (as either a case or control). This policy could not be 
implemented by other research studies in the Bristol area.
• Lists of participants are never given or sold to other researchers.
• The Scientific Advisory Committee assesses whether each new 
proposal needs to make use of ALSPAC data (Ethics Committee 
may also reject a proposal on these grounds).
There is no record of the LREC meeting or how the response was 
received. Sub-studies continued to be included within ALSPAC and 
reviewed by the Committee (see Box 10).
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The importance of the Committee’s painstaking review of all data 
collected by ALSPAC, whether by questionnaire, in research clinics or 
within the many sub-studies, was evaluated by David Jewell, who said:
“[The Committee] has considered, advised on and approved 
most of the studies and data collection that go on in ALSPAC 
and that involves very familiar principles of research ethics – of 
consent, risks and benefits, confidentiality, duty of care and 
things like that – and ALSPAC developed a certain expertise, 
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particularly on confidentiality. The … thing which just emerged 
out of the consideration of all the studies is therefore [that the 
Committee] had an oversight of the study as a whole.” (David 
Jewell, Oral History Interview, 2012)
This he admitted had not become clear to him until he had been 
a member of the Committee for over a decade. None of the other 
ALSPAC Committees that also had broad remits, such as the Steering 
Committee or Scientific Advisory Committee, reviewed all aspects of 
ALSPAC in such thorough detail. Other than Jean Golding, there were 
no others who had a grasp of both the detail and a wider perspective of 
the Study. The recognition of the importance of such all-encompassing 
oversight was rarely, if ever, acknowledged or documented.
David Jewell
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FIFTEEN
Influence beyond ALSPAC:  
extension of expertise
The Committee’s influence became considerably wider than just ALSPAC as its 
groundbreaking work became known. There were formal consultations not only by 
policymakers such as House of Lords Science and Technology Sub-Committee and 
the European Society of Human Genetics, but also by many other national and 
international cohort studies. Beyond the formal consultations, ALSPAC was an 
exemplar for other cohort studies and Jean Golding and her staff provided much 
informal guidance, without many realising how the Committee’s sound legal and 
ethical advice had underpinned the Study from the very beginning.
On several occasions, the ALSPAC Ethics and Law Committee were 
asked their advice by various national and international organisations. 
As the first ethics committee dealing with issues arising from the 
collection of genetic material from a population sample, advice on 
genetic issues was of particular importance. Although Marcus Pembrey 
was not a member of the Ethics Committee, as ALSPAC’s Director of 
Genetics, he was well aware of the Committee’s work and was involved 
with influential national and international policymaking bodies. He 
was consulted by the Committee if advice was sought on issues ranging 
from DNA banking and data storage to consent and confidentiality. 
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The Committee was seen as an example for other cohort studies at a 
time when there were few guidelines and little interest in the ethical 
issues raised by longitudinal birth cohorts such as ALSPAC by the 
National Health Service (NHS) Local Research Ethics Committees.
European Society of Human Genetics
In 1999, Marcus Pembrey asked Michael Furmston and the Committee 
to contribute to Guidelines on data storage and DNA banking for biomedical 
research (Godard et al, 2003), which was being developed by the 
Professional and Public Policy Committee (PPPC) of the European 
Society of Human Genetics. The PPPC was, in effect, the Society’s 
ethics committee1 and was simultaneously drafting guidelines on 
Insurance and Employment, Genetic Screening, and Genetic Services.2 
Professor Pembrey emphasised that the PPPC ‘… particularly want 
to learn from, and analyse, real examples of how professionals have 
tackled the issues raised by DNA banking.… [and] wish to include 
two contrasting examples of genetic epidemiology – ALSPAC and the 
proposed commercial deCODE healthcare database in Iceland.’3  The 
issues that the PPPC identified for debate were:
• consent requirements for banking and further use of human genetic 
material;
• protection of confidentiality;
• control and ownership;
• access to and sharing of banked samples;
• duration of storage and withdrawal of samples; 
• regulatory mechanisms of banking.
Michael Furmston and John Henderson (paediatrician and member of 
the Committee) attended a meeting in Paris, which brought together 
a total of 50 experts from 12 European countries from a diversity of 
backgrounds involved with DNA banking. The subsequent paper was 
reviewed by the ALSPAC Committee before publication (Godard et 
al, 2003).
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House of Lords Science and Technology Sub-Committee
In July 2000, Jean Golding received an invitation from the House of 
Lords Science and Technology Sub-Committee to submit a written 
contribution for their Inquiry into Human Genetic Databases. This 
inquiry was to focus on ‘current activity … [as] future regulatory 
requirements will be addressed by the Human Genetics Commission’4 
at a later date. Four years later, the Human Genetics Commission 
also consulted the ALSPAC Ethics and Law Committee, although 
with some ambivalence, as will be seen. The questions that the Sub-
Committee asked were extensive:
1. What current projects involve collecting genetic information on 
people in the UK? What other projects are about to start? Are 
there collections of material (eg tissue samples) that could be used 
to generate databases of DNA profiles?
2. Why are these genetic databases being assembled? How are these 
activities funded? What practical considerations will constrain 
developments? Are there alternative ways of fulfilling the objectives?
3. What is the genetic information that is being collected? How is it 
being stored and protected?
4. How do the organisations involved see their responsibilities 
regarding privacy, consent, future use, public accountability and 
intellectual property rights?
5. How do they see their activities in the area of genetic databases 
developing in the future? What advances in sequencing, screening 
and database technology are they anticipating?
6. What lessons should be learnt from genetic database initiatives in 
other countries?
The call for evidence noted that ‘It is recognised that individual 
witnesses may feel able to address only some of these [questions] … 
[therefore] evidence is expected principally from the bodies which 
are involved in maintaining, developing or using human genetic 
databases’. ALSPAC and one other UK longitudinal study (the North 
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Cumbrian Community Genetics Project) were asked to submit 
evidence, although ALSPAC was ‘used as an example of excellent 
practice in other submissions including those from the Wellcome Trust 
and MRC’.5 The other organisations approached to submit evidence 
were an amorphous and extremely wide-ranging group, all apparently 
‘maintaining, planning or using human genetic databases’ (see Figure 7).
The written submission approved by the Committee was entirely 
descriptive (see Box 11),6 unlike the written evidence submitted 
by Marcus Pembrey some years later to the Genomic Medicine 
Science and Technology Committee. Professor Pembrey cites his 
‘relevant expertise’ as ALSPAC’s Director of Genetics among many 
other prestigious posts and refers to the work of the ALSPAC Ethics 
Committee. It makes for entertaining reading as he does not hold back 
in his criticism of the Wellcome Trust’s ‘disproportionate influence 
on policy’ and their ‘naïve’ understanding of issues of wide access to 
data when related to ongoing cohort studies.7
Figure 7: Inquiry into Human Genetic Databases consultees
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Box 11: Summary of written submission to the House of Lords Science and Technology 
Sub-Committee
• Extraction of DNA included in the methodology from the beginning.
• Information given to Study mothers, including no feedback of genetic 
analyses.
• Governance of the Study, with list of advisory committees.
• Funding, including from commercial companies.
• Analysis of samples only with written consent (even if collected without 
consent through NHS sources).
• Recognition of limitations of DNA stock, especially with the advance of 
the human genome project, and therefore investigation into immortalised 
cell lines.
• Consent.
• Collaboration and methods of preserving anonymity.
Joint Human Genetics Commission and National Screening Committee
In 2003, again through Marcus Pembrey’s connections, the Joint 
Human Genetics Commission (HGC) and National Screening 
Committee (NSC) officially visited the ALSPAC Ethics and Law 




body that advised the Government on ethical and social aspects of a 
variety of genetic issues. At the time, it was chaired by Baroness Helena 
Kennedy QC and included Sir John Sulston and other highly esteemed 
individuals. It was disbanded in 2010 after the new Government’s 
review of all government quangos. The NSC role was to advise 
ministers and the NHS on aspects of population screening. The two 
committees had formed a joint sub-committee as they intended ‘… 
to consult both the public and ALSPAC experts about the feasibility 
and ethics of obtaining DNA samples from all children in the U.K. at 
birth. They had expressed interest in meeting members of the ALSPAC 
ethics committee, particularly the Study mothers.’8
Prior to the HGC/NSC sub-committee visit, the author and Marcus 
Pembrey were invited to attend a meeting in London to briefly discuss 
and plan the visit. At this meeting, one of the sub-committee expressed 
incomprehension as to why they should be consulting the ALSPAC 
Committee. It appeared that they did not feel that ALSPAC or the 
Ethics Committee had much to offer them. The two-day visit went 
ahead despite these reservations, with the University of Bristol’s Vice 
Chancellor himself hosting a dinner for both Committees in one of 
the University’s most attractive buildings, the 18th-century Royal Fort 
House. It was reported by the ALSPAC Committee members who 
attended this dinner that copious quantities of alcohol were consumed 
that evening. This might not be entirely irrelevant as the following day, 
the brief presentations given by Marcus Pembrey, Michael Furmston, 
Jean Golding and Alastair Campbell (Professor of Ethics in Medicine 
and member of the ALSPAC Committee) seemed to fall quite flat. 
Marcus Pembrey had recommended that the ‘presentations [should 
be] kept fairly short as members of the Commission tend to like to 
ask lots of questions and have time for more general discussions’.9 
There were, in fact, few questions and minimal discussion despite 
the relevance of the material presented, particularly by Marcus, 
who described ALSPAC’s contribution to developments in genetic 
screening/profiling. Perhaps it had been correct to assume that the 
ALSPAC Committee had nothing to contribute or possibly the dearth 
of questions was due to the Vice Chancellor’s lavish hospitality the 
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previous night. However, Jean Golding reported to the ALSPAC 
Committee ‘… that she had had some unofficial feedback from John 
Sulston. The subcommittee’s report at the end of the year would 
recommend to the government that adequate funding for studies like 
ALSPAC were vital if genetic screening at birth is to be beneficial.’10
UK Biobank and the Nuffield Trust
UK Biobank, the longitudinal study that recruited 500,000 individuals 
nationwide aged between 40 and 69 during 2006–10, has many 
similarities to ALSPAC despite being national, much larger and only 
recruiting adults of a certain age. The study had a lengthy period 
of planning and consultation, including producing an Ethics and 
Governance Framework (EGF) to ‘set standards for the project, and 
to ensure that safeguards are in place for scientifically and ethically 
approved research’.11 The draft EGF was developed in 2003 by a small 
Interim Advisory Committee chaired by Dr William Lowrance, a 
well-respected international consultant in health policy and ethics. 
The previous year, William Lowrance had led workshops for the 
Nuffield Trust on a variety of issues, culminating in the publication 
of Learning from experience: Privacy and the secondary use of data in health 
research (Lowrance, 2002). It was at one of these workshops that Dr 
Lowrance, much to his surprise, discovered that ALSPAC had been 
collecting genetic material from a population sample for over a decade. 
In November 2004, the UK Biobank set up an independent Ethics and 
Governance Council (EGC), chaired by Professor Alastair Campbell, 
to oversee adherence to the EGF. Professor Campbell was not only 
the University of Bristol’s first Director of the Centre for Ethics in 
Medicine (founded in June 1998), but had also been a member of 
the ALSPAC Ethics and Law Committee from 1996 for several years.
There is some confusion as to how much the ALSPAC Committee’s 
deliberations on the issues surrounding longitudinal genetic research 
influenced the UK Biobank’s EGF or EGC. Gordon Stirrat, a colleague 
of Alastair Campbell and a long-standing member of the ALSPAC 
Ethics and Law Committee, reported in October 2004, one month 
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prior to the establishment of the UK Biobank EGC, ‘that he had 
spoken to Alastair Campbell about the Biobank Ethics Committee. 
Professor Campbell said that there was no analogy between that 
committee and the ALSPAC Law and Ethics committee’.12 This 
did not deter Professor Stirrat from advising Professor Campbell 
to make use of the ALSPAC Committee’s expertise as, six months 
later, Professor Stirrat reported to the ALSPAC Committee that ‘… 
Professor Campbell had recently spoken to G.S. [Gordon Stirrat] 
about some of the issues his committee has to consider e.g. single gene 
disorders. G.S. strongly advised Professor Campbell to liaise with J.G. 
[Jean Golding] and M.F. [Michael Furmston] as the ALSPAC Law & 
Ethics Committee had grappled with such issues for many years.’13 
As far as is known, Alastair Campbell did not take up this suggestion. 
It is clear that there were many interlinking strands between the two 
ethics committees (as well as between other senior members of both 
organisations),14 and by 2011, Gordon Stirrat suggested that UK 
Biobank EGC was probably designed on the ALSPAC Committee 
(Overy et al, 2012, p 36).
Whatever the truth, ALSPAC influenced UK Biobank in other ways, 
as stated by Professor Rory Collins, Principal Investigator and Chief 
Executive of UK Biobank, when giving evidence to the Genomic 
Medicine – Science and Technology Parliamentary Committee in 
200815:
I believe that participation, particularly on a population-wide 
basis, in such studies is a great way for people to understand 
better what they can produce, in being part of something that 
will improve health. I can give you an example of this. The 
Wellcome Trust funded ALSPAC [which] is a study of children 
and mothers in Bristol. We are now recruiting into UK Biobank 
in Bristol and our recruitment rate there is twice as high as in any 
other part of the country in which we are recruiting. I cannot 
tell you that it is definitely because of ALSPAC, but many people 
who come in do talk about the ALSPAC study.
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This has been termed ‘the ALSPAC Effect’, as described at the Society 
of Longitudinal and Life Course Studies international conference in 
2014 (O’Hare, 2014).
National Children’s Study
The influence of the ALSPAC Committee was not restricted to 
the UK. When the US National Institutes of Health were planning 
the National Children’s Study, an ill-fated nationwide longitudinal 
birth cohort of 100,000, an ethics workshop was held as part of a 
lengthy consultation process. Representatives from seven established 
longitudinal cohort studies were invited to present their studies, with 
particular emphasis on the ethical problems encountered. ALSPAC 
was the only non-US-based cohort represented. The influence on the 
subsequent ethical decisions was almost certainly negligible16 as the 
minimalist approach to the feedback of results was not an accepted 
policy in the US at that time.
Apart from the formal consultations, when the Committee’s 
expertise was recognised and advice actively sought, it is difficult to 
gauge how influential the Committee was beyond ALSPAC. It is likely 
that the influence was somewhat concealed. ALSPAC was an exemplar 
for many longitudinal studies that have since been set up and advice 
was frequently sought from Jean Golding and her staff on many aspects 
of the Study. She arranged carefully organised and much-appreciated 
personalised tours of ALSPAC’s clinics and departments for numerous 
visitors. She also edited a well-received guide to longitudinal studies 
(Golding et al, 2009) commissioned by the World Health Organisation 
together with the US National Institutes of Health, based largely on 
her experience with ALSPAC, which included a paper on the ethics 
of longitudinal cohort studies (Birmingham and Doyle, 2009). Perhaps 
not known by those seeking advice (or those learning from ALSPAC 
without formal consultation) was how significant the Committee had 




Jean Golding believed that ALSPAC would have developed quite differently 
if the radical idea of the Study having its own ethics committee had not been 
implemented. There was no question that she valued the support of the Committee 
but whether the Study would have been so different without its own sound legal 
and ethical advice is disputed by some. The fact that there were no major ethical 
calamities must be in no small part due to the Committee’s influence; first, 
establishing principles, and then producing compatible policies when presented 
with the real issues emerging from the Study. These were early days for research 
ethics committees and the style and structure of the Committee did not comply 
with today’s idea of best practice. Computing was also in its infancy and a complex 
and original system known as the ‘Ethical Divide’ was designed to protect the Study 
participants’ anonymity, the key principle on which the Study was founded. The 
Committee was aware of the pioneering nature of its own work and was not only 
willing to advise a variety of influential organisations, but also supported academic 
publications that described its method and impact. Pragmatic solutions to the 
myriad of ethical issues were found at a time when there were no governance 
structures in place for medical research of any kind, let alone a study of ALSPAC’s 
ambition and complexity.
The success of the ALSPAC Ethics and Law Committee as a supportive, 
advisory group to the Director is evident from Jean Golding’s own 
account. Apart from the meetings being “a joy”, which is almost 
certainly the only time meetings of a research ethics committee have 
been described as such, she credited the Committee with much of 
ALSPAC’s success: “From my point of view, the importance was [that] 
this body of opinion and advice … was there, meeting every month 
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or so, without which I don’t think ALSPAC would have developed 
in the way it did at all”.1 Although too modest to articulate how it 
did develop, others are less reticent. The ‘Jean Golding Institute for 
data-intensive research’ within the University of Bristol, established 
in 2016, states on its website2:
The Institute is named after Jean Golding OBE, Emeritus 
Professor of Paediatric and Perinatal Epidemiology and founder 
of the Avon Longitudinal Study of Parents and Children 
(ALSPAC or Children of the Nineties). For over two decades this 
ground breaking study of over 14,000 pregnant women and their 
children has given world-leading insight into the environmental 
and genetic factors that affect human development – and shown 
the power of using data-intensive research to improve people’s 
lives.
Committee members will testify to the research being ‘data-intensive’, 
having developed a remit of comprehensive oversight and having 
reviewed nearly all the primary data collections in detail over many 
years. The ‘world leading insights’ have been recognised also, as 
is evident by the World Health Organisation commissioning Jean 
Golding to write A guide to undertaking a Birth cohort study: Purposes, 
pitfalls and practicalities (Golding et al, 2009), which included a chapter 
on ethics and governance (Birmingham and Doyle, 2009). The 
influence of the Committee on the whole Study is difficult to quantify. 
David Baum and others on the Steering Committee recognised the 
importance of the ethical dimensions of such an ambitious longitudinal 
study and therefore instigated an Ethics and Law Committee attached 
to the Study itself – an entirely new concept. Their grasp of the 
ethical issues significantly influenced the design of the Study so as 
to include the principle of anonymity and broad consent for the 
use of genetic material prior to the Ethics and Law Committee’s 
involvement. Richard Ashcroft considered the impact of the Ethics and 
Law Committee on the Study as a whole when interviewed in 2013:
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“… what made ALSPAC work wasn’t getting high-quality 
ethical advice from a committee, it was a very well-conceived 
study, very well organised with very strong clear leadership 
and an extremely good relationship with its participants and 
the wider community and if any of those things hadn’t been in 
place, then no matter how good its Ethics Committee was, it 
would have failed. And if you take the Ethics Committee out of 
that picture, well, who knows what difference that would have 
made? I think it did make a difference, certainly at the outset, 
and there were probably certain key moments in the history of 
ALSPAC where it did play a critical role.” (Richard Ashcroft, 
Oral History Interview, 2013)
One of the key moments at the outset was captured in David 
Baum’s memo when he wrote of ‘establishing the absolute principle 
of non-attributability’ (see Figure 1 in Chapter One), that is, 
the anonymisation, or more precisely pseudo-anonymisation, as 
longitudinal and other data linkage was essential to the Study. This 
was embedded in the Study methodology alongside ‘Consent’, the 
other key principle identified by Michael Fursmston at the very first 
Committee meeting. The principle of non-attributability had to be 
incorporated into all the Committee’s evolving policies, such as child 
protection, the disclosure of individual results or linkage to external 
databases, although Michael Furmston was quite clear that it was the 
Committee’s remit to decide if and when, in specific circumstances, 
this principle should be disregarded.
As promised to the Study participants on enrolment, ‘a very 
complicated set of procedures’ had to be designed to incorporate 
this principle in order to ‘ensure that no one will be able to link the 
information that you give us with your name’.3 This was in 1990 when 
computers were in their infancy and were only just being introduced 
into offices throughout the country. The implementation of this 
fundamental ethical principle stipulated by the Committee, known 
variously as the ‘Ethical Divide’ or the ‘Golden Rule’, fell to David 
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Carmichael, the ALSPAC Data Manger. When asked about the origins 
of the ‘Ethical Divide’ in 2016, he stated with characteristic modesty:
I don’t claim to have invented the Divide, at all. The original 
specification for ALSPAC said (I paraphrase) that no-one would 
be able to pick up a questionnaire and link that back to a real 
person nor link contents from one questionnaire to another, 
except anonymously. My interpretation was quite literal, hence 
the myriad of IDs, one for each collection point.… The protocol 
also stated that person data (name, address, etc.) would not be 
stored on the same computer as research data. At the start that 
was simple to enforce, but I knew that networking, which 
was really just beginning then, would make this unlikely to be 
sustainable. Hence the overkill of a separate ID per collection 
point. This I wouldn’t do now, but it was a new aspect of data 
collection that had really [never] been dealt with [before]. (David 
Carmichael, personal correspondence, November 2016)
Although eventually abandoned as too cumbersome, credit must be 
given to David Carmichael for establishing ‘the Divide’ and, with 
it, not only the application of the Committee’s principles, but also 
an ethos within the staff group of respect for confidentiality and 
an understanding of the principle of anonymity guaranteed to the 
Cohort. Trust in the researchers’ integrity by the Study participants 
had to be established rapidly if the Study was to succeed. As a large 
local study, Cohort families were everywhere, including within the 
staff group itself, and any breach of the guarantee could have had 
disastrous repercussions.
As it transpired, there were no major catastrophes, which must be 
in no small part due to the Committee’s influence; first, establishing 
principles, and then producing compatible policies when presented 
with the real issues emerging from the Study, while gradually taking 
on the unacknowledged oversight of ALSPAC’s activities. There were 
inconsistencies, omissions and some harsh decisions when trying to 
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adhere to the principles but they were dealing with rapidly evolving 
research with few established guidelines.
The structure of research ethics committees was also not established 
and the ALSPAC Ethics and Law Committee certainly did not 
conform to current practice as to how a committee should be set up 
and conducted:
• Committee members themselves questioned how independent they 
could or should be, even when they acquired Institutional Review 
Board registration in the US and, with it, formal change in status 
from advisory to independent. Jean Golding was encouraged to 
continue on the Committee after her retirement and her status as 
a ‘non-voting member’ seemed entirely inconsequential.
• For Study participants to serve as full members of the Committee 
was regarded as progressive and appropriate by some at the time. 
Having ‘service users’ or ‘stakeholders’ involved in research design 
and ethics is becoming almost mandatory nowadays, although 
UK Biobank’s Ethics and Governance Council does not replicate 
this practice as it is thought that it might compromise their 
independence.
• New Committee members were chosen through informal 
recommendation by other Committee members or those known to 
them, resulting in the similarity of members, who were all white, 
middle-class professionals. Jean Golding favoured membership 
by invitation as she thought advertising for members attracted 
individuals with an ‘axe to grind’. She was quite prepared to take 
risks, though, and invited onto the Committee one impressive 
and subsequently long-standing member who was initially 
recommended with the qualification that they were ‘a bit of a 
maverick’.
• Terms of reference did not exist until just before Michael Furmston 
retired as Chair. He retrospectively articulated the remit of the 
Committee that had been established over the previous 16 years in 
the broadest possible terms, with a succinct 60 words.
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• Minutes were sometimes intentionally embellished and although 
Elizabeth Mumford and the author endeavoured to ensure that they 
were not misleading in any way, Michael Furmston once cheerfully 
held that Elizabeth Mumford documented what should have been 
said, not necessarily what was said.
• The Chair remained in situ for 16 years and many other Committee 
members served for well over a decade. This was vital to the 
Committee’s method of working as, otherwise, in Gordon Stirrat’s 
words, ‘some of the folk memory would be lost’.
• The informality and affability between Committee members, 
appreciated by many as essential in facilitating open and honest 
discussion, however difficult the issues, was considered by some, 
both then and now, as too casual.
As Tim Chambers reflected when remembering his time on the 
Committee:
“There was a serious core to it, but it was slightly, sort of, well, 
‘we’ll get some good brains together and we’ll chew this through’ 
[but] as a first ethics committee in the University, how [else] do 
you get these things started?”4
A major part of the ‘serious core’ and crucial to the Committee’s 
work was the legal guidance from the two lawyers on the Committee. 
There was little in English law specifically related to medical research 
of any kind, let alone observational studies such as ALSPAC. Michael 
Furmston and Elizabeth Mumford were always mindful that they might 
have to defend the Committee’s decisions in court. They therefore 
ensured that they always had confidence that any ruling on a decision 
would most likely be in ALSPAC’s favour. They were never put to 
that particular test.
The Committee, aware of the pioneering nature of their work, 
supported academic undertakings concerning their own methodology 
and impact. Alastair Campbell, a member of the Committee and 
Professor of Medical Ethics, brought one such academic initiative 
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before the Committee in 1994. He suggested a study of the 
Committee’s decision-making, based on the Committee minutes 
and referring to the literature in the area. This was considered too 
similar to work already under way by Elizabeth Mumford but the 
Committee welcomed his suggestion of a comparison between the 
ALSPAC Committee and other comparable committees. It is not 
clear how many other comparable committees there were nationally 
or internationally, but, unfortunately, the study did not materialise. 
Elizabeth Mumford went on to publish two papers (Mumford, 1999a, 
1999b), which were well received by both the Committee and the 
Local Research Ethics Committees.
The Committee’s interests went beyond their own work, however, 
and in 1999, Richard Ashcroft proposed a study, designed by himself, 
Marcus Pembrey and some of the other Committee members, 
‘investigating the perceptions of adult and child participants about the 
ethical safeguards adopted for their protection’.5 The methodology 
of this proposal developed into a far more independent investigation 
than originally suggested, and apart from Richard Ashcroft, all 
Committee members withdrew from any active participation in 
the Study. This prestigious three-year qualitative study,6 funded by 
the Wellcome Trust, not only deprived the Committee of Richard 
Ashcroft, who resigned due to a conflict of interest as he remained 
one of the principal investigators, but also put considerable strain on 
the relationship between his staff and the ALSPAC staff, including the 
author. He stated several times in his interview that “It was the most 
difficult piece of research I have ever done”. He also reflected that 
“In hindsight, it was a mixture of entirely understandable caution on 
the part of ALSPAC itself and Jean Golding in person, and a feeling 
that a very inexperienced junior, slightly hot-headed researcher, that 
is to say, me, could jeopardise things.”7  Despite the complexities of 
the interactions between the two staff groups, the results were of great 
value. Marcus Pembrey (who gave a joint presentation with one of 
Richard Ashcroft’s staff many years later) became visibly moved when 
describing a Study child’s concerns and how these had confirmed his 
long-held views:
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“… their main worry was … that the doctors would get bored 
with analysing it all because it takes so long … and they would 
move on and do something else and that all this effort that they 
individually and collectively had given to fill in all these forms 
and everything else, that somehow it wouldn’t be used in the 
future for research … and that the researchers would lose heart, 
give up and so on. Very insightful.… It chimed with the way 
I had always viewed the general public. They really are not 
bothered about you having all their information, and so on, 
yes. What they want is to cooperate and be true partners in this 
research and for us to not give up. And with people like Jean, you 
don’t give up.” (Marcus Pembrey, Oral History Interview, 2013)
Marcus Pembrey felt that this sub-study validated his strongly held 
belief that the addition of a genetic component to ALSPAC was not, 
at least for the Cohort participants, particularly problematic. This 
supposedly highly contentious aspect of the Study had, in fact, taken 
up very little of the Committee’s time, although it came into other 
areas that the Committee discussed at length, such as the consent for 
and collection and use of biological samples or divulging individual 
results. The emphasis on anonymity and confidentiality, alongside 
the carefully nurtured trust in the integrity of Jean Golding and her 
researchers, almost certainly pre-empted or alleviated the anxieties of 
the participants in this respect.
On Michael Furmston’s retirement from the Committee, Marcus 
Pembrey, who was a little more detached than some, having never been 
on the Committee, put its work into context when he wrote to him:
It is only with hindsight that one realises that ALSPAC was 
ground breaking in so many ways. The establishment and 
detailed work of the Law and Ethics Committee [sic] is a clear 
example. In a world of gene-hype on the one hand and anti-
genetics on the other, your committee’s work and judgements 
represent a triumph of rational policy making. Of course there 
have been and are tricky issues but your committee has done the 
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careful work necessary to find sensible workable solutions. What 
a contrast to the knee-jerk reaction brigade! (Marcus Pembrey, 
‘Letter to Michael Furmston’, 11 October 2007)
These insights could be applied to all of the ALSPAC Ethics and 
Law Committee’s work, not just to the genetic component. Sensible 
workable solutions were found for the tricky issues despite the 
occasional inconsistencies. This unique, pioneering committee surely 
does represent a triumph of rational policymaking.
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Postscript
The Avon Longitudinal Study of Parents and Children (ALSPAC) 
becomes more exceptional the more one learns about it. Led by Jean 
Golding and later George Davey Smith, it has clearly been a study 
that has continued in the pursuit of research into health and disease 
throughout the life course from early pregnancy onwards. If we are in 
the business of understanding the forebears of adult disorder (or health), 
then this is the way to do it. However, in delivering such an overarching 
and comprehensive screen of health and epidemiologically relevant 
data, this Study has, of course, needed to remain at the forefront of 
ethical practice and governance. This was not easy – at least when there 
were no formal structures to work to, as ALSPAC encountered in the 
early years. Participating in science now, one is faced with a clearly 
defined and executable set of requirements that ensure study activity 
is transparent, guided in full view of the participants and appropriate. 
This seems somewhat of a luxury given the testing times that ALSPAC 
previously encountered and it is to that endeavour (for ALSPAC and 
other studies like it) that the current scientific community must doff 
its cap. In this case, the tireless energy and contributions of Professors 
Jean Golding, David Baum, Marcus Pembury, Michael Furmston and 
other important contributors (so well described in this text) present a 
great lesson in the delivery of ethical research but also in the difficulties 
and idiosyncrasies seen along the way. Long may the Study continue.
Nicholas Timpson, Professor of Genetic Epidemiology,











5 Marcus Pembrey, Oral History Interview, 2013.
6 The UK county of Avon was abolished in 1996. It was situated 120 
miles west of London on the River Severn estuary. It had a population of 
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Appendix 1:  
ALSPAC Steering Committee:  
founding members
From ALSPAC Steering Committee minutes, 1987–89, page 164 
(ALSPAC Administrative Archive)
• Dr Jean Golding (Chair), Institute of Child Health, Bristol
• Professor Catherine Peckham, Institute of Child Health, London
• Professor Marcus Pembrey, Institute of Child Health, London
• Professor David Baum, Institute of Child Health, Bristol
• Professor Gordon Stirrat, Department of Obstetrics & Gynaecology, 
University of Bristol
• Dr Charles Pennock, Department of Pathology and Child Health, 
University of Bristol
• Dr Jon Pollock (Secretary), Institute of Child Health, Bristol
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Appendix 2:  
ALSPAC Ethics and Law Committee 
members: appointed 1990–2005
Ashcroft, Richard Ethicist 09/09/1998 to 31/03/2000
Bailey, Sarah Study Mother 08/02/1999 to 23/05/2002
Barnes, Hugh Child Psychiatrist 13/06/2000 to 31/03/2014
Baum, David Professor of Child Health 25/04/1990 to 24/03/1997
Bertram, Chris Philosopher 07/09/2000 to 17/10/2005
Karen Birmingham Research Nurse 01/12/1999 to 31/03/2014 
Secretary throughout
Bowles, Ruth Study Mother 12/03/2001 to present
Bryer, Sheila Study Mother 05/12/1994 to 05/07/1996 
Cadman, Marilyn Study Mother 08/02/1999 to 18/12/2000
Campbell, Alastair Professor of Ethics in 
Medicine
28/10/1996 to 03/03/1998
Chambers, Tim Consultant Paediatrician 22/05/1990 to 02/06/1997
Furmston, Michael Professor of Law 25/04/1990 to 19/02/2008 
Chair 25/04/1990 to 
05/09/2006
Golding, Jean Director of ALSPAC 25/04/1990 to 02/01/2009
Henderson, John Paediatrician 08/05/1997 to 17/10/2005
Hirschmann, David Philosopher 25/04/1990 to 24/03/1997
Jewell, David General Practitioner 13/06/2000 to 03/09/2013 
Chair 09/03/2010 to 
03/09/2013
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Keen, Peter Dean of the Faculty of 
Medicine
25/04/1990 to 12/12/1995
King, Ursula Professor of Theology 25/04/1990 to 10/12/1991
Lister Cheese, Ian Senior Medical Officer, 
Department of Health
25/04/1990 to 12/12/1995 




Lawyer, Expert on Medical 
Law
25/04/1990 to 06/10/2011 
Secretary 25/04/1990 to 
18/10/1999
Ness, Andy Epidemiologist 29/04/2003 to 17/10/2005
Nott, Jan School Nurse 30/09/2002 to 07/08/2008
O’Day, Ken Philosopher 03/11/1997 to 29/05/2000
Scholar, Phillippa Teacher 11/10/2004 to 05/09/2006
Stirrat, Gordon Obstetrician 25/04/1990 to 09/05/2000 
Re-joined 23/05/2002 to 
15/12/2009 
Chair 20/09/2006 to 
15/12/2009
Wallace, Ruth Study Mother 03/09/2002 to 09/03/2010
Watson, Norma Head teacher of Primary 
School
13/07/2000 to 06/09/2004
Webster Green, Joanna Study Mother 08/05/1997 to 19/01/1998
Williamson, Chris Health Visitor 05/02/1996 to 03/09/2002
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Appendix 4:  
Young Mothers paper by  
Elizabeth Mumford
ALSPAC Young Mothers
Although I was asked specifically to look at the 
question of young mothers (i.e. those under 16 or 
18), it seems to me that there are similar problems 
when adult mothers are incompetent (through physical 
or mental illness or handicap).
I Young Mothers
A) Mothers Under 16: Unlawful Sexual Intercourse
Under the Sexual Offences Act 1956, it is an offence 
for a man to have sexual intercourse with a girl 
under the age of 16. Thus, if a girl is pregnant 
at 16, her partner will inevitably have committed 
an offence. It is not, however, an offence for the 
girl herself to have under-age sexual relations, 
nor can she be guilty of aiding and abetting the 
boy/man, as she is perceived to be the victim of 
the offence.
From the point of view of the study, it would seem 
important that there be no way of identifying the 
partner of a mother who was under 16 at the time 
of conception. If we do not know his identity, we 
can assure the girl that the matter will be kept 
confidential. We can also avoid being subpoenaed 
(although this would be unlikely) in any prosecution 
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of the partner for the above-mentioned offences.
There is, of course, the possibility that the girl’s 
pregnancy is the result of incest or other sexual 
abuse. This might become evident in the course of 
an interview, in which case, we would be faced 
with the usual dilemma about what to disclose and 
to whom. There is also the separate question about 
whether the fact of a close genetic relationship 
between mother and father would be something about 
which those working on the genetic material should 
know.
B) Consent
1) To the taking of biological samples
The Family Law Reform Act 1969 states at s.8 that 
minors who have reached the age of 16 are competent 
to give valid consent to “medical treatment” etc. 
As the primary purpose for which the sample is 
being taken is to assess maternal/foetal health, 
this would seem to fit within the section and 
render the consent of a mother over 16 valid to 
the actual insertion of the needle and drawing of 
blood.
As regards mothers under 16, the law was clarified 
by the Gillick decision in the House of Lords. 
Nothing in statute or common law prohibits such 
children from giving consent to treatment and the 
test of whether an individual is competent to do 
so becomes one of her understanding and maturity, 
couple with the doctor’s view that the procedure 
in question is in her interests. Thus, most of our 
young mothers would have the right to consent to 
the withdrawal of blood for testing.
There is however some question as to whether a 
young woman is entitled in law to allow her blood 
to be further used for research purposes. Contracts 
purported to be entered into by minors are not 
usually legally binding, nor are minors entitled 
to dispose of their property by gift or sale unless 
it is to their benefit. While it is clear that the 
consent form we use is not a contract, there is 
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some question as to whether the person who provides 
blood or tissue has some property interest in it. 
The answer is far from clear, as the case law in 
the past has dealt more with money and tangible 
property. The most likely interpretation, in my 
view, is that the transaction would be seen as 
being “voidable” – that is to say that the girl 
could change her mind on reaching majority and 
choose to withdraw from the study and to have her 
samples destroyed – which of course she could do in 
any case. Incidentally, the answer is not to ask 
for permission from the girl’s parents, for they 
do not have the power to dispose of their minor 
children’s property either.
Using a different analogy – that of harm to the person 
rather than harm to some alleged property interest 
– it is possible under certain circumstances for 
a mature and comprehending minor to consent to 
things which are not for his or her benefit and 
which may be positively harmful. The mere fact 
that Parliament has had to enact statutes such 
as the Tattooing of Minors Act and the provisions 
on under-age sex suggests that in the absence of 
specific legislation, the minor’s consent is valid.
Finally, it is hard to think of what action might 
be brought against ALSPAC in this regard, as long 
as we have ensured that the girl in question is 
fully aware of what is intended in the use and 
storage of biological material and has consented.
2) The Questionnaires and Interviews
In general, it is probably the case that one is 
entitled to ask anyone anything one likes, whether 
the subject is a child or an adult. There are, 
however, one or two problems with these particular 
questions. The first is the practical matter of 
sending questionnaires to a home where it is possible 
that some or all family members are unaware of the 
girl’s pregnancy, or where the girl has not yet 
accepted the fact that she is pregnant or decided 
whether or not to keep the baby (both situations 
are quite prevalent among young mothers).
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From the legal point of view, there are two 
additional issues. The first concerns the rather 
old-fashioned idea that it is for the parent to 
decide the place and manner in which the child 
spends her time. (Children Act 1975—This phrase, 
but not, I think, the concept- will disappear 
with the coming into force of the Children Act 
1989 next year). Presumably control of the girl’s 
time includes whether or not she is to be filling 
in questionnaires or talking for two hours to an 
interviewer. Added to this is the fact that the 
interviewer may well be calling to see the teen-
aged mother at her parents’ home: thus, presumably 
they have some right to determine who will be 
received there and to insist on remaining present 
during the interview if they wish.
My feeling is that it is probably best to wait for 
complaints, rather than actively to seek parental 
consent to the girl’s participation, but I am not 
sure I have the right answer here.
The other matter is that of the questions on sexual 
history. There is a fine line between legitimate 
activities such as sex education (and, I think, 
this study) and activities which, when the subject 
is a minor, might be construed as the common law 
offence of outraging public decency (I am thinking 
here of a recent case actually involving a home-
made “questionnaire” about sexual activities which 
a schoolmaster had two boys read aloud to him and 
as a result of which he was charged). It might be 
prudent to omit the sex questions where the mother 
is under 16.
C) Mothers who are wards of course or in local 
authority care
I am not an expert in this area, but my feeling is 
that there is no substantial different between the 
position of these and other minor girls, as parent 
substitutes are required to act, at least for these 
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This category includes the cases of very young 
mothers who do not have the maturity to give consent 
or to answer questions and mothers, whether minors 
or not, who lack capacity due to mental handicap or 
mental or physical illness.
Presumably, it would still be of interest to have 
information about such women and this might be 
provided by their parents, guardians or other 
family members. The decision about whether a woman 
was capable of participating would ideally be 
made by the midwife/G.P. and following this, the 
questionnaires might be altered so as to eliminate 
those things which could not be answered by proxy 
(e.g. state of mind).
As concerns the biological material, it seems to 
be clear law that the parent of a minor may consent 
to his or her child’s participation in medical 
procedures that are not necessary to the child’s 
health (there are cases on blood testing for 
paternity) as long it is a “reasonable” decision 
for a parent to make and is not manifestly against 
the child’s interests. This would presumably 
apply here and might be extended to include adult 
incompetents. The question of property is again a 
difficult one. However, it is possible that an adult 
incompetent will have a guardian under the Mental 
Health Act, appointed to deal with her property. 
In such a case that person (if not the parent) it 
might be wise also to ask his/her consent to the 
biological testing.
*****
It might also be of interest at some point to 
discuss the question of women who are intending 
unusual parenting arrangements (surrogacy, ovum 
donation or even adoption). These cases may present 
both administrative and technical challenges.
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Appendix 5:  
The Children of the Nineties study 
(ALSPAC) and collaboration with 
pharmaceutical companies
The ‘Children of the Nineties’ study (ALSPAC) is dedicated 
to understanding the environmental and genetic influences on 
development from infancy to adult life, and how these affect our 
health and well-being. Eventually, the study will suggest ways in 
which common diseases in childhood and adult life can be prevented, 
or treated.
Principles underlying research in ALSPAC
A fundamental principle that governs the conduct of ALSPAC is 
that, like most studies supported by public agencies and charities, 
the discoveries that are made will end up in the public domain. 
There, they can be accessed freely by the international research 
community, by those who shape and provide public health services, by 
commercial companies searching for and developing new medicines, 
and, indeed, by any person or agency with an interest in health and 
welfare. ALSPAC recognises that the willingness of cohort families 
to continue giving so much of their time to the project depends on 
the protection of the principle that discoveries that come from the 
project are ultimately for the benefit of all.
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Support for research in ALSPAC
Bristol University, the Medical Research Council, the Wellcome 
Trust and other organisations provide ALSPAC with funds that help 
to maintain many of its ‘core’ functions, for example, the organisation 
of clinics, computer programming, statistics and communication 
with cohort members. However, this ‘core’ funding does not cover 
the exploitation of the research opportunities provided by the study. 
Consequently, ALSPAC and its collaborators must still seek funding 
for much of the collection, measurement and analysis of information 
from the cohort. Raising money to support research in ALSPAC is a 
major task for both ALSPAC and its collaborators, and success in doing 
so is critical in ensuring the study’s continued productivity.
Proposals for scientific work utilising the ALSPAC resource are 
initially scrutinised by ALSPAC’s advisory committees. The Law 
and Ethics Committee decides whether a project meets the required 
ethical standards, and other committees advise on whether a project 
reaches the necessary scientific standard. Subsequently, the fully costed 
proposal is submitted to grant-giving organisations (government 
research councils, or various charitable organisations), where they are 
subject to further independent review.
If a project meets the required (high) standard and is financially 
supported, arrangements are made to provide the research group, 
which may be based anywhere in the UK, or further afield, with 
access to the information and samples in ALSPAC that they need in 
order to answer their scientific question. If DNA samples need to be 
analysed as part of the project, small amounts of DNA from all the 
samples in the ALSPAC DNA bank are sent to a laboratory for the 
necessary measurements. The samples are completely anonymous as 
far as that laboratory is concerned. When the genetic analysis has been 
carried out, the results are returned to ALSPAC and linked with other 
information about the individuals whose DNA has been analysed. It is 
this process that allows statisticians to establish, for example, whether 
any genetic variation among cohort members is associated with a 
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particular outcome or test result, for example, with being tall, or 
being more likely to suffer from eczema, or with being fat and so on.
The value of ALSPAC is in the research that makes sense of all 
the information and samples, including DNA, which are held by 
it. Without research, the information and samples by themselves are 
of little or no value. ALSPAC does not ‘sell’ its resources, but shares 
them with the scientific community and, as a consequence, adds to 
the sum total of knowledge in the public domain by publishing the 
results in scientific journals and by disseminating information more 
widely through the press. The whole research process is controlled so 
that all the interests of ALSPAC and the cohort’s members (children 
and parents) are met.
Benefiting from the results of ALSPAC’s research
Pharmaceutical companies are among the many organisations that 
will benefit from the advances being made in understanding human 
genetic make-up. Information about what our genes do and how their 
functions contribute to a complete human being can provide clues 
to the design of new drugs. For example, by knowing all the genes 
that are responsible for the components of our immune systems, we 
can identify these components as possible targets for drugs that could 
be used to treat allergies, viral infections or autoimmune diseases. 
However, much of this part of drug discovery takes place in laboratories 
where the systems used to search for useful drugs are very simple 
when compared with a complete person living their life in a complex 
environment. Consequently, there is a large gap between discovering 
a possible drug and showing that it will have a beneficial effect and, 
importantly, be free of damaging side effects.
Part of the research that ALSPAC supports aims to discover how our 
individual genetic make-up affects the likelihood that we will develop 
common diseases, such as asthma, heart disease or adult diabetes. 
If we discovered that a particular version of a gene makes us more 
susceptible to asthma, then this would demonstrate that the product 
of this gene makes a critical contribution to the development of the 
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disease. This in turn makes this product a good candidate as a target 
for drugs designed to protect against or treat asthma. Equally (or more) 
importantly, because so much information is collected about each 
individual in ALSPAC, it is possible to discover whether changes in 
the properties of a gene have other effects on our health. This provides 
important clues as to whether a drug aimed at the gene product could 
have significant side effects and therefore be unsafe.
Adding value to ALSPAC
The results of research carried out in ALSPAC will contain information 
valuable to the pharmaceutical industry, which they will be able to 
access freely, along with everyone else, when it enters the public 
domain. Given ALSPAC’s need for financial support for research 
projects, there is a strong argument for inviting pharmaceutical 
companies to provide direct support for those projects where the results 
will be valuable to them. Indeed, important funders of ALSPAC, such 
as the Medical Research Council and the Wellcome Trust, expect 
that this will happen.
The conditions under which pharmaceutical firms would undertake 
collaborative research in ALSPAC would be at least as stringent as 
those that apply to academic collaborators. Indeed, commercial 
companies would expect that the conditions of collaboration would 
be legally binding. There would be no ‘sale’ of DNA or information, 
confidentiality would be protected, there would be a period during 
which the results would remain confidential to ALSPAC and the 
collaborating company, and the results would finally be published so 
they entered the public domain. The pharmaceutical company would 
learn more about the potential effectiveness and safety of its drugs.
ALSPAC would gain support for its research activities and add to 
the total sum of information produced by the study, which would not 
only contribute to the development of new drugs, but also further 
our understanding of the development of disease and might point to 




ALSPAC must continue to seek support for the research that will give 
value to the wealth of information that it has collected over the last 
10 years and that it continues to collect. The results of this research 
will be valuable to many, including the pharmaceutical industry, and 
it makes sense to seek support from them for the research from which 
they and everyone else will ultimately benefit. Provided this is done 
on the basis of agreements that do not compromise the overall aims of 
ALSPAC, or its relationship with the children and parents on whose 
continued cooperation the study depends, then such developments 
should only add to the value of this important study.
RWJ 10/05/02
196
PIONEERING ETHICS IN A LONGITUDINAL STUDY
A




of children 33, 70, 72, 90, 188
access
commercial 131, 132, 134
open 130
to data 49, 54-55, 105, 107-8, 
109, 110, 113, 126, 148, 150, 
192, 193
to personal results 90, 91
ALSPAC Ethics and Law 
Committee xvii, 9-20
advisory status 5, 7, 17, 23, 30, 
33, 34, 35, 38, 40, 139, 156, 160
agendas 33, 34
‘constitution’ of 17, 19, 56, 64
inconsistency of decision making 
17, 40, 53, 79, 81, 84, 87, 98, 
104, 113, 114
independence of 30, 160 
influence of 147-55, 157
initiation and development of 
xvii, 5-8, 9
innovative xviii, xix, 16, 163
Index
Page numbers for photographs, boxes and figures are in italics.
Institutional Review Board (IRB) 
status 37-8
lawyers’ contribution 12-14 see 
also Mumford
LRECs, interactions with 39-47, 
137, 139-40, 143
members 14, 15-6, 24-6, 160, 
161, 182-3
length of service 26
minutes 27-9
oversight of ALSPAC xx, 137-46
principles developed xviii, 10, 49
style 21-9
sub-studies 17, 36, 40, 41, 43, 51, 
137, 142-5 
terms of reference 19-20
the early years 11
altruism 117, 125
Alumni, University of Bristol xiii
anonymisation xviii, 37, 44, 54, 55, 
105-14, 158
anonymity xvi, xviii, xix, 6, 9, 17, 
49-55, 88, 94, 95, 97, 103, 104, 
142, 151, 156, 157, 163
anonymous referrals 86
Apgar scores 92-3
Archive, UK Data 55
197
Ashcroft, Richard ix, 7, 13, 22, 23, 
25, 33, 34, 36, 157-8, 162, 182
assent xviii, 56, 58, 141
attrition rates xx, 6, 34, 95, 100, 
104, 117-9, 122, 125, 140 
Avon 166
Avon Longitudinal Study of Parents 
and Children (ALSPAC) 1
Administrative Archive xiii, xxi, 
181
aims of 2
as a resource 1, 5, 35, 130, 133, 
193, 194
audacious project 3, 4, 7
catchment area 39
description of development xvii, 
1-5
design of 1
Effect, The ALSPAC 155
enrolment xvii, 4, 6, 32, 57, 106, 
118
Ethics Archive xii, xiii, xxi, 166-
77
innovative features xv, xvii-xviii, 
2, 49, 55
integrity of xx, 33, 51, 90, 159, 
163
methodology 1, 2, 32, 33, 57, 77, 
114, 118, 125, 139
newsletters 40, 101, 113, 117, 
118, 119, 122, 124, 125,126, 
127-9,135-6
staff xvi, 6, 17, 18, 27, 50, 51, 
111, 118-119, 124, 125, 159
abuse of 101-2 
trust in xvi, xix, 6, 50, 56, 68, 88, 
95, 97, 118, 159, 163
B
Barnes, Hugh xii, 125
Baum, David 3, 14
correspondence with LRECs 
30-1, 39
initiating the Committee xiv, 9, 
10, 157, 158
memo from 11
principles for Committee 10, 11, 
15, 18, 20, 49, 50
views of 10, 24, 30-1, 71, 127 
BCC see Bristol City Council
biological samples xv, 1, 5
as a gift 66
blood, taking of 41, 43, 44, 60, 
141-2 
consent for 37, 57-8, 60, 163, 
188-9, 191
legal status 66, 130, 191
Birmingham, Karen ix, xx-xxi, 
155, 157, 182
blood see biological samples
blood pressure 81, 83
BPA see British Paediatric 
Association
Bristol City Council vi, 113-5
British Paediatric Association vi, 
141
Brocher Foundation xii
Bryer, Sheila 15, 71, 82
Butler, Neville xv
C
Campbell, Alistair 13, 152, 153-4, 
161, 182
Carmichael, David 159
case law 16, 17
cell lines 5,10, 43, 56, 123, 130, 
132
Central Office for Research Ethics 
Committees vi, 43, 44
Centre for Ethics in Medicine 5, 19
Chambers, Tim ix, 14, 29, 182
opinions 3, 21, 22, 34, 42, 71, 
161
resignation 17, 27, 28, 29 
Child Health Database 106
198
PIONEERING ETHICS IN A LONGITUDINAL STUDY
child protection xix, 6, 50, 69-75, 
119, 142, 158
Children in Focus 4, 35, 41, 60, 81, 
82, 83, 141, 142
Children of the Nineties xviii, 1 see 
also ALSPAC
children’s assent and consent 58-9 
clinics (research examinations) 4, 5, 




measures 82, 121, 122
procedures 111
protection of child xix, 69, 72-4, 
121
protection of staff 101-2, 104
response rates 120, 124, 144
cohorts, UK national xiv, xv, 2, 5
Collins, Rory 154
comments on questionnaires 50, 53
commercial companies, 
involvement with 126-36, 192-5
computers and confidentiality 6, 
44, 156, 158, 159  
confidentiality xviii 




and staff 51, 159, 163
discussions of 33, 53, 91, 92, 
145-6
policy of 10, 17, 20, 51
rules of 53, 70, 114, 129, 195 
consent 49, 56-68 
adults lacking capacity 59-60, 
187-191
broad 56, 61-2, 63, 68, 157
for biological samples 37, 40, 51, 
52, 57, 60, 61, 66, 163
for linkage 37, 105, 109, 110-1, 
112, 113
form 56-7, 60, 61, 63, 64, 68, 
111, 112, 138, 141
for partner 63
implied 57, 60
informed xviii, 56-68, 123
of children 58-9
of mothers 57
aged under sixteen 188-189
of partners 61





withdrawal of 51, 65-6
controls, selection of 51-2
COREC see Central Office for 
Research Ethics Committees
D
Data Protection Act 110, 113 
Davey Smith, George 2, 44
Declaration of Helsinki 16
Department for Education and 
Science vi, 114
Department of the Environment 78
DfES see Department for Education 
and Science
disclosure, deductive xviii, 49, 51, 
54
disclosure of results xix, 50, 76-87, 
88-94, 120, 151, 158
Discovery Club 117, 122-4, 125 
DNA xv, 43, 123, 131, 132, 
148, 149, 152, 193, 194 see also 
genetics
E




ELSPAC see European Longitudinal 
Study of Pregnancy and 
Childhood
Emond, Alan 71, 72, 81
English law 16, 97, 161
enrolment in ALSPAC 32
environment, data regarding xiv, xv, 
xvii, 1, 2, 4, 10, 41, 78 
EPEG see Ethical Protection 
in Epidemiological Genetic 
Research: Participants’ Perspective
ERC see Ethics of Research 
Committee
Ethical Divide 18, 49, 50-1, 55, 
109, 156, 158, 159
Ethical Protection in 
Epidemiological Genetic 
Research: Participants’ Perspective 
vi, ix
Ethics and Law committee 
see ALSPAC Ethics and Law 
Committee
Ethics of Research Committee vi, 
93
ethnic minorities 24 
European Longitudinal Study of 
Pregnancy and Childhood vi, 1, 
2, 69, 179
European Society of Human 
Genetics xx, 148
F
Fair Processing Letter 113 
Family Law Reform Act 59, 188
Family Liaison Team 53, 59, 60, 66, 




Five Hundred Rule 17, 51-2
Focus clinics see clinics
‘Focus at 7’ 42, 72, 121-2
funders – pressure from 55 
funding 10, 52, 113, 124, 125, 
126, 127, 128, 132,193 see also 
commercial companies
Furmston, Michael x, 12 , 12
as chair xiv, 11, 26, 49, 56
documents contributed 36, 45, 
132, 142, 160-1
his style 21, 22-3, 29
involvement with LRECs 44, 45
opinions 85, 91, 92, 94, 158
G
genetic abnormalities 77
Genetic Advisory Committee 15, 
35, 54
genetic databases 149, 150
Genetic Knowledge Park 133, 175
genetics xvii 
consent for xviii, 56, 61, 62, 63, 
64, 68, 130
disclosure of results 77, 151
ethical issues xvii, xix, 44, 54, 133
legal advice 9
participants’ views of 163-4





Golding, Jean x, 33, 157
advice to other cohorts 155,157
and commercial companies 126, 
127, 128, 135
and intervention 70, 72, 78, 79, 
81, 85, 92, 93, 98, 104
and LRECs 40, 41, 44,143-4
correspondence to/from 27-8, 78, 
90, 93, 98-9, 104, 129, 134, 135 
formal presentations 149, 152, 
153
genetic involvement 2, 132
initiation of ALSPAC 1-2
200
PIONEERING ETHICS IN A LONGITUDINAL STUDY
input into ethics committee 15, 
33, 34, 36, 57, 101, 103, 110, 
113, 123
role on ALSPAC committees 15, 
18, 23, 125, 138
trust in 18, 33, 135
views on role of ethics committee 
7, 22, 23, 28, 114, 117, 143, 
156, 160 
H
health records see medical records
health visitor vii, 104, 106
hearing 71, 82, 83-4, 145
Henderson, John 66, 148, 182
HGC see Human Genetics 
Commission
Hirschmann, David 14, 65, 71, 72, 
182
House of Lords Science and 
Technology Sub-Committee xx, 
131, 147, 149-51
Human Genetics Commission 149, 
151-2, 176 






information to participants 62, 64-
5,185-6
too much or too little 68
Institutional Review Board vii, 
37-8
interventions
examples of 70-1, 72, 73, 78, 79, 
80, 81, 82, 85, 86, 90, 96
policy for xix, xx, 69, 74, 75, 76-
7, 78, 84, 86
IRB see Institutional Review Board
J
Jewell, David x, 4, 15, 19, 22, 86, 
91, 92, 138, 145, 146, 167, 176, 
182
Jones, Richard xii, 133, 134, 136, 
179, 192-6
K
Keen, Peter 14, 183
Kelly, Jill xii
L
Lancet, The 2, 179
lead poisoning 91
legal advice xvii, xix, 9, 13, 20, 59, 
61, 78, 88, 93-4, 99, 147, 161, 
188, 190, 191
Leverhulme Trust xii
linkage to other databases xix, 37, 
50, 54, 103, 105-15, 132, 158, 
159 see also educational records; 
medical records
Lister Cheese, Ian x, 14, 21, 183
Local Research Ethics Committee 
(NHS) vii, 5, 6, 31, 35-47, 66, 
106, 114, 137-40, 143, 144
Lowrance, William 153 
LREC see Local Research Ethics 
Committee  (NHS)
M
media 32, 117, 118, 119, 123-5
medical advice for intervention 
70, 71
medical records, linkage to 40, 50, 
92, 93, 105, 106-10, 111, 112
Medical Research Council vii, xiii, 
126, 130-2, 141, 150, 179
miscarriages 40, 103





MRC see Medical Research 
Council
MRI scans 85
Mumford, Elizabeth xi, 14, 96
as secretary 11-3
comments of 17, 47, 50, 56, 64
describing the Committee 5, 13, 
22-3, 24, 31-2
legal opinion 59, 66, 89-90, 94, 
99, 187-91
minutes of 17, 27, 28, 161
published work 16, 162
N
National Children’s Study 155
National Health Service 
collection of biological samples 60
governance 6, 25, 31, 38 see also 
LRECs
records 105, 106, 108, 109
National Screening Committee vii, 
151, 152
newsletter inserts 129, 136
NHS see National Health Service
non-attributability 10, 18, 49, 158
non-intervention see intervention




Office of National Statistics vii, 
109, 110
ONS see Office of National 
Statistics
otitis media with effusion 83 
P
Parents’ Advisory Group 77
participant information sheet vii, 64
partners of study mothers xviii, 25, 
58-9, 60, 61, 62, 100-1
paternal blood 60-1
paternal saliva 61
paternity 60-1, 88, 89, 90, 191
Patient Information Advisory 
Group vii, 105, 108
Peckham, Catherine 9, 181
Pembrey, Marcus xi, xxi, 151
advice to Committee on genetics 
147, 163
and cell lines 10
initiating contacts 148, 150, 152, 
153
role in design of ALSPAC 2, 3
view of Committee 163
views of participants 163
Pennock, Charles 181
pharmaceutical companies see 
commercial companies
phenome scan 133-6
PIAG see Patient Information 
Advisory Group
pilot studies 1, 80, 139-40
PIS see participant information 
sheet
Pollock, Jon 181
prize draw 122, 124-5
pseudo-anonymisation 158
psychological interviews 73-4
public relations team 119, 124, 125
Q
questionnaires xv, 4, 139-40 
and confidentiality 6, 17, 18, 53
and consent 57, 60
assistance with 35
comments written within xix, 50, 
53, 75, 96
for fathers/partners 25, 58, 100, 
101
for young mothers 52, 59-60, 
189, 191
202
PIONEERING ETHICS IN A LONGITUDINAL STUDY
questions in 9, 15, 19, 33, 52-3, 
73, 139, 140, 189, 190
requests for access to 90, 91, 92
R
radiological protection 78
RCP see Royal College of 
Physicians
REC see Research Ethics 
Committee (NHS)
requests to the committee xix, 50, 
52, 65, 66, 73, 74, 88-94, 95-104, 
99, 104, 118
response rates see attrition rates
results of tests
general feedback 77-85, 87
individual requests 88-94
Research Ethics Committee (NHS) 
vii, 30-2, 168, 169
rewards to participants 117
Royal College of Physicians vii, 
141, 180
S
Scientific Advisory Committee 15, 
35, 130, 139, 144
secondary analysis 35-6, 44, 55
sexual history, questions on 33, 139, 
187-8
Sexual Offences Act 187
sponsors 127, 128
Steering Committee 1, 5, 9, 10, 12, 
15, 61, 126, 146, 157, 170, 181
Stirrat, Gordon xi, 94
and LRECs 31, 42, 46
and membership of Committee 
12, 14, 26, 161
and UK Biobank 154
description of Committee 26, 33
disclosure of results 93 
storage of biological material 189
storage of data 147, 148




teenage mothers 52-3, 187-91
Teen Focus 1 vii
TF1 see Teen Focus 1
Timpson, Nicholas 165
U
UK Biobank 87, 153-5, 160
v
views of participants 162-3
volunteers, role of xiii, 97
W
Wellcome Trust xiii, 130, 150, 154, 
177, 193, 195
Wellcome Witnesses to Twentieth 
Century Medicine 5, 14 180
WHO see World Health 
Organization
Wilson, Linda xii
Witness Seminar see Wellcome 
Witnesses to Twentieth Century 
Medicine
Wolke, Dieter 112






















“A fascinating account of a pioneering 
study, which developed ethical 
procedures in an evolving context with no 
existing coherent framework.” 
Anna Tarrant, University of Lincoln
Available Open Access under CC-BY-NC 
licence
The Avon Longitudinal Study of Parents and 
Children (ALSPAC), also known as Children 
of the 90s, is a world-leading birth cohort 
study that uniquely enrolled participants in 
utero and obtained genetic material from 
a geographic population. It instigated the 
innovative but controversial ALSPAC Ethics 
and Law Committee.
This book describes in detail the early work 
of this Committee, from establishing the 
core ethical principles necessary to protect 
participants, to the evolution of policies 
concerning confidentiality and anonymity, 
consent, non-intervention and disclosure of 
individual results, data access and security. 
Quotes from interviews with early members 
of the Committee reflect not only on its 
pioneering work but also on the unusual style 
and inspirational leadership of the first Chair, 
Professor Michael Furmston.
This will be of interest to those involved in 
other cohort studies in understanding the 
evolution of ethical policies as ALSPAC 
developed.
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